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DEFINITION AND SYMPTOMS 
Pelvic organ prolapse (POP) can be defined as the descent of one or more female pelvic 
organs, including the bladder (visible as the descent of the anterior vaginal wall), uterus or 
post-hysterectomy vaginal cuff, and/or the small or large bowel (visible as the descent of 
the posterior vaginal wall) [1, 2]. To be clinically relevant, the presence of any such sign of 
POP should be correlated with relevant POP symptoms [1]. Those symptoms can be 
numerous and diverse, including vaginal bulging, bladder symptoms, pelvic pressure or 
pain, lower back pain, dyspareunia, and anorectal dysfunction [1]. Although POP is not a 
life-threatening disease, those bothersome symptoms can have a significant impact on 
quality of life, affecting social, physical and sexual well-being. 
The anatomical level of prolapse can be measured with the Pelvic Organ Prolapse 
Quantification (POP-Q) system [3]. According to this system, the most descended edge of 
the prolapse is measured in centimetres relative to the hymenal remnants, with the 
patient in the supine position performing maximum Valsalva manoeuvre. These 
measurements can be translated into five ordinal stages, i.e., stage 0–4, where stage 0 
implies perfect pelvic support and stage 4 implies a total prolapse/complete vaginal 
eversion. However, the level of POP does not always correlate with symptom severity [4]. 
 
PREVALENCE AND SOCIETAL COSTS 
POP is a common disorder, with up to 40% of women worldwide having some form of 
anatomical prolapse [5, 6]. Since the cumulative risk of developing POP increases with age 
[7], the total number of women suffering from POP will increase in the coming years due 
to the aging population. 
An American study calculated that by the year 2050, the number of women suffering from 
POP will increase by 46%, from 3.3 in 2010 to 4.9 million in the US alone [7]. The number of 
women undergoing POP surgery will increase by 48%, from 166,000 in 2010 to 245,970 in 
2050 [8]. With a recurrence rate varying between 29 and 58% [9-12], this will lead to high 
numbers of women suffering from recurrent POP. These predictions not only have 
implications for the individual patient but also for society, as this will lead to a 
considerable increase in health care costs. Since the total costs for POP surgery in 2005 
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were already 144 million euros in Germany, and 81 and 83 million euros in France and 
England, respectively, this increase in costs may be considered substantial [13]. 
Additionally, it will put a significant pressure on the health care providers taking care of 
these women. These predictions underline the importance of developing improved 
therapeutic and, ultimately, preventive strategies for POP. 
 
THERAPEUTIC OPTIONS IN POP 
When a patient needs treatment for POP, management basically falls into two main 
categories: nonsurgical, which includes pelvic floor muscle training (PFMT) and pessary 
use, versus surgical treatment, which can be reconstructive - with or without mesh 
material - or obliterative [14]. As for the nonsurgical treatment options, a recent review 
showed that PFMT led to a significant improvement of prolapse symptoms and anatomical 
POP, however without reducing the need for further treatment [15]. Furthermore, it is 
known that adherence to PFMT programs is suboptimal. Pessary therapy is considered to 
be patient-friendly, safe, with high patient-satisfaction and relatively harmless side effects. 
However, side effects do appear in more than 50% of women with long term pessary use, 
which could be one of the reasons that continuation rates of more than 5 years are low 
(14-48%), especially in younger women (< 65 years of age). Furthermore, women who are 
sexually active tend to prefer surgery above conservative therapeutic measures [16]. 
As for the surgical treatment options, it is known that surgery with native tissue repair, 
especially in the anterior compartment, has a high rate of recurrence. Therefore, 
alternative repair methods were developed, i.e., with mesh materials. According to the 
latest Cochrane review [17], anterior colporrhaphy has a significantly higher recurrence 
rate as compared to any transvaginal polypropylene mesh (46% vs. 14%, relative risk (RR) 
3.23; 95% confidence interval (CI) 2.55 to 4.10), with a significantly higher subjective failure 
rate as well (28% vs. 17%, RR 1.64; 95% CI 1.24 to 2.16). However, recurrences in the apical 
or posterior compartment and de novo stress urinary incontinence occur significantly 
more often with transobturator meshes than for native tissue anterior repair. Additionally, 
mesh erosions are reported in 11.4% of patients, with surgical interventions being 
13
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performed in 6.8%. Taken together, this makes mesh repair indeed a better treatment 
option regarding cure rate, but at the expense of more as well as more serious side effects. 
 
RISK FACTORS 
In order to be able to develop effective preventive measures, knowledge about risk factors 
for the development of POP is essential. These risk factors have been the subject of many 
scientific studies. If one thing has become clear, it is that the etiology of POP is complex 
and multifactorial. 
Often-mentioned risk factors are age, parity, vaginal delivery, menopause and high BMI. 
Nevertheless, studies investigating these different risk factors often show conflicting 
results [5, 6, 18-27]. Moreover, those factors do not explain why some normal-weight, 
nulliparous women already develop POP at a very young age, whereas other multiparous 
women never develop POP during their lives. Apparently, not all women are equally 
susceptible to the (environmental) risk factors for developing POP. 
A trusted model for the development of pelvic floor dysfunctions - including POP - was 
described by Bump and Norton [28]. They divided the different risk factors into 
predisposing factors (e.g., hereditary factors, collagen distribution), inciting factors (e.g., 
vaginal delivery), promoting factors (e.g., obesity) and decompensating factors (e.g., 
aging). 
In recent years increasing evidence showed that hereditary factors play an important role 
in the development of POP. Jack et al. [29] analysed the inheritance pattern of POP in ten 
families of women with early development of POP and demonstrated that the disease was 
inherited in a dominant way with incomplete but high penetrance. Moreover, sisters of the 
index patients had a fivefold increased risk of developing POP themself, as compared to 
women in the general population. Subsequent family studies confirmed this finding, 
showing that a positive family history of POP puts a woman at increased risk of developing 
POP herself [19, 24, 30-32]. In fact, studies that also took environmental factors into 
account [33, 34] still demonstrated a familial predisposition to POP, which further suggests 
an important role for hereditary factors in the development of POP. 
CHAPTER 1
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PATHOGENESIS: THE COLLAGEN-HYPOTHESIS 
In search for the underlying pathophysiological mechanism of POP, Jackson et al. [35] were 
the first to publish a hypothesis underlining the importance of collagen. Based on the 
analysis of vaginal tissue of premenopausal women with and without POP, they reported 
that vaginal tissue of women with POP showed an altered collagen metabolism, with a 
decreased total collagen content and an increased collagen turnover. Especially immature, 
newly formed collagen was degraded more rapidly, resulting in an increased amount of 
mature collagen, which is supposed to be more fragile. This finding was confirmed by the 
review of Kerkhof et al. [36]. In general, the collagen I/III ratio was decreased, which likely 
results in increased tissue laxity. 
A reduction in collagen I/III ratio was also found in the skin and anterior rectus sheath 
fascia of patients with a primary and recurrent inguinal or incisional hernia [37]. The same 
was true for the collagen I/III ratio of the vascular wall of patients with varicose veins [38]. 
Other support for the collagen-hypothesis as the common denominator in a group of 
‘collagen-associated disorders’, came from studies in women with Ehlers-Danlos syndrome 
(EDS). EDS is an inherited disorder that can be caused by multiple defects located in genes 
encoding collagen type I, III or V or in one of the genes encoding enzymes that are 
involved in the collagen biosynthesis [39]. Women with EDS have a known increased risk 
of developing POP [40]. In addition, EDS patients can show a wide variety of clinical 
manifestations including joint hypermobility, cardiac valve prolapse, arterial aneurysms, 
recurrent rectal prolapse in early childhood and inguinal, umbilical or other hernias [39], all 
linked to a generalized connective tissue/collagen weakness. 
To further confirm this hypothesis, investigators [41-44] have been studying the 
relationship between the amount of collagen and other components of the extracellular 
matrix (ECM) in end organs such as the vaginal wall and pelvic ligaments. The problem 
with these studies is that they cannot prove whether these changes are a cause or 
consequence of POP. The question remains whether there is tissue weakness because of 
the changes in collagen and other ECM components or whether these changes are the 
result of the stretching of tissue due to POP. Furthermore, it is not only the number of 
affected ECM components that counts as changes in the molecular structure of the 
different ECM components may alter the strength of the ECM as a whole, without altering 
15
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their number. Therefore, the focus has shifted from studying changes in end organs to 
changes in the genes encoding for the components of the ECM [45-47]. 
 
THE GENETICS OF A COMPLEX DISORDER SUCH AS POP 
Generally speaking, there are two types of genetic disorders; monogenic or single gene 
disorders vs. polygenic or complex disorders. The vast majority of the genetically 
determined disorders belong to the last group. 
A monogenic disorder is a disorder caused by a mutation in a single gene (also called a 
Mendelian disease) [48], possibly minimally influenced by modifier genes or 
environmental factors. Examples are sickle cell disease and cystic fibrosis [49]. On the 
contrary, a complex disorder is thought to be caused by a combination and interplay of 
multiple genetic variants/risk factors, each with a (relatively) small effect, and various 
environmental factors [49]. In this way, combinations of different genetic variants and 
environmental risk factors can cause the same disease in individual patients [50], which is 
the case for e.g., diabetes [51, 52], hypertension [53, 54] and POP [55]. 
In broad terms, genetic susceptibility factors can be divided into rare and common 
variants. Rare genetic variants include mutations in single genes that cause monogenic 
disorders (see above) and copy number variations (deletions or duplications of one or 
more genes). Common genetic variants are typically single nucleotide polymorphisms 
(SNPs) that are often not located in (the protein-coding part of) genes and are identified 
through candidate gene and genome-wide association studies [56]. 
 
GENETIC RESEARCH 
Basically, there are two ways of conducting genetic research, i.e., in a hypothesis-driven 
and hypothesis-free manner. 
In case of hypothesis-driven research, the focus is on one or more candidate genes that are 
expected to be causally related to the disorder based on the presumed function of the 
CHAPTER 1
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proteins they encode and theoretical knowledge about the pathogenesis of the disorder 
in question. Typically, one or more SNPs that are located in one candidate gene are 
studied for their association with the disorder using this type of genetic research. For 
example, SNPs in the ECM-linked genes COL1A1 [57], FBLN5 [58], and MMP9 [59] have been 
studied for their association with POP. 
There are different types of hypothesis-free genetic research. The best-known method is 
the genome-wide association study (GWAS), in which hundreds of thousands of SNPs 
across the genome - covering all protein-coding genes - are tested for association with a 
disease in a large sample of cases versus controls (consisting of hundreds to thousands of 
individuals) [50]. Although being thorough and extensive, current GWASs are only able to 
detect relatively common SNPs with a so-called minor allele frequency (MAF) of > 5%, 
leaving out the more rare SNPs [50]. Furthermore, the SNPs that are identified through 
GWASs are often located in the non-protein coding part of genes or outside genes, and 
thus, as opposed to mutations - SNPs or other, more complex variants in the coding parts 
of a gene (the exons) - they do not give rise to direct changes in protein structure and 
hence protein function. Instead, those SNPs may act by altering gene expression. 
A second and more recently developed hypothesis-free method that identifies genetic 
variants for polygenic conditions is sequencing, i.e., not just screening for a very large 
number of SNPs but identifying the exact nucleotide order of the DNA. This sequencing 
can be done for the whole genome (whole-genome sequencing, WGS) or for the exome, 
all exons from all protein-coding genes combined (exome sequencing, ES) of disease cases 
and controls. Both methods are able to detect rare variants, including SNPs with a MAF < 5 
% (see above) [60]. 
Because WGS and ES are still relatively expensive when conducting large-scale genetic 
research, exome genotyping arrays (or exome chips) were introduced as an affordable 
alternative. Exome chips are designed to focus on (relatively) rare SNPs in the exome, 
implying that in comparison with GWAS [61], the identified variants affect protein 
structure and hence function (see above) more directly. 
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OUTLINE OF THE THESIS 
The general goal of this thesis was to identify genetic risk factors and biological processes 
contributing to POP etiology. 
The specific aims of this thesis were: 
- To provide an overview of the available literature evidence on the relation between 
POP and a positive family history of the disease, and to investigate this relation in an 
independent cohort (Chapters 2 and 3). 
- To assess the relation between POP and other disorders known to be associated with 
changes in collagen composition (Chapter 3). 
- To investigate, using polymerase chain reaction - restriction fragment length 
polymorphism (PCR-RFLP) analysis, whether SNPs in the alpha 1 chain of the type III 
collagen protein-encoding gene (COL3A1) are associated with POP (Chapter 4). 
- To test the reliability of the high resolution melting (HRM) analysis as an alternative for 
PCR-RFLP analysis in the detection of rs1800255, a SNP in COL3A1 (Chapter 5). 
- To test the association between POP and rs1800255 with HRM analysis in a case cohort 
study (Chapter 6). 
- To identify exonic variants that are significantly associated with POP by using exome 
chip analysis (Chapter 7). 
- To build a molecular landscape in which the significant genes from the exome chip 
analysis and other POP candidate genes/proteins implicated through the literature are 
integrated and that provides novel insights into the mechanisms that are involved in 
the POP pathogenesis and leads for novel drug targets (Chapter 7). 
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ABSTRACT 
Introduction and hypothesis 
There is growing evidence that pelvic organ prolapse (POP) is at least partly caused by 
underlying hereditary risk factors. The aim of our study was to provide a systematic 
literature review and meta-analysis of clinical studies on family history of POP as a risk 
factor for POP in individual women. 
Methods 
The databases PubMed and Embase were searched. Clinical studies reporting on family 
history of POP in relation to POP in individual women were included. 
Results 
Sixteen studies were included, of which eight enabled us to calculate a pooled odds ratio 
(OR). The pooled OR of POP in case of a positive family history of POP was 2.58 (95% 
confidence interval 2.12-3.15). 
Conclusions 
Women with POP are substantially more likely to have family members with the same 
condition compared to women without POP. This strengthens the hypothesis that genetic 
predisposition plays an important role in the development of POP.  
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INTRODUCTION 
Pelvic Organ Prolapse (POP) is a major health care problem with prevalence varying from 8 
to 41% [1, 2] and has a substantial impact on quality of life [3]. Women with POP 
symptoms not only experience physical complaints, but also encounter more problems 
regarding general health, personal relationships and sexual function [3]. 
In order to reduce the number of women developing POP, it is important to know the 
possible risk and protective factors. The aetiology of POP is considered to be multifactorial. 
Research groups investigated a large variety of risk factors for POP, such as parity [2, 4-11], 
body mass index (BMI) [2, 4, 5, 7, 8, 10-13], menopausal state [4, 7-10, 12, 14] and previous 
hysterectomy [2, 9, 11, 13] with often conflicting results. One of the reasons for these 
conflicting results might be the fact that not all women are equally susceptible to POP. 
Some women with multiple risk factors never develop POP, whereas others with little to 
no risk factors develop POP [15], sometimes already at a young age. Bump and Norton [16] 
were the first to describe a model for the development of pelvic floor dysfunctions. They 
divided the different risk factors into predisposing factors (e.g. hereditary factors, collagen 
distribution), inciting factors (e.g. vaginal delivery), promoting factors (e.g. obesity) and 
decompensating factors (e.g. aging). 
There is growing evidence that predisposing hereditary factors are indeed important in 
the development of POP. For instance, Buchsbaum et al. [17] found a high rate of 
concordance between the POP stage of a parous woman and her nulliparous sister, 
thereby suggesting a familial predisposition toward the development of this disorder. 
Altman et al. [18] investigated the prevalence of surgical treatment for POP in both 
dizygotic and monozygotic female twin pairs, knowing that dizygotic twins share 
approximately 50 % of their DNA, while monozygotic twins are 100 % identical. They 
found that the influence of genetic factors was substantial, attributing to 40 % of the 
variation of liability for POP. Analysis of the familial inheritance pattern of POP was 
performed by Jack et al. [19]. They studied ten families of young women presenting with 
severe POP. In these families, POP was transmitted in a dominant fashion with an 
incomplete, but high degree of penetrance, through both maternal and paternal relatives. 
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A genetic risk for developing POP in members of affected families has important 
implications for clinical practice. Individual risk assessment for POP and POP recurrence 
might have consequences for both preventive strategies and the choice of (surgical) 
treatments. 
The aim of our study was to provide a systematic literature review and meta-analysis of 
clinical studies on family history of POP as a risk factor for POP in individual women. 
 
MATERIALS AND METHODS 
The databases PubMed and Embase were searched in association with a senior librarian up 
to 1 June 2011. The search terms used for each database included different terms for POP, 
genetics, inheritance and family and are presented in detail in the Appendices 1 and 2. 
References of relevant studies were cross-checked for additional studies. Two authors (S.L. 
and K.K.) evaluated all studies independently. Any disagreement was discussed and 
resolved in a consensus meeting. 
Clinical studies reporting on familial history of POP in a cohort of women with and without 
POP were included. In case a study only provided information on family history in the POP 
group, this study was included as an “uncontrolled study”. Publications reporting on 
patients with symptoms other than POP such as incontinence, rectal prolapse, perineal 
descent, ureterocele and/or urethral prolapse only were excluded as well as review articles, 
case reports and studies reporting on less than ten (index) patients. Different studies 
reporting on the same patient cohort were included once. There were no language 
restrictions. 
In all relevant studies data on study design, study population, sample size, analyses for 
possible confounders, definition of POP, definition of positive family history and baseline 
characteristics were collected. The baseline characteristics that were taken into account 
were age, parity, vaginal deliveries, menopausal status, previous surgery for POP, previous 
hysterectomy and BMI. Most importantly, data on positive family history of POP in relation 
to absence or presence of POP in the (index) patient were collected. In case an article did 
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not provide the above-mentioned information, authors were asked to supply the data 
needed within an acceptable time frame. In case of missing data with regard to family 
history in relation to individual POP status, these data were excluded from final analysis. 
The number of patients with a positive family history in both POP and control groups was 
used to calculate the crude odds ratio (OR) of each study. The pooled OR with the 95 % 
confidence interval (CI) is presented. The heterogeneity index (I2) was used to measure the 
inconsistency between the studies [20]. 
 
RESULTS 
Results of the search 
The PubMed search revealed 3,531 studies, and the Embase search revealed an additional 
609 studies. No studies were revealed by cross-checking; 4,085 of these studies could be 
excluded on the basis of title and/or abstract. The remaining 55 studies were read by 
paper. In total 16 studies fulfilled the inclusion criteria. The reasons for excluding the other 
39 studies are indicated in Fig. 1. The (twin) sister studies were excluded because although 
these studies evaluated POP in the (twin) sister, they did not investigate the presence of 
POP in all sisters. The results of these studies were therefore not a reliable representation 
of the family history. 
Study design and participants 
In total 4,354 participants were included in this meta-analysis and review: 2,413 women 
with POP and 1,941 without POP (Tables 1 and 2). Of the 2,413 cases with POP, 1,107 could 
be included in the meta-analysis. The remaining 1,306 were included as uncontrolled 
studies. 
The 16 included studies consisted of 7 cohort studies and 9 case-control studies (Tables 1 
and 2). Four of the case-control studies were designed as matched case-control studies, 
matching for age [21-24], parity [21, 22, 24], menopausal status [22], hospital at which 
hysterectomy was performed [22], year of surgery [22], indication [22] and type of surgery 
[22]. In two of the nine case-control studies [23, 25], only the women with POP were asked 
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whether they had relatives with POP. Therefore, only the women in the POP group were 
included for analysis in this review. In two of the case-control studies [22, 26] the control 
group contained some women with previous POP surgery. Since this could not be 
regarded as a valid control group, the studies were classified as uncontrolled. Four cohort 
studies [27-30] did not include a control group and only reported on women with POP. In 
all other studies both women with and without POP were asked whether they had a 
positive family history of POP. Two studies only included women with a previous 
hysterectomy [22, 26]. 
Figure 1. Database search flow chart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n = number of studies 
Studies excluded after 
reading title and abstract 
n = 4085 
Evaluation of full text article 
n = 55 
Studies identified from electronic 
database search 
PubMed (n = 3531) 
Embase (n = 609) 
n = 4140 
Excluded studies          n 
- Review, clinical opinion or commentary        6 
- No outcome measurement of interest      22 
- (Twin-)sister study          4 
- Positive family history as inclusion criterion    3 
- Same study population used         3 
- Family history only known in nulliparous    1 
- Total         39 
Studies included in systematic 
review 
n = 16 
Controlled studies 
n = 8 
Uncontrolled studies 
n = 8 
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Definition of POP 
The definition of POP varied between studies (Tables 1 and 2); four studies used the Pelvic 
Organ Prolapse Quantification (POP-Q) system of which two defined POP as POP-Q stage 
≥II [21, 27] and one as POP-Q stage III/IV [8]. One study provided information on all 
different POP-Q stages [31]. We decided to choose POP-Q stage ≥II as a cut-off point. Three 
studies used the Baden-Walker halfway scoring system; one defining POP as Baden-Walker 
grade 2 [25], one as ≥grade 1 [32] and one as second- or third-degree uterovaginal 
prolapse and/or third-degree cystocele [4]. Three other studies did not mention any 
classification system but used the terms “below the hymenal remnants” [22], “≥grade 2” 
[23] and uterine prolapse stage II/III [28] without referring to any grading system. In six 
studies, the POP group consisted only of women who had either undergone POP surgery 
or were scheduled for it [22, 23, 25-28]. Three of these studies used POP surgery or vaginal 
vault surgery as the definition of POP, without further defining the severity of POP [26, 29, 
30]. In addition three studies used symptoms as assessed with questionnaires to identify 
women with POP [7, 24, 33]. 
 
Definition of family history 
The definition of family history was not homogeneous throughout the studies either; two 
studies included both mother and sisters in the family history [27, 33], one study included 
mother and grandmothers [21], one study mother, grandmothers and sisters [29], two 
studies only the mother [4, 7] and two studies all first-degree family members [8, 30]. 
Six studies did not specify the degree of relationship [22, 24-26, 28, 31]. A special remark 
should be made regarding the study of McLennan et al. [32], as they also included male 
and female relatives with a history of hernia. With the data provided, we were not able to 
recalculate the number of women with only family members affected with POP. 
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Baseline characteristics 
Baseline characteristics of the 16 included studies are outlined in Tables 1 and 2. Table 1 
presents baseline characteristics of the controlled studies and Table 2 of the uncontrolled 
studies. 
 
Statistical power 
Only three studies [21, 26, 33] reported that a power analysis was performed for sample 
size calculation. The power calculation of the study of Braekken et al. [21], however, was 
based on the expected difference in joint hypermobility. 
 
Confounders 
Except for the study of Sewell et al. [31] all individual studies considered possible 
confounding factors, either through statistical analyses or through study design. 
 
Results on family history of POP 
The (crude) ORs of the eight controlled studies are presented in a forest plot (Fig. 2). All but 
two studies [21, 31] showed a statistically significant difference in the prevalence of 
positive family history of POP between women with POP and women without this 
condition. 
Eight studies [23, 25-30] only investigated family history in women with POP. Therefore, no 
OR could be calculated. The number and percentages of women with a positive family 
history in these studies are shown in Table 2. 
The overall OR of POP in case of a positive family history of POP as compared to a negative 
family history was 2.58 (95 % CI 2.12-3.15). Note that the study of McLennan et al. [32] also 
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included male and female relatives with a history of hernia. When excluding this study, the 
OR was slightly different (2.54; 95 % CI 2.02-3.20). 
Finally, we also calculated the pooled OR, using the adjusted OR if presented in the 
individual studies (data not shown). By using these data, we found that the pooled OR was 
lower but still statistically significantly larger than 1. 
Figure 2. Forest plot of the eight controlled studies 
Results for family history and recurrences of POP 
One study [27] analysed risk factors for the recurrence of POP in 212 women undergoing 
surgery for symptomatic POP. After a median follow-up of 24 months (range 1-84 months), 
36 patients (17 %) presented with recurrence of POP. After correcting for other possible 
risk factors, such as age, parity, mode of delivery and BMI, family history was not found to 
be a risk factor for the recurrence of POP. Only preoperative POP-Q stage IV appeared to 
be associated. 
Abbreviations: M-H, Mantel-Haenszel; Fixed, fixed effect model; 
POP, pelvic organ prolapse; Neg, negative; Pos, positive. 
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DISCUSSION 
Summary of main results 
This paper summarizes the available literature on family history of POP in women with and 
without POP. All but two studies [21, 31] found a statistically significant difference in the 
prevalence of positive family history between women with POP and women without this 
condition. A meta-analysis of these studies resulted in a substantially increased risk for 
POP in case of a positive family history. In conclusion, there is strong evidence that women 
with at least one female family member with POP have a significantly higher risk of 
developing POP. 
This suggests an underlying genetic susceptibility. Over recent years, different research 
groups have been looking for possible gene candidates, by searching for DNA 
polymorphisms associated with POP. A number of DNA polymorphisms associated with 
POP have been identified so far: laminin γ1 [34], estrogen receptor α and β [35, 36], 
progesterone receptor [37], collagen, type III, alpha 1 [38-41] and matrix 
metalloproteinase-9 [42]. However, not all studies find the same associations. Both Kluivers 
et al. [38] and Chen et al. [39] concluded that the AA genotype of the collagen, type III, 
alpha 1 (COL3A1) polymorphism in exon 30 was significantly associated with POP in 
Caucasian and Taiwanese females, respectively. However, Jeon et al. [40] found that the 
GG genotype of the COL3A1 polymorphism in exon 31 was significantly more prevalent 
among Korean women with POP, whereas Martins et al. [41] found no correlation between 
this COL3A1 polymorphism and POP in their population of Brazilian women. As was 
already suggested by Martins et al. [41], these differences could be explained by the fact 
that these studies were performed in ethnically different populations with different 
background risks of POP. 
Only one study so far looked at family history and the risk of recurrence of POP. If there is 
an underlying hereditary factor causing weaknesses in the pelvic floor, e.g. by changes in 
collagen strength, this might lead to impaired healing properties after surgery and 
therefore to more recurrences. If this is the case, first-line treatment with mesh material 
might be indicated for patients with positive family history. The study of Jeon et al. [27], 
however, did not find such an association and only found preoperative POP-Q stage IV to 
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be a risk factor for recurrence. This last finding is in line with the study of Salvatore et al. 
[43], who confirmed that preoperative stage ≥III was the only risk factor for recurrences. 
 
Uncontrolled studies 
As for the studies not included in the meta-analysis, the mean percentage of POP patients 
with a positive family history was 28%. This is comparable with the mean percentage of 
the controlled studies. It is notable that three of the studies [23, 25, 28] in the uncontrolled 
group consist of rather young women less than 40 years of age. One could hypothesize 
that when young women develop POP, there must be an underlying hereditary factor 
causing early decompensation of the pelvic floor. It might therefore be possible that those 
young women more often have family members with POP. The above-mentioned studies, 
however, do not show an increase in positive family history among these young women. 
This is in contrast with the study of Shilo et al. [30] that shows a more than fivefold increase 
in positive family history among women under the age of 45 years as compared to women 
above the age of 55. 
 
Strengths and limitations 
The strength of this review is that all articles on family history and POP were taken into 
account, without any language limitations. This resulted in a complete overview of studies 
in ethnically diverse populations, from the European, Asian and North and South American 
continents. It is therefore reasonable to suggest that the observed hereditary susceptibility 
is present in women worldwide, irrespective of possible population-dependent 
background risks. Nevertheless, it remains possible that different DNA polymorphisms are 
responsible for the increased risk of POP among women of different ethnic descent. 
In total eight studies could be used for the meta-analysis. Since these are all the studies 
available at the moment, we feel that we are drawing our conclusions on the best available 
evidence. Moreover, all studies point in the same direction, which makes it unlikely that 
additional research will alter our results drastically. 
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As can be seen in Table 1, baseline characteristics of the studies were not totally similar. In 
most studies, the mean parity was 1 to 2. However, the women in the POP group of the 
study of Rodrigues et al, had a mean of 4.5 deliveries. Besides, in some studies the women 
included were clearly younger than in other studies. Of course, this also had its influence 
on menopausal status. 
Likewise, the design of the studies was not always identical; five of the eight studies were 
case-control studies, whereas the other three were cohort studies. Furthermore, the 
definition of the POP and control groups differed between studies. 
Regarding the statistics used, we found no statistical heterogeneity between the studies 
(I2=0; p=0.47, χ2 for heterogeneity); therefore, the pooled OR is presented. 
As already said, the studies were not homogeneous regarding their definition of POP. Most 
studies used anatomical landmarks to divide women into case and control groups. Some 
however chose more strict criteria, e.g. only included women with POP-Q stage III or IV 
urogenital prolapse in the case group and women with POP-Q stage 0 or I in the control 
group [8]. It seems plausible that by applying more strict criteria, the difference in 
prevalence of positive family history between groups would be more pronounced. 
However, this was not depicted in our meta-analysis. 
Three studies [7, 24, 33] used questionnaires to define the presence or absence of POP. 
Symptoms of POP, however, do not always fully correspond to the existence of anatomical 
POP. For example, in the study of Samuelsson et al. [11] 10 % of the women with POP 
reported a “sense of heaviness in the lower abdomen” compared to 8 % of the women 
without anatomical POP, a difference that was not statistically significant. Barber et al. [44] 
performed a study to identify the symptoms that most accurately predicted the presence 
or absence of POP. They found that the question “Do you usually have a bulge or 
something falling out that you can see or feel in your vaginal area” had the best 
discriminative capability. The study of Tan et al. [45] confirmed that there was a significant 
relationship between symptoms of vaginal bulging and POP on gynaecological 
examination. The studies by Miedel et al. [33], Sharma et al. [24] and Slieker-ten Hove et al. 
[7] used this question for discriminative purposes and were therefore included in this 
review. 
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The definition of family history also varied between studies. It is likely that in studies using 
broader criteria, more women will report a positive family history. However, this is likely to 
be the same for both POP patients and controls. Therefore, this will not necessarily 
introduce bias. 
Except for three studies [7, 24, 33], all studies were performed among women visiting an 
outpatient department for regular check-up, prolapse complaints or other benign 
gynaecological conditions. These results therefore may not be generalizable to the general 
population. However, the results of the two cohort studies conducted in the general 
population [7, 33] and the population-based case-control study [24] show the same 
results. It seems therefore plausible that both in low- and high-risk populations positive 
family history is an important risk factor for the development of POP. 
Recall bias might play a role in the differences found between patients and controls. 
Because POP patients are more focused on POP complaints, they may be more aware of 
similar complaints in relatives and therefore more often report a positive family history 
compared to controls. However, evidence for recall bias was absent in comparable studies 
on family history of myocardial infarction and colorectal cancer [46, 47]. The controls in 
these studies reported family history in first- and second-degree relatives as accurately as 
the patients did. 
Finally, regarding possible publication bias, it needs to be noted that we only used 
published studies and abstracts for our review and meta-analysis. We performed a funnel 
plot and found no deviation from a symmetrical shape. Publication bias seems therefore 
unlikely. 
 
Authors’ conclusions 
This meta-analysis of 8 studies with 1,107 POP patients and 1,941 controls showed that 
women with POP are substantially more likely to have family members with the same 
condition compared to women without POP. This demonstrates that a positive family 
history is an important risk factor for POP. The fact that the uncontrolled studies showed a 
high percentage of positive family history in POP patients further underlines this 
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conclusion. It strengthens the hypothesis that genetic predisposition plays an important 
role in the development of POP. 
This information is important for clinical practice from a preventive point of view. 
Although not all known risk factors for POP may be modifiable, risk factors such as obesity 
[2, 10, 12] and heavy physical work [7] are. In addition, pelvic floor physiotherapy might 
reduce the risk of developing POP. Although statistical evidence that (peripartum) pelvic 
floor exercises can decrease the risk of developing POP later in life is lacking [48], it is 
known that pelvic floor muscle function is significantly related to POP [21]. Furthermore, a 
recent study showed that pelvic floor muscle training supervised by a physical therapist 
leads to an increased volume of the pubovisceral muscle, a decreased hiatal area and an 
elevated resting position of the bladder and rectum [49]. This suggests that pelvic floor 
physiotherapy can play a role in primary and secondary prevention of POP and might 
therefore be of great importance in women with an increased risk of POP. 
Vaginal delivery can have a detrimental effect on pelvic floor muscle strength and could 
thus promote POP. Although there are some studies reporting an association between 
caesarean section and a reduced prevalence of POP [50, 51], the preventive value of a 
primary caesarean section is unproven. A recent large study [52] did not find a significant 
difference between frequency of POP 20 years after caesarean or vaginal birth. Since a 
caesarean section is an invasive procedure with potentially substantial risks for the mother, 
we do not advocate this until there is more evidence of a protective effect available. 
In conclusion, we summarized the evidence available on family history as a risk factor for 
the development of POP. Our primary conclusion was that there is a substantially 
increased risk for POP in case of a positive family history. This knowledge might influence 
the way patients with a positive family history could be treated. From a preventive point of 
view, patients could be informed about risk factors and how to try to avoid them and 
could be advised to perform pelvic floor exercises before problems arise. Until now, there 
is no evidence that vaginal delivery should be discouraged. On theoretical grounds, first-
line treatment with mesh material might be indicated for patients with positive family 
history. To the best of our knowledge, no studies on this topic have been conducted so far, 
so this hypothesis should be the subject of future research. 
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APPENDICES 
Appendix 1. Full PubMed literature search terms 
(("genetics"[MeSH Terms] OR "genetics"[Subheading] OR "Genetic Predisposition to 
Disease"[Mesh] OR genetic* OR inheritance OR family OR families OR familial OR gene OR 
genes OR DNA)) AND ("Pelvic Organ Prolapse"[Mesh] OR ((pelvic OR vaginal OR uterus OR 
bladder OR rectum OR rectal OR bowel OR vagina OR urethra OR perineal OR perineum OR 
uterine OR cervix OR cervical OR vault OR cuff OR genital OR urogenital) AND (descent OR 
prolapse)) OR uterine prolapse OR rectal prolapse OR cystocele OR rectocele OR enterocele 
OR proctocele OR sigmoidoceles OR peritoneocele OR ureterocele OR cystourethrocele OR 
cysto-urethrocele OR pelvic floor dysfunction). 
Appendix 2. Full Embase literature search terms 
exp genetics/ or genetics.fs. or exp genetic predisposition/ or (genetic* or inheritance or 
family or families or familial or gene or genes or DNA ).mp. AND exp pelvic organ prolapse/ 
or ((pelvic or vaginal or uterus or bladder or rectum or rectal or bowel or vagina or urethra 
or perineal or perineum or uterine or cervix or cervical or vault or cuff or genital or 
urogenital).mp. AND (descent or prolapse).mp.) or (uterine prolapse or rectal prolapse or 
cystocele or rectocele or enterocele or proctocele or sigmoidoceles or peritoneocele or 
ureterocele or cystourethrocele or cysto-urethrocele or pelvic floor dysfunction).mp. 
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ABSTRACT 
Introduction and hypothesis 
Pelvic organ prolapse (POP) and other disorders, such as varicose veins and joint 
hypermobility, have been associated with changes in collagen strength and metabolism. 
We hypothesized that these various disorders were more prevalent in both POP patients 
and their family members. 
Methods 
In this study, the prevalence of various collagen-associated disorders, including POP, was 
compared between POP patients (n=110) and control patients (n=100) and their first and 
second degree family members. 
Results 
POP patients reported a higher prevalence of varicose veins, joint hypermobility and rectal 
prolapse and were more likely to have family members with POP as compared to the 
control group (p<0.01). In contrast, the family members of the POP group did not report a 
higher prevalence of collagen-associated disorders compared to the family members of 
the control group (p=0.82). 
Conclusions 
POP and other collagen-associated disorders may have a common aetiology, originating at 
the molecular level of the collagens.  
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INTRODUCTION 
Pelvic organ prolapse (POP) is a common condition among adult vaginally parous women 
of all ages, with reported prevalence numbers up to 37% [1]. It has previously been stated 
that an alteration in collagen metabolism is relevant in the aetiology of POP. Jackson et al. 
have formulated this finding in 1996, and it has been supported since [2, 3]. 
Collagen is a fibrous protein and the main component of connective tissue. It provides 
tensile strength to skin, tendons and bones [2]. In the 1930s, the first evidence for a regular 
structure of collagen molecules was found, and so far, more than 20 subtypes have been 
identified. Types I, III, and V are the principal components to provide strength to soft 
tissues. Collagen type I is non-elastic and confers great resistance to tensile forces, whereas 
collagen type III has elastic properties and is prevailing in more flexible tissues. Both type I 
and III collagens are present in granulation tissue during wound repair [3]. Type V collagen 
is a quantitatively minor fibrillar collagen, but it is widely distributed in a variety of tissues 
[4]. An increase in collagen type III and V is associated with a decrease in mechanical 
strength of connective tissue due to decreased fibre size. It is generally agreed that a 
higher I to III ratio in tissues is indicative of greater strength, whereas a lower ratio may 
result in tissue laxity [3]. Collagen-associated disorders may arise from genetic defects, 
which can affect any step in the normal collagen production. 
The most eminent inherited collagen-associated disorder is the Ehlers-Danlos syndrome 
(EDS). This syndrome consists of a heterogeneous group of clinical features caused by 
underlying defects in the collagen type I, III, and V gene as well as defects in proteins 
important for the post-translational modifications and processing of these collagens [5]. It 
is known that female patients with EDS have a higher risk of developing POP [6]. Besides, 
both male and female patients with one of the different subtypes of EDS reported a higher 
prevalence of joint hypermobility; arterial rupture; rupture of diaphragm; atrophic scarring; 
varicose veins; cardiac valvular disease, such as cardiac valve prolapse; rectal prolapse and 
inguinal, umbilical or other hernias [5]. Other investigators have focused on these different 
diseases in the general population and their relation to collagen. They found changes in 
collagen quantity or composition of the different collagen subtypes in for example 
patients with POP [2, 3], inguinal hernia [7-10], varicose veins [11-13], arterial aneurysm 
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[14] and joint hypermobility [15]. This suggests a common pathophysiologic pathway for 
both POP and the above-mentioned disorders. 
If changes in collagen are an underlying cause of all these disorders, one would expect 
that they coexist in the same patient. Moreover, if these collagen changes are based on 
genetic defects, family members of these patients are expected to be affected more often. 
Miedel et al. have found that a history of conditions suggestive of deficient connective 
tissues, such as varicose veins, hernia and hemorrhoid, was significantly associated with 
symptomatic POP in these women [16]. Furthermore, it has been reported that patients 
with abdominal aorta aneurysm are at higher risk for inguinal hernia repair and abdominal 
wall hernias [17, 18] and that POP patients more often report joint laxity [19-21]. Until now 
however, it is not known whether the incidence of these collagen-associated disorders is 
higher in families of women with POP, which would be expected in case of inheritable 
collagen disorders. 
The aim of this study was to assess the association between POP and other collagen-
associated disorders. We hypothesized that POP patients more often have concomitant 
collagen-associated disorders as compared to controls. Furthermore, we hypothesized 
that these various disorders, including POP, are more prevalent in the genetically related 
first and second degree family members of POP patients than in family members of 
controls. 
 
MATERIALS AND METHODS 
An observational cohort study was conducted among consecutive gynaecological patients 
between January 2007 and August 2010 at the Department of Obstetrics and Gynaecology 
of the Radboud University Nijmegen Medical Centre, the Netherlands. During the study 
period, all these patients underwent gynaecological examination and they completed a 
questionnaire on parity and hormonal status, smoking habits, weight, height and medical 
and surgical history. Besides, information on POP in their first and second degree female 
family members was obtained. Additionally, detailed questions on the presence of 
conditions suggestive of deficient connective tissue in the patients and their family 
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members were completed by the patients presenting at our department between January 
2009 and August 2010. 
Data were also used from women previously included in another study protocol, in which 
female family members were elaborately interviewed on their medical history, including 
specific questions on gynaecological history. Data were collected either by telephone 
interview or by written questionnaire. The primary outcome of that study was the 
prevalence of premature ovarian failure (POF, i.e. amenorrhea before age of 40 years) in 
families with a patient with Fragile X syndrome [22]. These women did not undergo 
gynaecological examination at our department. 
All our gynaecological patients as well as the first female family member of the families 
that were interviewed for the POF study are subsequently referred to as index cases. 
Index cases were considered a “POP index case” if they had clinical signs of POP on 
gynaecological examination (POP-Q stage two or higher) [23] and/or had undergone POP 
surgery in the past. Women who were not examined at our department, but who had 
undergone POP operation(s) previously or were diagnosed with POP by a medical 
professional, were also included in this group. 
Women were classified as being a “control index case” if they had no signs and symptoms 
of POP, at the time of the study or in the past. Female family members were considered as 
having POP if they had undergone POP operation(s) previously or were diagnosed with 
POP by a medical professional. 
Index cases and first and second degree family members, both male and female, were 
considered as having a collagen-associated disorder if they had a history of one or more of 
the following diseases: arterial aneurysm, inguinal hernia, cardiac valve prolapse, varicose 
veins, intervertebral disc displacement (i.e. nucleus pulposus hernia), umbilical hernia, 
joint hypermobility and rectal prolapse. Joint hypermobility was considered present if a 
person responded positive on the question if they had ever had a luxation or sprain of a 
joint. Subsequently, these eight disorders are referred to as the collagen-associated 
disorders. Two disorders were assessed separately with one being fascia wound 
dehiscence and the other diaphragmatic hernia. Fascia wound dehiscence was mentioned 
separately because to develop this disorder, one had to have undergone abdominal 
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surgery and furthermore, fascia wound dehiscence could be the result of operation 
technique. Diaphragmatic hernia was assessed separately because this might be the result 
of an embryologic development disorder which does not necessarily reflect a collagen-
associated disorder as such and moreover, this disorder might be present without the 
patient knowing. 
Both POP and control index cases had to fulfill two inclusion criteria: because POP in 
general develops later in life, all index cases had to be 50 years or older at the time of 
participation. Since vaginal delivery is regarded as the major risk factor for the 
development of POP, all index cases had to be vaginally parous as well. Exclusion criteria 
for all index cases were the presence of genetic diseases with a known increased risk of 
POP, such as Ehlers-Danlos syndrome, and furthermore, inadequate comprehension of the 
Dutch language. 
The study protocol was approved by the institutional research ethics committee under 
number CMO 2007/043 and informed consent was obtained from all participants. 
 
Statistical methods 
The Kruskal-Wallis test was used to test differences between the two groups for statistical 
significance in case of continuous variables and the Fisher’s exact test was used in case of 
2x2 tables. Multivariate logistic regression was used to study possible confounders in the 
relation between presence of collagen-associated disorders and POP, using the index 
cases only. The dependent variable was presence of collagen-associated disorders. 
Confounders of interest in this study were: parity, BMI, smoking, menopause and 
pulmonary disease. Analyses were performed using SPSS 16.0 (Chicago, IL, USA) for 
Windows. p values below .05 were considered statistical significant. 
 
RESULTS 
A total of 237 women met the inclusion criteria for index case. Of these, 165 were included 
during routine clinical practice and 72 were from the study on POF. Twenty-seven medical 
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records did not include information on collagen-associated disorders in either the patient 
or her family members, neither was there information available on the prevalence of POP 
in female family members and we were not able to obtain this information otherwise. 
These women were therefore excluded from analyses. Thus, 110 POP index cases and 100 
control index cases were included in this study. 
Figure 1 shows a flowchart of the study. The POP and control index cases are subdivided 
according to inclusion during routine clinical practice and inclusion from the POF-study. 
Figure 1. Flowchart of index cases included in the study  
  
 
27 index cases lost due to 
missing information 
 
 
 
 
 
 
 
 
 
 
 
 
 
POP, pelvic organ prolapse. POF, premature ovarian failure  
 
Table 1 shows the number of families of POP and control index cases by their number of 
siblings and their number of children. POP index cases had in 78% of the cases “average” 
sized families with 54 women having two children and 32 women having three children 
((54+32)/110=78%), compared to 67% in control index cases ((38+29)/100). Control index 
cases more often had larger families (≥5 children) compared to POP index cases (17% 
(17/100) and 5% (6/110), respectively). On average, the number of siblings was the same 
between both groups even though 7% (8/110) of POP index cases had two siblings 
237 index cases met 
inclusion criteria 
110 POP index cases 100 control index cases 
routine clinical 
practice 
POF-study 
n = 101 n = 9 
POF-study routine clinical 
practice 
n = 37 n = 63 
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compared to 17% (17/100) of control index cases. Consequently, more POP index cases 
had ≥5 siblings compared to control index cases, 45% (49/110) and 32% (32/100), 
respectively. 
 
Table 1. Size and structure of families of POP and control index cases 
  Number of Siblings   
 Number of Children 0 1 2 3 4 ≥5 Unknown Total 
POP 0 - - - - - - - - 
 1 - 3 1 1 3 3 2 13 
 2 1 3 5 11 5 21 8 54 
 3 - 3 1 2 3 19 4 32 
 4 - - - 1 1 3 - 5 
 ≥5 - - 1 1 1 3 - 6 
 Total 1 9 8 16 13 49 14 110 
Control 0 - - - - - - - - 
 1 1 - 2 3 - 3 1 10 
 2 1 2 7 1 9 12 6 38 
 3 - 3 5 5 1 11 4 29 
 4 - 1 1 1 1 2 - 6 
 ≥5 - 1 2 3 3 4 4 17 
 Total 2 7 17 13 14 32 15 100 
POP pelvic organ prolapse 
 
 
Table 2 outlines the baseline characteristics of the index cases as well as the number of 
collagen-associated disorders in both POP and control index cases and in their first and 
second degree family members. Both groups of index cases were comparable with regard 
to age, BMI, menopause and pulmonary disease. There was a statistical significant 
difference between both groups regarding number of children and smoking (p=0.03 and 
p=0.02, respectively). Varicose veins, hypermobility and rectal prolapse were significantly 
more often reported by POP index cases (p<0.01). Regarding the presence of at least one 
collagen-associated disorder, a statistical significant difference was found between both 
groups (p<0.01), with collagen-associated disorders being more prevalent in the group of 
POP index cases. Using logistic regression, the relation between POP and collagen-
associated disorders was similar after correction for parity and smoking. 
Mothers of POP index cases were nearly four times more likely to have (had) POP 
themselves as compared to mothers of control index cases (p<0.01) whereas sisters of POP 
index cases were nearly nine times more likely to have (had) POP compared to sisters of 
control index cases (p<0.01). 
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Table 2. Characteristics and disorders of POP and control index cases and their first and second 
degree family members 
 POP   Control  
Index cases Total n (%) or 
median 
[range] 
Total n (%) or 
median 
[range] 
p 
value 
Age [years] 110 63 [51–89] 100 64 [51–95] 0.37 
Children [number] 110 2 [1–11] 100 3 [1–10] 0.03 
BMI [kg/m2] 84 25 [17–41] 90 25 [19–42] 0.33 
Smokinga 65 21 (32) 83 38 (46) 0.02 
Menopauseb 93 89 (96) 94 89 (95) 0.14 
Pulmonary diseasec 54 7 (13) 84 9 (11) 0.09 
Collagen-associated disordersd       
- AAA 59 0 (0) 84 1 (1) 1.00 
- Inguinal hernia 55 0 (0) 84 0 (0) 1.00 
- Cardiac valve prolapse  58 0 (0) 84 2 (2) 0.51 
- Varicose veins 55 15 (27) 84 5 (6) <0.01 
- Intervertebral disc displacement 53 5 (9) 84 8 (10) 1.00 
- Umbilical hernia 53 3 (6) 84 2 (2) 0.38 
- Joint hypermobility 63 12 (19) 82 2 (2) <0.01 
- Rectal prolapse 53 13 (25) 84  0 (0) <0.01 
Presence of collagen-associated  
  disordere 
63 31 (49) 84  18 (21) <0.01 
Fascia wound dehiscence 53 2 (4) 84  1 (1) 0.56 
Diaphragmatic hernia 52 1 (2) 84  1 (1) 1.00 
First and second degree family members      
Prolaps        
- Mother 110 77 (70) 100 20 (20) <0.01 
- Sisters 231 78 (34) 166 6 (4) <0.01 
Collagen-associated disordersd        
- AAA 59 1 (2) 84 1 (1) 1.00 
- Inguinal hernia 55 7 (13) 84 1 (1) 0.62 
- Cardiac valve prolapse 58 0 (0) 84 2 (2) 0.23 
- Varicose veins 55 5 (9) 84 8 (10) 0.53 
- Intervertebral disc displacement 53 9 (17) 84 8 (10) 0.78 
- Umbilical hernia 53 0 (0) 84 1 (1) 0.48 
- Joint hypermobility 63 0 (0) 82 2 (2) 0.23 
- Rectal prolapse 53 0 (0) 84 0 (0) 1.00 
Presence of collagen-associated  
  disordere 
63 12 (19) 84 12 (14) 0.82 
Fascia wound dehiscence 53 0 (0) 84 0 (0) 1.00 
Diaphragmatic hernia 52 1 (2) 84 2 (2) 0.61 
p value for difference between POP and control groups using Fisher’s Exact test except for patient 
characteristics for which Kruskal-Wallis test was used 
POP pelvic organ prolapse, BMI body mass index, AAA abdominal aorta aneurysm 
a Including former smokers 
b Including post-menopausal women using hormone replacement therapy 
c Including asthma, chronic obstructive pulmonary disease, bronchitis and other pulmonary 
diseases 
d Multiple diagnoses per person possible 
e At least one of the collagen-associated disorders mentioned above 
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A minimal larger percentage of family members of POP index cases was affected by a 
collagen-associated disorder. Nineteen percent (12/63) of POP index cases had a family 
member that was affected, while this accounted for 14% (12/84) of the control index cases. 
This difference was not statistically significant (p =0.82). 
 
DISCUSSION 
In this observational cohort study, we assessed whether the prevalence of collagen-
associated disorders was higher among women with POP and among their first and 
second degree family members compared to controls and their families. The presence of a 
collagen-associated disorder, independent of the number of reported collagen-associated 
disorders, was statistically significant higher in the POP index cases as compared to 
controls. Varicose veins, joint hypermobility and rectal prolapse were each significantly 
more prevalent in the POP index cases. With regard to the families of the index cases, a 
higher prevalence of POP among female family members of POP index cases was found. 
With our data, we were not able to identify a difference between both groups regarding 
the prevalence of collagen-associated disorders in first and second degree family 
members. To our best knowledge, no previous study has assessed the combination of 
these various collagen-associated disorders together, in relation to POP. 
Our study revealed that mothers and sisters of POP index cases were respectively nearly 
four and nine times more likely to report POP as compared to mothers and sisters of 
control index cases. This is in line with findings of previous studies that reported a higher 
risk of POP in women with mothers or sisters reporting POP [24-28]. Even though the 
aetiology of POP is complex, it is recognized to be multifactorial in its origin with an 
eminent contribution of genetics. A large twin study showed that heritability contributes 
significantly to the occurrence of POP [29]. These observations support the hypothesis that 
a genetic predisposition to the condition exists and therefore we expected more collagen-
associated disorders in women with POP and their first and second degree family 
members. 
Prevalence of POP is significantly correlated with the occurrence of a collagen-associated 
disorder. The presence of either varicose veins, joint hypermobility or rectal prolapse is 
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individually correlated to the presence of POP. The finding that a higher prevalence of 
varicose veins amongst POP index cases as compared to controls exist, is in agreement 
with observations of Miedel et al. [16]. Furthermore, we confirm the previously reported 
association between self-reported joint hypermobility and POP [19-21, 30]. The study of 
Hansell et al. showed that the influence of common genes may underlie the association 
between elbow mobility and POP [31]. Furthermore, Knuuti et al. found that women with 
joint hypermobility and recurrence of POP have significantly high concentrations of type III 
collagen [32]. Together with our findings, it seems likely that a common defect affecting 
collagen strength or metabolism is responsible for these two disorders. Whether this is 
also the case for rectal prolapse, the third collagen-associated disorder individually more 
frequent observed in POP patients, will need to be confirmed in additional studies. From a 
clinical point of view, other risk factors such as chronic constipation, excessive straining, 
and age might be a major risk factor for rectal prolapse, although the higher prevalence of 
rectal prolapse in EDS patients makes a genetic susceptibility likely as well. The underlying 
cause is most likely a combination of both genetic and non-genetic risk factors. 
Collagen-associated disorders in relation to POP are still poorly understood. Until now, 
connective tissues have been assessed through biochemical evaluation of the collagen 
metabolism in the local tissues, and only few genetic polymorphisms have been studied 
[33, 34]. The available data on the changes in local collagen metabolism are often 
conflicting. Most recent studies found a decrease in collagen I to III ratio and a higher level 
of collagen type III in both POP and other collagen-associated disorders. A recent study by 
Haviarova et al., for example, reported a lower collagen I to III ratio and significantly more 
collagen type III in varicose vein walls [11]. This was, however, in contrast with a previous 
report on down-regulated collagen type III and a significantly higher level of collagen I, 
resulting in an increased collagen I to III ratio [12]. Strengthened by our present findings, 
we speculate that the common denominator is a change in collagen strength originating 
from a genetic defect. Due to stretch and repair, the disorder itself may then lead to an 
alteration in the local collagen metabolism. Detailed assessment of changes on a 
molecular level and the effects on collagen turn-over and tensile strength in relation to 
POP is needed to unveil a possible common molecular basis of collagen-associated 
disorders arising in POP patients. 
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 Although the large sample size is a clear strength of the present study, we are aware of 
some limitations. We have included index cases from two populations. Both provided us 
with valuable information, but had their own limitations. In one population, the index 
cases have undergone gynaecological examination to assess for signs of POP and 
completed a questionnaire on their own and family members’ medical history. In these 
women, we were not able to interview the family members directly. Their medical 
information was obtained through the index cases, which may lead to underreporting of 
the disorders. For future research, a questionnaire or telephone interview addressing all 
family members, might meet these objections. In the other population that we included in 
this study, we were able to interview all individual female family members, but we were 
limited by the fact that no gynaecological examination was available in these women. 
There is no known association between POP and the presence of Fragile X syndrome or a 
premutation for this syndrome. Therefore, we considered the risk to develop POP to be 
equal for all women included in our study. 
In the baseline characteristics, our control index cases had a statistically significant higher 
number of children and they were more likely to smoke or to have smoked in the past, as 
compared to the POP index cases. The difference in parity and smoking between both 
groups was not considered a confounder in this study, since the relation between POP and 
collagen-associated disorders remained the same after applying multivariate logistic 
regression. 
In conclusion, our study shows that women with POP are more likely to have first and 
second degree family members with the same condition. POP index cases are more likely 
to have a collagen-associated disorder. Furthermore, when assessing varicose veins, joint 
hypermobility and rectal prolapse individually, these conditions are more common 
amongst women with POP. A common aetiology of these disorders, originating at the 
genetic level of collagen, seems likely. In this study, however, this relation was confined to 
POP patients. 
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ABSTRACT 
Introduction and hypothesis 
A familial tendency has been demonstrated in the etiology of pelvic organ prolapse (POP), 
but the specific genetic defects have not been identified. Type III collagen is an important 
factor in the repair of connective tissue, and gene polymorphisms may impair the tensile 
strength. We hypothesized that polymorphisms in the alpha 1 chain of the type III collagen 
protein-encoding gene (COL3A1) pose women at risk for POP. 
Methods 
In this case-control study, the prevalence of type III collagen polymorphisms was 
compared in women with and without signs and symptoms of POP. 
Results 
Two hundred and two POP patients and 102 normal parous controls were included. A 
homozygous single-nucleotide substitution in the coding region of type III collagen 
(COL3A1 2209G>A, rs1800255) was identified in 27 (13%) POP patients and three (3%) 
controls (odds ratio, 5.0; 95% confidence interval, 1.4-17.1). 
Conclusions 
The probability of POP was higher in women with COL3A1 2209G>A. This polymorphism 
showed to be a relevant risk factor for POP. 
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INTRODUCTION 
A hereditary disposition of pelvic organ prolapse (POP) has been assumed since a long 
time. In addition to nongenetic risk factors such as vaginal delivery, a strong familial 
tendency has been demonstrated [1-3]. Excessive stretching and tearing of the pelvic 
ligaments and muscles as a result of vaginal delivery is considered the predominant risk 
factor for POP [4]. Genetically mediated abnormalities in connective tissues and 
connective tissue repair may further predispose women to POP. For example, women with 
hereditary connective tissue disorders such as Ehlers-Danlos type IV or Marfan syndrome 
are at an increased risk of POP [5]. 
A decrease in type I collagen and an increase in type III collagen, as well as an increased 
expression of proteolytic enzymes, have been previously reported in individuals with POP. 
Type I collagen is responsible for the lion’s share of tensile strength in ligaments, whereas 
type III collagen is of special importance in the tissue repair following delivery or in case of 
POP [6]. Type III collagen polymorphisms may result in a suboptimal tissue repair. These 
polymorphisms have been reported in various other diseases in which an impaired tensile 
strength may be part of the molecular pathophysiology, including mitral valve prolapse 
[7], vascular aneurisms or rupture [8-13], and coronary artery disease [14]. A small recent 
study has furthermore suggested that a polymorphism in the collagen type III alpha 1 
chain (COL3A1 rs1800255) was related to POP in Taiwanese women [15]. In view of the 
high prevalence of POP and the low incidence of these polymorphisms, more genetic 
defects in COL3A1 are expected. The hypothesis in the present case-control study was that 
polymorphisms in COL3A1 are more prevalent in women with POP compared with 
controls. 
 
MATERIALS AND METHODS 
Consecutive Dutch women with POP who presented at the Department of Obstetrics and 
Gynecology of the Radboud University Nijmegen Medical Centre between January 2007 
and August 2008 were asked to participate in the study. The department is known as a 
national tertiary referral center for urogynecological dysfunctions. Vaginally parous Dutch 
women, who were free of symptoms and signs of POP (i.e., descent ≥1cm above the 
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hymenal remnants) and had had no previous POP surgery, were asked to participate in the 
control group. Since vaginal delivery is regarded as the major risk factor for the 
development of POP, nulliparous women were excluded from the control group. Exclusion 
criteria for both groups were genetic diseases with a known increased risk of POP (such as 
Ehlers-Danlos, Marfan, and Steinert’s disease) and problems with regards to the patient’s 
understanding of the study. This study was approved by the local institutional review 
board under number CMO 2007/043, and informed consent was obtained in all women. 
Data on age, parity, and the number of previous surgical POP procedures were collected. 
In all women, the age in years on August 1, 2008 was used in the study. The women 
(patients and controls) were assessed for anatomical signs of POP using the standardized 
and validated Pelvic Organ Prolapse Quantification (POP-Q) system. The most descended 
edge of the descent of the anterior vaginal wall, cervix/vaginal vault, or posterior vaginal 
wall was assessed in relation to the hymenal remnants in the supine position and on 
maximum Valsalva maneuver. In case a previous POP-Q staging showed more severe POP 
(e.g., from a preoperative assessment in a woman who was included postoperatively) and 
the previous POP-Q was documented by one of the three experienced urogynecologists in 
the department, the most severe POP stage was used in the study. 
Data on the presence of other possibly collagen-defect-mediated diseases (i.e., inguinal 
hernia, umbilical hernia, hernia nucleus pulposus, cardiac valve prolapse, vascular 
aneurism, varices, and postoperative abdominal fascia dehiscence) were collected from 
the patient’s charts. 
Genomic DNA was isolated from peripheral blood using the Nucleospin Blood Kit 
(Macherey-Nagel, Düren, Germany). Polymerase chain reactions (PCRs) were performed 
according to standard procedures in a total volume of 50 µL. Six amplicons were 
generated separately with the use of the primer pairs as specified in Table 1. Following 
amplification, polymorphisms were determined by restriction fragment length 
polymorphism (RFLP) analysis using the restriction enzymes as specified in Table 1. Sizes of 
the digested amplicons were determined by agarose gel electrophoresis, which showed 
the presence or absence of the specific polymorphisms. In an initial screening for the 
presence of the polymorphisms, the DNA of a subset of the POP patients was compared 
with a set of randomly selected anonymous DNA samples from the general population 
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(without knowledge of presence or absence of POP). In case the results from this initial 
screening suggested that a polymorphism was a relevant risk factor for POP, this was 
further tested in a larger sample size and compared with a group of women without POP. 
According to data from the HapMap project (http://www.hapmap.org), the allele 
frequency of A in rs1800255 in the general population in Italy was 25%. In view of the high 
prevalence of POP in the general population, we assumed a lower allele A frequency (5%) 
in our control group (where women with POP had been excluded). Thus, analysis of DNA 
samples from 200 POP patients and 100 controls would be sufficient to detect a 
statistically significant odds ratio for POP of at least 3.8 for a relevant polymorphism with a 
power of 80%. Data are presented as medians and range in case of continuous non-
normally distributed data and as absolute numbers with percentages in case of 
dichotomous variables. Fisher’s exact test was used in case of two-by-two tables. Tests for 
deviation from Hardy-Weinberg equilibrium were performed in the case and control 
groups; p values below 0.05 were considered statistically significant. Univariate logistic 
regression was used to study the differences in probability of POP between the COL3A1 
polymorphism types. The crude odds ratios with 95% confidence interval (95%CI) for the 
probability of POP are presented. Multivariate logistic regression was used to study 
whether age, parity, previous number of POP procedures, POP-Q stage, and the presence 
of other possibly collagen-defect-mediated diseases were possible confounders in the 
relation of POP and the COL3A1 polymorphism type. All data were analyzed using SAS 
10.0 (SAS Institute, Chicago, IL, USA). 
 
RESULTS 
The prevalence of six different polymorphisms was assessed in 50 POP and 30 control 
patients at an initial screening (Table 1). Only the COL3A1 2209G>A polymorphism 
appeared to be related to the probability of POP. Figure 1 shows an image of the 
corresponding PCR-RFLP analysis. The prevalence of this polymorphism was subsequently 
determined in 304 women, of whom 202 women were POP patients and 102 women were 
vaginally parous controls without POP. There was no overlap between the 30 controls in 
the initial screening (general population) and the 102 controls (women without POP) in 
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the subsequent larger population, but the first 50 POP patients were included in both 
comparisons. The women’s characteristics in relation to the probability of POP and the 
COL3A1 2209G>A polymorphism are presented in Table 2.  
Table 2. Women’s characteristics and the odds ratio of the probability of POP using univariate 
logistic regression 
 Women with POP 
(n=202) 
Controls 
(n=102) 
OR (95%CI)  
Age (years) 56 [33-88] 55 [37-90] NA 
Parity 2 [0-8] 2 [1-5] NA 
POP procedures 1 [0-7] 0 [0-0] NA 
POP-Q stagea   NA 
    Stage I 9 (5) 81 (83)  
    Stage II 83 (45) 17 (17)b  
    Stage III 80 (43) 0  
    Stage IV 12 (7) 0  
Collagen disease 17 (9) 3 (3) 3.3 (0.9-11.5) 
COL3A1 2209G>A    
    GG (normal) 100 (49) 55 (54) 1.0 (reference) 
    GA 77 (38) 44 (43) 0.9 (0.6-1.5) 
    AA 27 (13) 3 (3) 5.0 (1.4-17.1) 
Data are presented as medians [range] in case of continuous non-normally distributed data and as 
absolute numbers (percentages) in case of dichotomous variables 
95%CI 95% confidence interval, Collagen disease patients with other possibly collagen-mediated 
diseases, including inguinal hernia, umbilical hernia, hernia nucleus pulposus, cardiac valve 
prolapse, arterial aneurism, varices, and abdominal fascia dehiscence, NA not applicable, n number 
of patients, OR crude odds ratio for the probability of pelvic organ prolapse versus the absence of 
homozygous or hemizygous COL3A1 2209G>A polymorphism using univariate logistic regression, 
POP pelvic organ prolapse, POP procedures number of previous surgical POP procedures, POP-Q 
Pelvic Organ Prolapse Quantification system 
a POP-Q stage was unknown in 18 POP patients and four controls. 
b Note that the most descended edge was not beyond 1 cm above the hymen in the control group 
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DISCUSSION 
In the present study, a specific homozygous gene polymorphism in the alpha 1 chain of 
type III collagen (COL3A1 2209G>A, rs1800255) has been detected, which was associated 
with the probability of female POP in the Dutch population. The rs1800255 homozygous 
single-nucleotide substitution was recently linked to POP in Taiwanese women. Chen and 
coworkers [15] have independently calculated a similar prevalence and odds ratio for POP 
in the Taiwanese population compared to that in the Dutch population. Their report 
strengthens our findings and shows the relevance of the polymorphism in different 
genetic populations. 
Type III collagen is a right-handed triple helix composed of three type III collagen chains. 
The homozygous single-nucleotide substitution results in an alanine to threonine amino 
acid substitution at position 698 in all chains within the helical domain. The aliphatic 
hydroxyl side chain of threonine is more hydrophilic compared to the aliphatic side chain 
of alanine and could result in a local distortion and unwinding of the triple helical 
conformation of type III collagen. Although evidence is lacking, this could affect the tensile 
strength of the type III collagen fibers. Alternatively, the amino acid substitution could 
alter the binding affinity of collagen-binding molecules. The binding sites of known type III 
collagen-binding proteins (e.g., von Willebrand factor, discoidin domain receptor 2, SPARC, 
and α2β1 integrin) are not located at position 698, but approximately 100 amino acids 
towards the N-terminal domain [16]. Further studies towards the functional consequences 
of this polymorphism will contribute to a better understanding of the pathogenesis of 
POP. 
A limitation of the study is that, although the homozygous COL3A1 2209G>A 
polymorphism has been observed significantly more often in POP patients compared with 
normal controls, it is present in only 13% of POP patients. This implies that the majority of 
POP was related to other factors. In view of the familial tendency of POP, more relevant 
polymorphisms are expected. Four other research groups have previously studied gene 
polymorphisms related to POP. The first group has found that the alpha and beta 
haplotype estrogen receptors were associated with POP with a relative risk of two [17]. 
Two different groups have reported that a polymorphism in the alpha 1 chain of type I 
collagen (COL1A1) was not associated with POP, although an association with urinary 
 
Figure 1. Analysis of the COL3A1 2209G>A 
gene polymorphism by PCR-RFLP assay. 
Genomic DNA was amplified using specific 
primer sequences which generate a 192-bp 
fragment containing the polymorphic site. 
PCR products were digested with the 
restriction endonuclease AluI, and 
subsequently, separated by 1% agarose gel 
electrophoresis with ethidium bromide 
staining and visualized under ultraviolet 
transillumination. The COL3A1 wild-type 
allele (G/G) resulted in two fragments of 172 
and 22 bp (not visible), whereas the 
homozygous COL3A1 gene variant (A/A) 
resulted in one fragment of 192 bp because 
of the elimination of the AluI restriction site. 
The heterozygous sample (G/A) contains a 
band at 192 and 172 bp. Fragment sizes of 
the 50-bp DNA ladder are indicated. The 
bands at approximately 50 bp are nonspecific 
primer dimer products.                  . 
 
 
The Hardy-Weinberg equilibrium was met in the cases and controls (p=0.06 and p= 0.11, 
respectively). The crude odds ratio for the probability of POP in a woman with a 
homozygous 2209G>A polymorphism was 5.0 (95%CI, 1.4-17.1). The hemizygous 
polymorphism did not correlate with the probability of POP. Armitrage’s trend test 
confirmed that the correlation with POP had an autosomal recessive character (p=0.06). In 
this population, using the multivariate logistic regression, we found that neither age nor 
parity were confounders for this risk of a homozygous polymorphism. This was similarly 
the case for POP-Q stage, previous surgical POP procedures, and the presence of other 
possibly collagen-defect-mediated diseases. 
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DISCUSSION 
In the present study, a specific homozygous gene polymorphism in the alpha 1 chain of 
type III collagen (COL3A1 2209G>A, rs1800255) has been detected, which was associated 
with the probability of female POP in the Dutch population. The rs1800255 homozygous 
single-nucleotide substitution was recently linked to POP in Taiwanese women. Chen and 
coworkers [15] have independently calculated a similar prevalence and odds ratio for POP 
in the Taiwanese population compared to that in the Dutch population. Their report 
strengthens our findings and shows the relevance of the polymorphism in different 
genetic populations. 
Type III collagen is a right-handed triple helix composed of three type III collagen chains. 
The homozygous single-nucleotide substitution results in an alanine to threonine amino 
acid substitution at position 698 in all chains within the helical domain. The aliphatic 
hydroxyl side chain of threonine is more hydrophilic compared to the aliphatic side chain 
of alanine and could result in a local distortion and unwinding of the triple helical 
conformation of type III collagen. Although evidence is lacking, this could affect the tensile 
strength of the type III collagen fibers. Alternatively, the amino acid substitution could 
alter the binding affinity of collagen-binding molecules. The binding sites of known type III 
collagen-binding proteins (e.g., von Willebrand factor, discoidin domain receptor 2, SPARC, 
and α2β1 integrin) are not located at position 698, but approximately 100 amino acids 
towards the N-terminal domain [16]. Further studies towards the functional consequences 
of this polymorphism will contribute to a better understanding of the pathogenesis of 
POP. 
A limitation of the study is that, although the homozygous COL3A1 2209G>A 
polymorphism has been observed significantly more often in POP patients compared with 
normal controls, it is present in only 13% of POP patients. This implies that the majority of 
POP was related to other factors. In view of the familial tendency of POP, more relevant 
polymorphisms are expected. Four other research groups have previously studied gene 
polymorphisms related to POP. The first group has found that the alpha and beta 
haplotype estrogen receptors were associated with POP with a relative risk of two [17]. 
Two different groups have reported that a polymorphism in the alpha 1 chain of type I 
collagen (COL1A1) was not associated with POP, although an association with urinary 
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incontinence was present [18-20]. The fourth research group has found that a 
polymorphism in the promoter of the laminin gamma 1 (LAMC1) was weakly associated 
with POP [21]. Laminin has been shown to be essential in the interaction with the 
extracellular matrix which consists of collagen. The changes in laminin might thus 
represent an explanation for the reduced collagen content in the connective tissues in 
women with POP. 
Further basic research on the pathogenesis of POP has focused on differences in the 
content and quality of collagen, elastin, smooth muscle, skeletal muscle, and hormonal 
receptors in the various end organs, such as vaginal tissue, ligaments, levator ani muscles, 
and paraurethral tissues [22-28]. Even gene expressions in these end organs have been 
studied [29, 30]. The mechanical stretch on the pelvic ligaments during onset and 
progression of POP results in gene expression of the fibril-forming type I and III collagens. 
Consequently, all these studies have one essential problem in common, which is the fact 
that they do not provide the proof that a certain abnormality is the cause and not the 
consequence of POP. All reported differences in gene and protein expression in end organ 
tissue could thus reflect a wound healing reaction in response to POP. 
The detection of known polymorphisms is relatively cheap, whereas the socioeconomic 
impact of POP is substantial. The knowledge of these hereditary risk factors, in 
combination with environmental and behavioral risk factors (e.g., body mass index, history 
of physical activity or heavy weight lifting, or chronic asthma and constipation), would 
enable the development of individual risk assessment models. These risk models would be 
helpful in clinical trials on preventive strategies, such as the omission of (operative) vaginal 
delivery and the use of mesh material in POP surgery where patients could then be 
stratified for their POP risk. 
There may, however, also be a downside from the fact that POP has a genetic background. 
There are possible ethical and financial implications where insurance companies request 
the results from genetic screening in order to exclude persons or treatment for certain 
genetically mediated diseases. Societal discussion on this and similar issues is much 
needed. 
In conclusion, COL3A1 2209G>A, a homozygous single-nucleotide substitution in the type 
III collagen-encoding gene, correlates with the probability of female POP. This genetic 
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defect may impair the tensile strength of type III collagen, which is responsible for tissue 
repair after extensive stretching of ligaments such as seen during delivery and in POP. 
More relevant genetic polymorphisms are expected to play a role in POP and will be 
subject to future research. The future screening for various polymorphisms may allow 
simple and cost-effective preventive measures in women at high risk for POP. 
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ABSTRACT 
Background 
We have recently identified a homozygous nucleotide substitution in exon 30 of type III 
collagen (COL3A1 2209G>A, rs1800255) as a risk factor for the development of pelvic 
organ prolapse. This polymorphism is also associated with mitral valve prolapse. Patients 
could benefit from preventive actions when identified prior to clinical evidence of the 
disease. High resolution melting (HRM) analysis is a low-cost, high-throughput technique 
to identify DNA polymorphisms. The purpose of this study was to investigate whether 
HRM is an accurate method to detect the above mentioned polymorphism in DNA from 
blood samples. 
Methods 
A total of 36 randomly selected DNA samples from pelvic organ prolapse patients were 
analyzed in duplicate using polymerase chain reaction (PCR)-based restriction fragment 
length polymorphism (PCR-RFLP) and sequence analysis. Using the latter as the gold 
standard, all samples were subjected to HRM analysis with the use of specific primers and 
an unlabelled probe. 
Results 
Compared to sequence analysis, PCR-RFLP resulted in 2 incorrect diagnoses. High 
resolution melting analysis demonstrated unique melting profiles for wild-type, as well as 
heterozygous and homozygous polymorphisms, with 100% accuracy. 
 
Conclusion 
High resolution melting is a fast, and sensitive screening method to detect the rs1800255 
polymorphism. 
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INTRODUCTION 
Pelvic organ prolapse is a major health care problem [1, 2] with a large impact on women’s 
quality of life [3]. For many years, a hereditary disposition of pelvic organ prolapse has 
been assumed, and a strong familial tendency has been demonstrated [4-7]. The 
identification of gene polymorphisms associated with pelvic organ prolapse and the 
subsequent development of a rapid screening method would be of great value in the 
identification of patients at risk. Simple and effective preventive measures would then be 
feasible. 
Using labor-intensive, polymerase chain reaction (PCR)-based restriction fragment length 
polymorphism (PCR-RFLP) analysis, we recently identified a homozygous nucleotide 
substitution in exon 30 of the type III collagen gene (COL3A1 2209G>A, rs1800255) that is 
associated with pelvic organ prolapse in a large cohort of patients [8]. This confirmed the 
results of 2 previous small scale studies [9, 10]. The polymorphism was detected in 13.4% 
of patients with pelvic organ prolapse as compared to 2.9% in controls (ie, parous women 
without pelvic organ prolapse). The odds ratio for the presence of pelvic organ prolapse in 
patients with this homozygous 2209G>A polymorphism was 5.0 (95% confidence interval 
1.4; 17.1). 
In addition to pelvic organ prolapse, the rs1800255 polymorphism has been previously 
related to floppy mitral valves and mitral valve prolapse [11]. In general, mitral valve 
prolapse is asymptomatic but can lead to mitral valve regurgitation and subsequently to 
enlargement and damage to the left ventricle and heart failure. In order to screen large 
groups of patients for the presence of this polymorphism, a rapid, reliable, and cost-
effective method is needed. 
High resolution melting (HRM) is used to identify DNA mutations based on minor changes 
in DNA melting curves and has been used to genotype mutations in patients with 
achondroplasia and cystic fibrosis [12, 13]. Compared to DNA sequence analysis and 
conventional PCR-RFLP, HRM is a rapid, sensitive, and relatively inexpensive method to 
screen for gene polymorphisms in a large population [14]. In order to obtain 100% 
specificity, the primer pair and probe used in HRM must unmistakably detect all 
homozygous and heterozygous nucleotide substitutions. 
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The purpose of this study was to develop specific primers and an unlabeled probe to be 
used in HRM analysis for the rs1800255 polymorphism. DNA samples were also subjected 
to PCR-RFLP analysis and sequence analysis. High resolution melting analysis 
demonstrated 100% sensitivity in the detection of heterozygous and homozygous 
nucleotide substitutions. 
 
MATERIALS AND METHODS 
Patients 
This study included 36 women with pelvic organ prolapse who were randomly selected 
from the 304 women described in our recent study [8]. This study was approved by the 
local institutional review board (IRB) under number CMO 2007/043 and informed consent 
was obtained from all the women. 
 
Sequence Analysis 
Genomic DNA was isolated from peripheral blood using the Nucleospin Blood Kit 
(Macherey-Nagel, Düren, Germany). To amplify the part of exon 30 containing the COL3A1 
2209G>A substitution (NM_000090, rs1800255), PCRs were performed according to 
standard procedures on a total of 50 μL containing 6 pmol of primer (5-GCC CCA GGA CTT 
AGA GGT G and 5-CCT TGC AGA CCA GGA GT, Invitrogen). Subsequently, the 192nt 
amplicon was purified using Multi-Screen PCRμ96 plates and a vacuum manifold (Millipore, 
Billerica, MA), and submitted to the sequence facility at the Radboud University Nijmegen 
Medical Centre for sequence analysis. The forward and reverse sequences were 
determined separately using the primers described above. 
 
PCR-RFLP 
Following amplification as described above, presence of the polymorphism was 
determined by RFLP analysis using the restriction enzyme AluI (New England Biolabs, 
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Frankfurt am Main, Germany) and products resolved on 1.5% agarose gel containing 
ethidiumbromide. In the case of homozygous 2209G, the AluI-digested amplicon should 
reveal bands at 171 and 22 nucleotides. In the case of homozygous 2209A, a single band at 
192 nucleotides was expected, and in the case of heterozygousity bands at 192, 171, and 
22 were visible. Each DNA sample was analyzed at least in duplicate and results 
interpreted by 2 of the authors. 
 
HRM 
For HRM analysis of rs1800255, an unlabeled probe assay was set up. The probe was 
designed to match the least frequent allele to increase specificity. A mixture of 10 μL 
containing 10 ng genomic DNA, 4 μL of the 2.5x LightScanner® Master Mix containing 
LCGreen® PLUS (Idaho Technology, Salt Lake City, UT), 0.1 μM forward primer 5-TGG TGA 
ACG TGG ACC TCC TGG ATT G-3 (position 189572274-189572298 on chromosome 2 of the 
genomic sequence of COL3A1), 0.5 μM reversed primer 5-GGT GAA TGG AAT GCT GTG 
GAG TTA CCT TT-3 (position 189572352–189572380), and HPLC-purified 0.5 μM probe 5-
GGA CTT AGA GGT GGA ACT-3 GGT CCC-block (position 189572311–189572334) was 
prepared. A C3 spacer (Operon Biotechnologies, Cologne, Germany) was used as a 3-foot 
block on the probe to prevent extension during PCR. The mixture was overlayed with 15 
μL mineral oil, and PCR amplification was conducted at initial denaturation for 2 min at 
95°C followed by 50 cycles of denaturation for 30 sec at 95°C, primer annealing for 30 sec 
at 69°C, and extension for 30 sec at 74°C. A final denaturing and subsequent reannealing 
step were carried out for 30 sec at 95°C and 30 sec at 25°C, respectively. The 96 wells 
LightScanner® System (Idaho Technology, Salt Lake City, UT) was used to analyze the 
DNA/dye complexes by high-resolution thermal denaturation [15]. Melting curves were 
generated by ramping between 55°C and 95°C at 0.1°C/s. The LightScanner software 
(version 1.5) was used for genotyping analysis, using the software’s default settings. The 
region of the probe melt was bracketed and fluorescence was normalized. The melting 
curves were displayed as derivative melting peaks and clustered by auto-grouping. 
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RESULTS 
All DNA samples were analyzed by PCR-RFLP (Figure 1A) and compared to the sequence 
analysis results (Figure 1B). A total of 12 wild-type, 17 heterozygous, and 7 homozygous 
samples were found by sequence analysis. Consensus between the 2 observers was 
reached in all cases. A discrepancy was encountered in 2 DNA samples by RCR-RFLP, which 
showed to be heterozygous samples by sequence analysis but appeared as a homozygous 
substitution (sample 20) and wild-type (sample 25) in PCR-RFLP analysis (Table 1). As such, 
2 of the 36 samples (5.6%) were erroneously diagnosed by PCR-RFLP. 
To test the accuracy of HRM analysis, melting curves profiles were generated and 
compared with the sequencing data. The normalized melting profiles of the 3 variants 
were clearly distinct (Figure 1C). In all cases, consensus with sequence analysis was 
obtained. 
 
Figure 1. Detection of the rs1800255 
(COL3A1 2209G>A) polymorphism by PCR-
RFLP, sequence analysis and HRM. (A) PCR-
RFLP revealed a single amplicon at 192bp for 
the undigested control (ctrl), which is 
completely digested into a 171bp amplicon 
in case of 2209G (wild-type). A 192 and 
171bp amplicon was observed in a case of a 
heterozygous substitution, and no digestion 
occurred in a case of a homozygous COL3A1 
2209G>A substitution. (B) Sequence analysis 
of genomic DNA indicates the polymorphic 
nucleotide (arrow). Reverse sequence 
analysis results are shown. (C) Normalized 
melting peaks are presented as a function of 
the melting temperature. In this graph, the 
curves labeled 1, 2, and 3 are melting peaks 
of wild type, heterozygous, and homozygous 
samples respectively. 
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Table 1. Comparison of DNA Sequencing, PCR-RFLP and HRM 
Sample Number Sequence Analysis PCR-RFLP HRM 
1 GG GG variant 1 
2 GG GG variant 1 
3 GG GG variant 1 
4 GG GG variant 1 
5 GG GG variant 1 
6 GG GG variant 1 
7 GG GG variant 1 
8 GG GG variant 1 
9 GG GG variant 1 
10 GG GG variant 1 
11 GG GG variant 1 
12 GG GG variant 1 
13 GA GA variant 2 
14 GA GA variant 2 
15 GA GA variant 2 
16 GA GA variant 2 
17 GA GA variant 2 
18 GA GA variant 2 
19 GA GA variant 2 
20 GA AA variant 2 
21 GA GA variant 2 
22 GA GA variant 2 
23 GA GA variant 2 
24 GA GA variant 2 
25 GA GG variant 2 
26 GA GA variant 2 
27 GA GA variant 2 
28 GA GA variant 2 
29 GA GA variant 2 
30 AA AA variant 3 
31 AA AA variant 3 
32 AA AA variant 3 
33 AA AA variant 3 
34 AA AA variant 3 
35 AA AA variant 3 
36 AA AA variant 3 
PCR-RFLP polymerase chain reaction-restriction fragment length polymorphism, HRM high resolution 
melting 
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The samples causing discrepancies when comparing the PCR-RFLP analysis results with 
sequencing data were unmistakably recognized as variant 3 (ie, a heterozygous 
polymorphism [Table 1]). This makes HRM analysis a more objective, high-throughput, 
cost-effective method with 100% accuracy for the rs1800255 polymorphism. 
 
DISCUSSION 
This study was conducted to assess the accuracy of HRM in comparison with PCR-RFLP, 
with sequence analysis used as the gold standard technique. In the search for an objective 
and faster screening method for the rs1800255 polymorphism, which is related to pelvic 
organ prolapse and mitral valve prolapse, a specific primer pair and an unlabeled probe 
were developed for use in the HRM analysis. Accuracy of 100% was obtained for both the 
heterozygous and homozygous nucleotide substitutions, whereas correct prediction of 
the polymorphism by PCR-RFLP analysis failed in 2 of 36 samples. 
Detection of DNA mutations with the use of PCR-RFLP and DNA sequence analysis are 
laborious and time consuming. Furthermore, interpretation of the digestion profiles can 
be subjective in cases of suboptimal digestion. Comparison of the 3 different assay 
techniques for the detection of the rs1800255 polymorphism revealed clear advantages 
and no disadvantages of HRM over PCR-RFLP and DNA sequencing. High resolution 
melting was fast, objective, cost-effective, and 100% accurate in the detection of the 
polymorphism. The PCR-RFLP assay can cause a false result in cases of incomplete 
digestion or inferior quality of the DNA template. Furthermore, the interpretation of the 
data can be subjective in cases of heterozygosity when multiple bands are present. The 
HRM assay is a single tube assay that does not require any addition of reagents after the 
PCR setup, which reduces the possibility of mistakes and erroneous conclusions. 
The melting curves in HRM analysis are clustered by auto-grouping and only identify 
samples with similar melting curves. These melting curves are determined by the 
nucleotide sequence. In this sample set, only 3 variant curves were observed. Sequencing 
also revealed only 3 possibilities (GG, GA, or AA), which perfectly corresponded with the 3 
variant curves. If a sample contains an alternative substitution at the same position, eg, G 
to C, additional melting curve variants (GC and/or CC) would have been revealed. 
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Subsequent sequence analysis is then required to determine the nature of the 
substitution(s). 
In conclusion, the HRM protocol we have developed facilitates easy detection of the 
rs1800255 polymorphism. It can be used for further validation of the relative risk for pelvic 
organ prolapse and mitral valve prolapse, which are associated with this COL3A1 2209G>A 
nucleotide substitution. Prospectively, it contributes to the identification of patients at risk 
for pelvic organ prolapse and mitral valve prolapse who would benefit from preventive 
measures. 
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ABSTRACT 
Introduction and hypothesis 
The rs1800255, COL3A1 2209 G>A polymorphism in the alpha 1 chain of collagen type III 
has been associated with an increased risk of pelvic organ prolapse (POP). In one of our 
previous studies however, polymerase chain reaction-based restriction fragment length 
polymorphism (PCR-RFLP) misdiagnosed rs1800255, COL3A1 2209 G>A in 6% of cases. The 
high-resolution melting (HRM) analysis on the contrary obtained a 100 % accordance for 
this specific polymorphism and was used in the present study to validate this risk factor for 
POP. 
Methods 
In this case-control study, women with and without symptoms of POP were included and 
compared. DNA was extracted from blood samples. HRM analysis was used to assess for 
the presence of the homozygous rs1800255. Groups were compared using the Pearson 
chi-square, Mann-Whitney, and t tests. The discrepancy between HRM and PCR-RFLP 
results was investigated using PCR-RFLP results available from our previous study. 
Results 
The study included 354 women: 272 patients with POP and 82 controls; 18 (7 %) cases 
versus 3 (4 %) controls had a homozygous rs1800255, COL3A1 2209 G>A polymorphism 
(odds ratio 1.9, 95 % confidence interval 0.5-6.9, compared to the wild type), and thus no 
association between POP and the homozygous polymorphism could be demonstrated. A 
discrepancy between HRM and PCR-RFLP results was found in 8 % of the samples. 
Conclusions 
The previously found statistically significant association between the rs1800255, COL3A1 
2209 G>A polymorphism as measured with PCR-RFLP and POP could no longer be 
demonstrated. This raises concerns regarding the results of other association studies using 
PCR-RFLP.
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INTRODUCTION 
Pelvic organ prolapse (POP) is known to have a multifactorial etiology. Over recent years, 
the importance of genetics in the development of POP has become increasingly evident. 
Studies among (twin) sisters have shown that there is a high concordance in POP stage 
between sisters, irrespective of parity [1, 2], and that genetic factors attribute to 40 % of 
the variation of liability for POP [3]. Until now, a variety of different polymorphisms have 
been described in relation to POP. Part of these polymorphisms concern genes encoding 
proteins that are important substances of the extracellular matrix [4-10]. Others concern 
genes encoding for hormone receptors [11-13]. 
In 2009, our research group published a report on a polymorphism in the alpha 1 chain of 
the type III collagen protein-encoding gene (rs1800255, COL3A1 2209 G>A) [5]. In that 
publication, we presented a case-control study on the presence of polymorphisms in the 
gene encoding for COL3A1 and their association with POP. To detect these 
polymorphisms, we used polymerase chain reactions (PCRs) followed by restriction 
fragment length polymorphism (RFLP) analysis for DNA analysis. We found that the 
homozygous form of one of these polymorphisms (rs1800255, COL3A1 2209 G>A 
polymorphism) was associated with POP with an odds ratio (OR) of 5.0 (95 % confidence 
interval 1.4-17.1) compared to the wild type. Our results were in concordance with data 
published on the prevalence of this polymorphism in Taiwanese POP patients using the 
same analysis technique [6]. 
In order to bring this promising finding within reach for everyday practice, the accuracy of 
high-resolution melting (HRM) analysis was assessed. The HRM analysis is a low-cost, high-
throughput technique to identify DNA polymorphisms by using the differences in melting 
curves between the different amplicons. However, HRM analysis cannot be used 
unthinkingly, since the accuracy of the analysis depends on the melting behavior of each 
specific DNA sequence. This melting behavior is determined by many factors like for 
instance the length of the amplicon and GC content [14] as well as the use of only a primer 
pair or in combination with a probe. Therefore, the results obtained differ for each specific 
case. This makes it sometimes impossible to identify all mutations correctly. For example, 
in an attempt to use HRM analysis for screening of glucose-6-phosphate dehydrogenase 
gene mutations in men, all cases were identified as ‘normal’ because hemizygotes and 
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wild types created almost identical melting curve profiles. It was only after improvement 
of the procedure that it was possible to identify all but one mutation correctly [15]. The 
same kind of problem occurred in an attempt to use HRM analysis for the identification of 
different genotypes in sickle cell disease. With the use of HRM, seven of nine genotypes 
could be distinguished from the wild type without any problem. It was however 
impossible to differentiate the last two genotypes with use of the HRM analysis method, 
while only one curve was created for both genotypes [16]. In this case, sequencing 
remained necessary for detection. Nevertheless, there are also numerous cases in which 
100 % accordance between the results of the HRM analysis and sequencing is obtained. 
For example, in the detection of hemoglobin-beta gene mutation in ß-thalassemia [17] 
and the detection of mutations in the HFE gene in hemochromatosis [18], the results of the 
HRM screening analysis were 100 % consistent with DNA sequencing. The reason for the 
100 % accordance in these cases was the fact that the individual DNA variants all produced 
melting curves that were clearly distinguishable from each other. 
Using DNA sequencing as the gold standard, we performed a study comparing the 
accuracy of PCR-RFLP and HRM for the detection of the rs1800255, COL3A1 2209 G>A 
polymorphism in 36 randomly selected DNA samples [19]. That study demonstrated 100 % 
accordance between HRM analysis and sequencing, with unambiguously distinctive 
melting profiles for heterozygous, homozygous and wild-type variants. This result was 
obtained by using an asymmetric amplification in combination with a probe that 
maximally increased the HRM specificity. However, 6% of the results obtained by PCR-RFLP 
were incorrect as compared to HRM and direct sequencing [19]. 
This inconsistency has resulted in the current study in which the primary aim was to verify 
the association between the rs1800255, COL3A1 2209 G>A polymorphism and POP by 
using the HRM analysis method. Our secondary goal was to investigate the discrepancy 
between HRM and PCR-RFLP results in this cohort. 
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MATERIALS AND METHODS 
Patients 
Patients with POP, presenting themselves between January 2007 and September 2009 at 
the Department of Obstetrics and Gynecology of the Radboud University Medical Center, 
were asked to participate. As controls, vaginally parous women without symptoms of POP 
[i.e., most descended edge of the Pelvic Organ Prolapse Quantification (POP-Q) staging 
system was not beyond 1 cm above the hymen] and without previous POP surgery visiting 
the department during the same period were included. All women included were 
Caucasian of Dutch descent. The cases and controls partially overlapped the subjects of 
our first study [5], who were recruited between January 2007 and August 2008. Exclusion 
criteria for both groups were hereditary diseases with a known increased risk of POP, such 
as Ehlers-Danlos syndrome, and problems with the patient’s understanding of the study. 
Data on age, parity, and the number of previous POP procedures were collected from all 
patients. Date at first visit was defined as the date of the first clinic visit. Date of first 
complaints was defined as the year of onset of the first POP complaints or otherwise the 
year of the (first) POP treatment. All women underwent gynecologic examination for the 
assessment of the POP-Q stage. Women were examined in a gynecological chair, in a 45° 
position, performing maximum Valsalva for all measurements of the POP-Q scale except 
total vaginal length (TVL), which was assessed during rest. The study was approved by the 
local Institutional Review Board (IRB) under number CMO 2007/043 and informed consent 
was obtained from all of the women. 
 
Laboratory analysis 
Genomic DNA was isolated from peripheral blood. DNA was isolated using the NucleoSpin 
Blood Kit (Macherey-Nagel, Düren, Germany) according the supplier’s protocol. PCRs were 
performed according to standard procedures in a total volume of 25 μl, containing 50 ng 
DNA (OD260/280 and 260/230 both >1.8 as measured by nanodrop), 0.4 pmol/µl of each 
primer (5’-GCC CCA GGA CTT AGA GGT G and 5’-CCT TGC AGA CCA GGA GT, Invitrogen), 
2.5 mM MgCl2, 0.2 mM dNTP (Roche, Mannheim, Germany), and 0.012 U/µL ThermoPerfect 
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taq polymerase (Integro, Leuvenheim, The Netherlands). PCR was performed according to 
the following protocol: 5 min 95 °C, 30 x [1 min 95 °C, 45 s 62 °C, 45 s 72 °C], 5 min 72 °C. 
Subsequently, the 192nt amplicon was purified using MultiScreen PCRµ96 plates and a 
vacuum manifold (Millipore, Billerica, MA, USA) and submitted to the sequence facility at 
the Radboud University Medical Center for sequence analysis. The forward and reverse 
sequences were determined separately using the primers described above. Following 
amplification as described above, presence of the rs1800255 polymorphism was 
determined subsequently by RFLP [19]. Ten microliters of PCR mix was digested with 2U 
AluI (New England Biolabs, Frankfurt am Main, Germany) in a final volume of 20 µl 1x 
Buffer A (New England Biolabs) at 37 °C overnight. Digestion products were resolved on a 
1.5 % agarose gel containing ethidium bromide. In the case of homozygous 2209G, the 
AluI-digested amplicon should reveal bands at171 and 22 nucleotides. In the case of 
homozygous 2209A, a single band at 192 nucleotides was expected, and in the case of 
heterozygosity bands at 192, 171, and 22 were visible. Each DNA sample was analyzed at 
least in duplicate and results interpreted by two of the authors (LCvK, JRD). 
HRM was performed with HPLC purified primers and probes purchased from Qiagen 
Operon (Cologne, Germany). A 10-µl mixture containing 10 ng genomic DNA, 4 μl of the 
2.5x LightScanner Master Mix containing LCGreen Plus® (Idaho Technology, Salt Lake City, 
UT, USA), 0.1 μM forward primer 5’-TGG TGA ACG TGG ACC TCC TGG ATT G-3’ (position 
189572274-189572298 on chromosome 2 of the genomic sequence of rs1800255, COL3A1 
2209 G>A polymorphism), 0.5 μM reversed primer 5’-GTT GAA TGG AAT GCT GTG GAG TTA 
CCT TT-3’ (position 189572352-189572380), and 0.5 μM probe 5’-GGA CTT AGA GGT GGA 
ACT-3’ GGT CCC-block (position 189572311-189572334) was prepared. The probe 
contained a C3 spacer (Operon Biotechnologies, Cologne, Germany) that functioned as a 
3-foot block on the probe to prevent extension during PCR. The mixture was overlaid with 
15 μl mineral oil, and PCR amplification was conducted at initial denaturation for 2 min at 
95 °C followed by 50 cycles of denaturation for 30 s at 25 °C, respectively. The use of 
asymmetric amplification in combination with a probe strongly increases the HRM 
specificity. This was confirmed by a validation experiment in which sequencing of the 
single 106 nt amplicon that was generated in this PCR contained the expected sequence. 
The 96-well LightScanner® System (Idaho Technology) was used to analyze the DNA/dye 
complex by high-resolution thermal denaturation. Melting curves were generated by 
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ramping between 55 and 95 °C at 0.1 °C/s. The LightScanner software (version 1.5) was 
used for genotyping analysis. The region of the probe melt was bracketed and 
fluorescence was normalized. The melting curves were displayed as derivative melting 
peaks and clustered by auto-grouping as reported previously [19]. 
 
Statistics 
Missing data were excluded from analysis. The Pearson chi-square test was used to 
compare categorical variables. All other variables were analyzed using independent 
samples t test and Mann-Whitney U test. A test for deviation from Hardy–Weinberg 
equilibrium was performed in the control group; two-sided p values below 0.05 were 
considered statistically significant. For the power calculation, the assumptions in our 
previous study were used [5]. All data were analyzed using Statistical Package for the 
Social Sciences (SPSS) software, version 20.0. 
 
RESULTS 
A total of 354 women were included; 272 patients with POP and 82 controls. Using the 
same assumptions as for our previous study [5], this resulted in a power of 85 % for the 
present study. The baseline characteristics of the POP and the control groups are 
presented in Table 1. There were no significant differences between the women with POP 
and the controls with regard to age at first visit and body mass index (BMI). Parity, 
however, was significantly different between the two groups, with parity being slightly 
higher among POP patients. There was no apparent deviation from Hardy-Weinberg 
equilibrium (p=0.21). 
A total of 354 DNA samples were analyzed with the HRM analysis method. Of those 
samples, 214 (60 %) had previously been analyzed in the PCR-RLFP analysis on rs1800255, 
COL3A1 2209 G>A polymorphism [5]. A discrepancy between HRM and PCR-RFLP was 
found in 17 samples, leading to a reclassification rate of 8 % (95 % confidence interval of 
4.9-12.4) (Table 2). 
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Table 1. Baseline characteristics of cases and controls  
 Women with POP Controls p valuea OR (95 % CI) 
 (n=272) (n=82)   
Age at first visit (years)b 55 ± 13 (n=269) 57 ± 12 (n=82) 0.49  
Age at first complaints 
(years)b 
48 ± 13 (n=253)     
Parityc 2 [0-6] (n=269) 2 [1-7]  (n=80) 0.03  
Previous POP 
proceduresc 
1 [0-5] (n=271) 0 [0-0]  (n=82) NA  
POP-Q Staged  (n=267)  (n=76) NA   
    0 0  36 (47)    
    I 12 (4)e  40 (53)    
    II 116 (43)  0    
    III 128 (48)  0    
    IV 11 (4)  0    
BMI (kg/m2)b 25 ± 4 (n=230) 25 ± 5 (n=64) 0.16  
Menopaused
 
 163 (71) (n=228) 51 (64) (n=80)  1.4 (0.8-2.4) 
COL3A1 2209G>Ad  (n=272)  (n=82)   
    GG (normal) 137 (50)  44 (54)   1.0 (reference) 
    GA 117 (43)  35 (43)   1.1 (0.6-1.8) 
    AA 18 (7)  3 (4)   1.9 (0.5-6.9) 
POP pelvic organ prolapse, POP-Q Pelvic Organ Prolapse Quantification system, BMI body mass 
index, NA not applicable, OR odds ratio, CI confidence interval 
a p value=significance level as assessed with the independent samples t test (age at first visit, BMI) 
and Mann-Whitney U test (parity) 
b Data are presented as mean ± σ
 
c Median [range]
 
d Absolute numbers (percentages)
 
e All women with POP-Q stage I had undergone at least one previous POP surgery in other centers, 
but reliable POP-Q measurements before this operation were not available 
 
The relation between POP and the COL3A1 2209G>A polymorphism is presented in Table 
1. No association between POP and the homozygous rs1800255, COL3A1 2209 G>A 
polymorphism could be demonstrated in the present study, with an OR of 1.9 (95 % 
confidence interval of 0.5-6.9) found. Findings were similar after adjustment for parity. 
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Table 2. Agreement on the rs1800255, COL3A1 2209 G>A polymorphism status using PCR-RFLP 
versus HRM (n=214) 
PCR-RFLP HRM   
 GG GA AA 
GG 86 2 0 
GA 5 94 1 
AA 0 9 17 
PCR-RFLP polymerase chain reaction-restriction fragment length polymorphism, HRM high 
resolution melting 

DISCUSSION 
This study was performed to validate the association between POP and the homozygous 
polymorphism in the alpha 1 chain of collagen type III (rs1800255, COL3A1 2209 G>A 
polymorphism) after (re)analysis of the DNA samples with the more accurate HRM analysis 
technique. The results showed that a statistically significant association could no longer be 
demonstrated. 
In our review of the literature describing clinical studies on hereditary factors in POP [20], a 
discrepancy between the different studies on COL3A1 polymorphism and POP was 
described. Jeon et al. [7] found that the GG genotype of the COL3A1 polymorphism in 
exon 31 was significantly associated with POP, whereas Martins et al. [8] found no 
correlation between this COL3A1 polymorphism and POP in their population. Our initial 
explanation for these differences was that the studies were performed in ethnically 
different populations with different background risks of POP. However, with the present 
knowledge, these differences may also be explained by the fact that the methodology to 
detect this single nucleotide variant (PCR-RFLP) was not sufficiently accurate for the 
analyses in these studies. The same may hold true for the discrepancy found in the results 
of the studies on the laminin gamma-1 (LAMC1) polymorphism [rs10911193 (C/T)] 
performed by Nikolova et al. [4] and Chen et al. [10]. The study group of Nikolova et al. [4] 
using the accurate sequencing method for their analyses found a statistically significant 
correlation between the LAMC1 gene polymorphism and POP, whereas Chen et al. [10] 
using PCR-RFLP analysis found no association. One explanation for the diminished 
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accuracy of PCR-RFLP is the subjective reading of the electrophoresis patterns, as 
previously reported [19]. Other investigators have similarly described discordant results 
between PCR-RFLP and direct sequencing. Peters et al. [21] examined the association 
between three tumor necrosis factor alpha (TNF-α) promoter polymorphisms and severe 
sepsis after traumatic injury. Of 46 samples, 4 (9 %) were incorrectly classified as 
heterozygous by RFLP, whereas they were classified as GG-homozygous by sequencing. 
This error rate is in line with what we have published previously [19] and in this study 
using a larger sample set (6 and 8 %, respectively). 
One limitation of our current study is the fact that 90 of the 304 subjects (30 %) of our 
previous PCR-RLFP analysis on rs1800255 [5] were not included because the sample was 
exhausted in our other studies. This hampers the full validation of the previous study 
results and obviously it cannot be ruled out that this could have influenced the current 
outcome. However, due to the additional samples, we still had over 80 % power to detect 
an OR of at least 3.8, the number used in the power calculation of our first study [5]. 
Nonetheless, to be able to detect an OR of around 2.0 or less, the sample size should have 
been larger. Furthermore, it should be noted that we did not use DNA sequencing, the 
gold standard method for analyzing DNA, in our present study. However, in our previous 
study [19], the HRM analysis showed a 100 % accordance with DNA sequencing for the 
analysis of this specific polymorphism, which is in line with other publications [22, 23]. 
Furthermore, the patterns of the derivate melt curves were unambiguous. For this reason, 
we decided to use this rapid and inexpensive analysis method. 
In conclusion, the previously reported statistically significant association between the 
rs1800255, COL3A1 2209 G>A polymorphism and POP was not confirmed in this study 
with more accurate measurement tools. Although a relation between POP status and 
genetic background has been proven [3, 24] and a relation with collagen status has been 
suggested [25], this specific polymorphism does not seem to have any additional value in 
the prediction of POP. However, since POP is likely to be a multigenic disorder, where the 
relatively small influence of multiple genes adds up to the risk of developing POP, a follow-
up study with a larger sample size would be advisable. 
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Our findings raise concerns regarding studies using PCR-RFLP. Most studies on POP and 
polymorphisms utilized PCR-RFLP analysis and might therefore be prone to the same 
inaccuracy. Although we cannot extrapolate the results of our analysis to other studies 
using PCR-RFLP, we feel that researchers studying the association between diseases and 
polymorphisms should take this information on accuracy of measurement tools into 
account. 
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ABSTRACT 
Introduction 
Pelvic organ prolapse (POP) is caused by a complex interplay of genetic and 
environmental factors. To provide insights into the pathophysiological mechanisms 
underlying the disease, we have integrated the results from a large scale exome chip study 
with published genetic and expression data to generate a molecular landscape of POP. 
Materials and Methods 
Blood samples of 526 women with POP and 1,911 control individuals were genotyped 
using an exome chip containing more than 240,000 exonic markers. We then conducted 
extensive literature analyses of the top-ranked genes from the exome chip and genes 
implicated in POP through other evidence, including genetic association studies and 
expression studies in POP patients. 
Results 
The exome chip study yielded significant association between POP and exonic variants in 
44 unique genes. The proteins encoded by 20 of these genes fit into a molecular 
landscape, together with 28 other POP candidate proteins and two POP-implicated 
microRNAs. The molecular POP landscape is located in epithelial cells and fibroblasts of the 
urogenital tract and harbors four main biological processes - epithelial-mesenchymal 
transition, immune response activation, modulation of the extracellular matrix, and 
fibroblast survival and apoptosis - that interact with each other and are regulated through 
signaling involving female sex hormones and the cytokine TGFB1. 
Conclusion 
Our findings provide detailed and novel insights into the genetically determined 
mechanisms that are involved in the pathogenesis of POP. Furthermore, our molecular 
landscape yields important leads for existing drugs that could be repurposed and for to be 
developed disease-modifying treatments of POP. 
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 INTRODUCTION 
Pelvic organ prolapse (POP) represents a major health care burden in women, with a 
reported prevalence of up to 40% [1, 2]. POP is not life-threatening but its bothersome 
symptoms have a significant impact on quality of life. The life-time risk for any surgical 
intervention for prolapse is 19% [3] and the total costs for POP surgery are substantial [4]. 
POP has a multifactorial etiology in which both hereditary and environmental factors play 
a role. Parity, vaginal delivery, age, and high body mass index (BMI) have been firmly 
identified as environmental risk factors [5] and could all cause defects of fibrous and 
muscular pelvic floor tissues. Familial susceptibility to these defects seems likely, since 
women with POP more often have family members with POP compared to women 
without POP [6]. Further evidence for a genetic background of POP has emerged from twin 
studies [7, 8].  
Initially, the focus of genetic research was on candidate gene-specific single nucleotide 
polymorphisms (SNPs). In a number of these candidate genes, SNPs have been found to be 
(putatively) associated with POP, including genes encoding steroid hormone receptors, 
collagens type I and III, and multiple matrix metalloproteinases. However, only one SNP, 
rs1800012 in the COL1A1 gene, has demonstrated replicable association with POP in a 
recent meta-analysis of all candidate gene association studies [9]. In addition, a genome-
wide association study (GWAS) has identified five SNPs associated with POP that were 
nominally replicated [10].  
As is the case in many other fields of medicine, the translational step from genetic and 
other etiological data towards clinically useful information - i.e., diagnostic biomarkers and 
disease-modifying treatments - still needs to be made in the field of POP. Therefore, in the 
present study, we have integrated the results from the first exome chip study of POP - 
which suggested multiple novel candidate genes implicated through exonic variants 
found in women with POP - with publically available genetic and expression data to 
generate a molecular landscape of POP. In turn, this landscape provides more detailed and 
novel insights into the biological processes that, when impaired, could be involved in the 
pathogenesis of POP. Furthermore, the POP landscape provides leads for existing drugs 
that could be repurposed and for novel, disease-modifying treatments of POP that could 
be developed. 
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MATERIALS AND METHODS 
Exome chip study 
Participants 
For the exome chip study, a case-control design was used, in which the case group 
consisted of women who presented with POP (some of whom had recurrent POP) at the 
department of Obstetrics and Gynaecology of the Radboud university medical center 
(Radboudumc), Nijmegen, The Netherlands, between January 2007 and February 2011. 
POP was defined as stage II or more, according to the Pelvic Organ Prolapse Quantification 
(POP-Q) system [11], i.e., descent of the leading edge of the prolapse of at least 1 cm above 
the hymenal remnants. POP had already been surgically treated in some women at the 
time of inclusion. Exclusion criteria were genetic diseases with a known increased risk of 
POP (such as the Ehlers-Danlos and Marfan syndromes, and myotonic dystrophy type 1) 
and problems with the patient’s understanding of the study. As the control group, we 
used subjects from the Nijmegen Biomedical Study, a general population-based survey 
conducted by Radboudumc's Departments for Health Evidence and Department of 
Laboratory Medicine. Further details about the selection of the participants for the exome 
chip study are provided in the Supplementary Methods. 
 
Laboratory analysis and genotyping, Quality Control (QC), Population Structure and Statistical 
Analysis 
Further details are provided in the Supplementary Methods. 
 
Molecular landscape building 
Applying the approach that we previously used for multiple neurodevelopmental 
disorders [12-14], we then built a molecular landscape of POP. First, we searched the 
literature for the (putative) function of all candidate genes implicated through the exome 
chip study as well as other POP candidates implicated via other evidence, including 
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genetic association studies, miRNA/mRNA/protein expression studies and/or genetic 
animal model studies. 
For this literature analysis, we used the UniProt Protein Knowledge Base 
(http://www.uniprot.org/uniprot) to gather basic information on the function of all 
candidate genes and their encoded proteins. Based on the biological processes that have 
already been suggested to be impaired in POP, we then searched PubMed 
(http://www.ncbi.nlm.nih.gov/sites/entrez) for all genes/proteins and using the search 
terms “collagen”, “connective tissue”, “fibrosis”, “pelvic” and “pelvic organ”. Further, we 
searched PubMed for all functional interactions between all candidate proteins. Lastly, 
based on all gathered information, we generated a protein interaction landscape. The 
figure of the landscape was made using the drawing program Serif DrawPlus version 4.0 
(www.serif.com). 
 
RESULTS 
Exome chip study 
Participant characteristics are presented in Table 1. Compared to cases, controls were on 
average 10 years older (female controls 5 years vs. male controls 15 years older), and had a 
higher ratio of postmenopausal females. Since the prevalence of POP increases with age 
and is probably associated with postmenopausal state - making it likely that some of the 
controls had POP as well - the results of our study may therefore be attenuated. 
In total, we identified 49 markers with Bonferroni-corrected P < 0.05 (uncorrected P < 
1.17x10-6). After excluding two intronic markers (rs11152369 and rs12025416), a marker 
within a pseudogene (rs2021368), and two exonic but synonymous markers (rs143357491 
and rs143539514), a total of 44 statistically significant exonic and (potentially) deleterious 
markers/variants - including 41 missense mutations (single nucleotide variants or SNVs), 1 
frameshift mutation, 1 splice site mutation and 1 stop-gain mutation - were left. The list of 
these mutations and the unique genes they affect is provided in Table 2. 
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Table 1. Characteristics of POP cases and controls that were analyzed in our exome chip study 
Characteristic Cases (n=526)* Controls (n=1,911)* P value 
Gender 
    Female 
    Male 
 
526 (100; 526) 
- 
 
961 (50; 1,911) 
950 (50; 1,911) 
 
NA 
Agea (years) 51.3 ± 13.5 [21-87; 522] 61.0 ± 10.3 [27-78; 1,911] < 0.01f 
Parityb 2.4 ± 1.1 [0-9; 515] 2.3 ± 1.1 [0-10; 792] 0.46f 
BMI (kg/m2) 25.6 ± 3.9 [15-42; 393] 25.7 ± 3.9 [16-56; 1,868] 0.68f 
Previous POP surgery  
    0 
    1 
 ≥2 
 
277 (52.8; 525) 
150 (28.6; 525) 
98 (18.7; 525) 
NA NA 
POP-related 
complaintsc 48.9 ± 32.3 [0-100; 323] NA NA 
POP-Q staged 
    Stage 0 
    Stage I 
    Stage II 
    Stage III 
    Stage IV 
 
2 (0.4; 502) 
12 (2.4; 502) 
217 (43.2; 502) 
248 (49.4; 502) 
23 (4.6; 502) 
 
NA 
 
 
 
 
 
NA 
 
 
 
 
Postmenopausale 278 (73; 380) 772 (81; 956) < 0.01g 
* Data are presented as mean ± standard deviation [range; n] in case of continuously distributed 
data and as absolute numbers (percentages; n) in case of categorical data 
a Age at diagnosis for cases, age at time of survey/sampling for controls 
b Only for female participants 
c Measured with and reported as 'total score' from the validated Dutch translation of the Urogenital 
Distress Inventory (UDI) 
d Because the genetic background does not change over time, women were included in the exome 
chip study as a POP case at any time after diagnosis. This could also be after successful 
reconstructive surgery, which explains the lower stages in some POP cases (who had already been 
surgically treated). In all POP cases, the worst stage available in the medical file was used. 
e Only for female participants, this was assessed through the NBS participant's answer to the 
question: ‘Did you ever experience menopausal symptoms (e.g., hot flushes)', with possible 'yes', 
'no' or 'not applicable' (I am not in the menopause yet) 
f P value calculated with independent samples t-test  
g P value calculated with chi-square test 
Abbreviations: BMI, body mass index; NA, not applicable; POP, pelvic organ prolapse; POP-Q, Pelvic 
Organ Prolapse Quantification system 
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Interestingly, of the 40 mutations for which a Combined Annotation-Dependent Depletion 
(CADD) score was available - a single pathogenicity score that is calculated through 
combining 63 distinct computational prediction methods [15], including the Grantham 
score for missense mutations [16] - 16 had a CADD score > 20 and 5 had a CADD score > 10 
but < 20 (Table 2), indicating that these mutations are predicted to be among the 1 and 
10% most deleterious of all possible substitutions in the human genome, respectively [15, 
17]. This implies that a considerable proportion of the mutations that we identified 
through our exome chip study have a damaging effect on protein function. 
 
Molecular Landscape of POP 
A molecular landscape was built in which 20 of the 44 proteins encoded by the genes from 
the exome chip study (Table 2) interact functionally, together with 28 other POP 
candidates as well as 2 POP-implicated microRNAs (Supplementary Table 1; in this table, 
the level of evidence implicating each gene/protein in POP etiology is indicated). The 
molecular landscape of POP is shown in Figure 1 and the landscape also contains 10 
proteins/molecules - indicated in white - that have not been directly linked to POP (yet) 
but show important functional interactions within the landscape. 
The molecular POP landscape shown in Figure 1 is located in covering layer epithelial cells 
as well as the underlying extracellular matrix (ECM) and fibroblasts of the female 
urogenital tract. Four main biological processes operate within the landscape i.e., 
epithelial-mesenchymal transition (EMT), immune response activation, modulation of the 
ECM, and fibroblast survival and apoptosis. These processes interact with each other and 
are regulated through signaling cascades involving female hormones and by the cytokine 
TGFB1. In the Supplementary Information, a detailed description of the evidence linking 
all the proteins in the landscape is provided. However, here we give a more succinct 
account of the most important landscape processes and signaling cascades. 
The first and most important process in the landscape is EMT. Under normal conditions, 
epithelial cells are connected to their environment through cell-cell interactions as well as 
cell-ECM interactions. Among the cell-cell interactions are epithelial cadherin (E-
cadherin/CDH1)-based adherens junctions that stabilize epithelial cell-cell adhesion. EMT 
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is characterized by a 'cadherin switch', which is initiated when epithelial cells start 
producing less CDH1 and more of the mesenchymal marker N-cadherin (CDH2) (not 
shown). This in turn results in loss of epithelial cell-cell adhesion and the epithelial cells 
gradually transforming into mesenchymal cells which further differentiate into e.g., 
fibroblasts. This process involves the key transcription factor SMAD3 and is negatively 
regulated by three sex hormone-bound receptors - the estrogen receptors ESR1 and ESR2 
and the progesterone receptor (PGR) - that each upregulate CDH1 expression and hence 
prevent EMT. Conversely, TGFB1 induces EMT as it downregulates CDH1 expression. 
Secondly, protein members of both the major histocompatibility complex (MHC) I - i.e., 
HLA-E – and MHC II - i.e., HLA-DQA1 and HLA-DQB1 - are expressed in epithelial cells of the 
female reproductive tract, where they are involved in regulating the activity of the 
immune response through presenting foreign antigens to circulating T lymphocytes (not 
shown). TGFB1 is involved in this process through regulating all three HLA proteins, in part 
through upregulating the expression of beta-2-microglobulin (B2M), an EMT-inducing 
extracellular protein that mediates antigen presentation. 
Further, the ECM provides support to epithelial cells and fibroblasts and modulation of the 
ECM is essential for many pathophysiological processes such as tissue growth, wound 
healing, and fibrosis. The ECM is composed of different molecules, including elastin (ELN), 
and collagen (COL) fibers as well as proteins that crosslink or regulate the degradation of 
ELN and COL, e.g., LOX/LOXL1 and various matrix metalloproteinases (MMPs), respectively. 
TGFB1 is involved in ECM remodelling through regulating the expression of the majority of 
the ECM proteins in the landscape. 
Since fibroblasts are responsible for the synthesis and secretion of the main ECM 
components through SMAD3 - which also plays a major role in EMT (see above) - fibroblast 
survival and apoptosis (and hence proper functioning) is another important landscape 
process. TRAIL, a cytokine of the tumor necrosis factor (TNF) family, regulates fibroblast 
survival and apoptosis through its receptors and signaling involving pro-apoptotic 
proteins such as NFKB and CASP3. As with the three other main processes, TGFB1 is a key 
regulator, e.g., through regulating the expression of TRAIL-R1 and CASP3, and activating 
NFKB. 
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menopause is a factor in the onset of POP. Both lower serum levels of estradiol [25-27] and 
lower serum and urine levels of progesterone (metabolites) [25, 28] have been associated 
with an increased risk of POP. Hence, hormone replacement therapy (HRT) in 
postmenopausal women could have a favourable effect on the progression of POP or even 
prevent the disease from developing. However, studies on the effect of HRT in POP 
patients show conflicting results as negative [29], protective [30] or no effects [2, 31, 32] of 
HRT on POP onset and progression have been reported. Therefore, we suggest that future 
studies on the effect of HRT on POP take into consideration possible confounding factors 
such as endogenous sex hormone levels, menopause duration or whether POP patients 
have less functioning hormone receptors due to genetic variation. 
The cytokine TGFB1 represents the "common denominator" that regulates all four 
biological processes in the landscape and most notably, TGFB1 is involved in ECM 
remodelling and regulating fibroblast function. Moreover, the literature indicates an 
important role for TGFB1 itself in POP etiology, and TGFB1 has an effect at both the level of 
altered protein expression [33-35] and the functional level [36]. Therefore, TGFB1 would be 
an interesting target for novel treatments of POP. However, as a result of the diverse 
effects of TGFB1 (signaling), drugs targeting the expression or function of the genes 
encoding TGFB1 or its receptors are likely to be associated with an array of side effects. 
Hence, it would be better to use drugs that selectively target individual signaling 
pathways downstream of the TGFB1 receptor, and halofuginone may be such a drug [37]. 
Halofuginone specifically inhibits the phosphorylation and subsequent activation of 
SMAD3 after TGFB1 stimulation [38, 39]. Moreover, in various cell and animal models - 
including the rat uterus - halofuginone administration was also shown to inhibit the de 
novo synthesis and expression of type 1 collagens, such as the important landscape 
protein COL1A1 [40, 41]. Lastly, clinical trials in humans have indicated that oral or topical 
application - as a cream - of halofuginone is safe, well-tolerated and has a beneficial effect - 
with minimal side effects - on skin diseases such as sclerodermia [37, 42], making it a good 
candidate to further evaluate as a "repurposed" drug for the prevention and/or treatment 
of POP. 
Another novel and (partial) TGFB1-modulating treatment option for POP may be 
metformin, an oral anti-diabetic drug that affects multiple genes/proteins and processes in 
our POP landscape. First and foremost, metformin reduces the expression of extracellular 
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DISCUSSION 
We integrated the available genetic and expression data with our results from the first 
exome chip study in POP patients compared to controls into a protein interaction 
landscape of the disease. The landscape contains approximately half of the proteins 
encoded by the novel candidate genes identified through the exome chip. Further, the 
POP landscape reveals four main biological processes that are affected in POP and that 
operate in covering layer epithelial cells and underlying ECM and fibroblasts of the female 
urogenital tract, i.e., EMT, immune response activation, ECM modulation and fibroblast 
survival and apoptosis. Of note, none of the "classical" POP candidate genes - that were 
identified through genetic association studies and that mainly encode ECM proteins - were 
found to contain significantly associated exonic variants in our study. In addition, our POP 
landscape does not assume or represent a "sequence of events" i.e., a number of biological 
processes and signaling cascades that occur in a spatially and temporally distinct order. 
Instead, a deficit in any or a combination of the four main landscape processes or their 
constituting signaling cascades, possibly aggravated through environmental risk factors 
and caused by variants in one or more genes, can lead to POP in various degrees of 
severity. 
Multiple signaling cascades in the landscape are regulated by the female sex hormones, 
i.e., estrogen in its active form estradiol and progesterone. These hormones indirectly 
affect oxidative stress levels in epithelial cells and fibroblasts of the urogenital tract as both 
progesterone-activated PGR [18] and estradiol-activated ESR2 [19] upregulate the 
expression of the enzyme GGCT. Together with two other enzymes from the landscape, 
GPX1 and GSTP1, GGCT is involved in the metabolism of glutathione [20], an important 
antioxidant necessary for preventing oxidative stress-induced cellular damage by reactive 
oxygen species (ROS) [21]. Interestingly, ROS production by fibroblasts of women without 
POP was significantly increased through mechanical stress [22] and oxidative stress 
biomarkers were increased in the uterosacral ligaments of POP patients [23]. ROS can also 
directly induce EMT [24], corroborating the role of oxidative stress in POP development. 
Although sex hormones influence many landscape processes and cascades, their role in 
the etiology of POP is not completely understood. Increasing age and postmenopausal 
state are risk factors for POP [5] and it is thought that the hypoestrogenic state after the 
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have less functioning hormone receptors due to genetic variation. 
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important role for TGFB1 itself in POP etiology, and TGFB1 has an effect at both the level of 
altered protein expression [33-35] and the functional level [36]. Therefore, TGFB1 would be 
an interesting target for novel treatments of POP. However, as a result of the diverse 
effects of TGFB1 (signaling), drugs targeting the expression or function of the genes 
encoding TGFB1 or its receptors are likely to be associated with an array of side effects. 
Hence, it would be better to use drugs that selectively target individual signaling 
pathways downstream of the TGFB1 receptor, and halofuginone may be such a drug [37]. 
Halofuginone specifically inhibits the phosphorylation and subsequent activation of 
SMAD3 after TGFB1 stimulation [38, 39]. Moreover, in various cell and animal models - 
including the rat uterus - halofuginone administration was also shown to inhibit the de 
novo synthesis and expression of type 1 collagens, such as the important landscape 
protein COL1A1 [40, 41]. Lastly, clinical trials in humans have indicated that oral or topical 
application - as a cream - of halofuginone is safe, well-tolerated and has a beneficial effect - 
with minimal side effects - on skin diseases such as sclerodermia [37, 42], making it a good 
candidate to further evaluate as a "repurposed" drug for the prevention and/or treatment 
of POP. 
Another novel and (partial) TGFB1-modulating treatment option for POP may be 
metformin, an oral anti-diabetic drug that affects multiple genes/proteins and processes in 
our POP landscape. First and foremost, metformin reduces the expression of extracellular 
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TGFB1 [43, 44] and it decreases TGFB1-promoted loss of CDH1 [45, 46], which results in less 
EMT. Further, metformin regulates female sex hormone signaling as it suppresses the 
expression of miR-221 [47, 48] and miR-222 [47], two POP-implicated microRNAs that 
downregulate ESR1 expression. Metformin also inhibits TGFB1-induced synthesis of type 1 
collagens by fibroblasts through suppressing SMAD3 phosphorylation [49-51]. Based on 
these data and like halofuginone, metformin could be studied as a repurposed preventive 
or therapeutic drug for POP. 
In conclusion, the molecular landscape that we built based on the results from our exome 
chip study and available literature data provides detailed and novel insights into the 
genetic etiology of POP. Although further research is necessary to replicate the exome 
chip findings and to functionally validate the novel insights from the landscape so they 
could be developed into disease-modifying drugs, our landscape already provides leads 
for existing drugs that could be tested as repurposed compounds in selected groups of 
POP patients. 
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SUPPLEMENTARY METHODS 
Exome chip study  
Participants 
In total, 21,756 age- and sex-stratified, randomly selected inhabitants of the municipality 
of Nijmegen received an invitation to fill out a postal questionnaire on e.g., lifestyle and 
medical history, and to donate a blood sample of 8.5 ml in a serum separator tube and a 10 
ml EDTA blood sample. The response to the questionnaire was 43% (n=9,350) and 69% 
(n=6,468) of the responders also donated blood samples. For 1,931 of the individuals who 
donated blood, exome chip data were available. Because the controls were sampled from 
the general population and due to the high prevalence of POP in the population, it is likely 
that some of the controls had POP as well. Moreover, the control group also contained 
male subjects who cannot develop POP but can pass on (potentially) deleterious 
mutations to their offspring [1]. Taken together, this could attenuate the effect of some 
pathogenic mutations in the exome chip study that we conducted. For both cases and 
controls, data on age, parity, and BMI were collected. For cases only, data on previous POP 
surgery, the POP-Q stage as well as POP complaints as measured with the validated Dutch 
translation of the Urogenital Distress Inventory (UDI) [2] were also collected. The UDI 
records the presence or absence of specific symptoms, and associated bother on a four-
point Likert scale. The scores of the UDI are transformed to a continuous scale, ranging 
from 0 (no bother) to 100 (greatly bothersome). According to this continuous scale, 
women without symptoms and women with symptoms but without any bother are scored 
equally. The exome chip study was approved by the local institutional review board in an 
amendment of CMO numbers 2007/043 and 2010/071. 
 
Laboratory analysis and genotyping 
Blood samples were drawn from all cases. Genomic DNA was isolated from peripheral 
blood using the Nucleospin Blood Kit (Macherey-Nagel, Du ̈ren, Germany). Both case and 
control samples were genotyped (Illumina Exome BeadChip v1.1 (Illumina® San Diego, 
California, USA)) and called at the Human Genome Facility and the department of 
Epidemiology, Erasmus MC, Rotterdam. Calling was done in GenomeStudio using default 
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cluster files provided by Illumina (HumanExome-12v1-1_A.egt), followed by calling of non-
called variants using zCall [3]. 
 
Quality Control (QC) 
Data on 242,901 genetic markers and 2,479 individuals were available prior to 
implementation of QC, which was implemented using PLINK software. Of the 2,479 
individuals, 548 were classified as cases, while the remaining 1,931 individuals were 
considered to be controls. Given the nature of the studied phenotype, all cases were 
female while the controls consisted of 978 females and 953 males. Prior to QC, the total 
genotype calling rate was 0.999053. A total of 12 individuals (11 cases and 1 control) were 
removed for low per-individual calling rate (<0.95), while the same per-marker calling rate 
criterion (<0.95) led to the removal of 82 markers. Further QC steps in the combined 
case/control population included checks of markers for low minor allele frequency (MAF) 
(MAF <0.005, failed by 199,851 markers), deviation from Hardy-Weinberg equilibrium 
(HWE) (p<10-4, 280 markers), differential missingness with respect to phenotype (via --test-
missing, p<10-3, 88 markers) and haplotype (via --test-mishap, p<10-6, 14 markers). 
Furthermore, individuals were checked for sex discordance (via --check-sex, 10 
individuals), individual duplicity or high-relatedness (via --genome, PI_HAT≥0.9 [4], 7 
individuals), heterozygosity (via --het, with conf. int. based on MAD, 13 individuals). Lastly, 
heterozygous haploid genotypes and non-missing non-male Y chromosome genotypes 
were set to missing values. After QC, there were 42,586 markers and 2,437 individuals 
(1,487 females and 950 males; 526 cases, 1,911 controls) left.  
 
Population structure  
Since principal component analysis uncovered evidence of population structure in the 
data, we performed clustering analysis using R function hclust() with method ward.D [5]. 
The dissimilarity structure was produced by dist() using the first 5 components produced 
by PLINK's multidimensional scaling (MDS) analysis (via --mds-plot 10) to estimate 
continuous axes of ancestry. Using the output of R function NbClust(), the desired number 
of clusters was set to 3. The case/control counts in the resulting three clusters were 
120/474, 145/439 and 261/998. 
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Statistical Analysis  
Using the quality controlled clustered data, we analysed the 42,586 markers (see above) 
for association with POP using the Cochran-Mantel-Haenszel (CMH) test’s asymptotic P 
values via PLINK’s --mh option at the Bonferroni corrected level of significance 
0.05/42,586=1.17x10-6. 
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Upon phosphorylation and activation by TGFB1 (see above), phosphorylated SMAD3 
translocates to the nucleus and promotes EMT [57, 58]. 
Further, ZFYVE9 binds and forms a functional complex with the ER membrane-located 
ANKLE2 [59], and inhibits EMT through upregulating the expression of CDH1 [60]. 
TGFB1 is additionally involved in modulating the SMAD3-ZFYVE9-ANKLE2 complex 
through downregulating the expression of ZFYVE9 [60] and regulating ANKLE2 
expression [61]. 
Within epithelial cells, the activation and translocation of SMAD3 to the nucleus is also 
positively regulated by the adaptor protein NFKB [62]. In turn, NFKB is activated by 
cytoplasmic FASTKD1 and RRM2 [63, 64], and downstream of TGFB1 signaling [65]. 
Furthermore, SMAD3 and TGFB1 upregulate each other's expression [66, 67]. When 
activated in the nucleus by e.g., AHNAK (see above), SMAD3 downregulates the 
expression of the nuclear estrogen receptor ESR1 [68]. In turn, through binding and 
forming a complex with its natural ligand, the female sex hormone estradiol (E), ESR1 
upregulates the expression of AHNAK [69, 70]. The POP-implicated microRNAs miR-221 
and miR-222 also negatively regulate ESR1 expression through binding and destabilizing 
the ESR1 mRNA [71]. Epithelial NOP56 [72] also binds and interacts with estradiol-bound 
ESR1 [70]. Moreover, USP4 is an enzyme that deubiquitinates ADORA2A - an epithelial and 
mesenchymal receptor that is bound and activated by extracellular adenosine (A) [73] - 
which increases the amount of functional receptors at the cell membrane [74]. The A-
ADORA2A complex is also involved in upregulating the expression of CDH1 [75] and 
hence inhibiting EMT [76] (see above). Apart from downregulating ESR1 and CDH1 (see 
above), nuclear SMAD3 upregulates the expression of the other nuclear estrogen receptor 
ESR2 [68]. Further, E-bound ESR1 and ESR2 upregulate and downregulate the expression 
of PGR - the nuclear receptor for the pregnancy hormone progesterone (P) - respectively 
[77]. Interestingly, through our exome chip analysis, we identified POP patients with 
mutations in the genes encoding AKR1C1 and AKR1D1, two functionally related enzymes 
that negatively regulate the production of P through promoting its conversion into 
inactive P metabolites [73]. P-activated PGR [78] and E-activated ESR2 [79] upregulate the 
expression of GGCT, one of the major enzymes involved in the metabolism of the 
important cellular antioxidant glutathione (G) [80] that is highly expressed in the nucleus 
and cytoplasm of epithelial cells of the reproductive system [81]. GPX1 and GSTP1 are 
  
SUPPLEMENTARY INFORMATION 
FIGURE 1 - POP LANDSCAPE DESCRIPTION 
In the description of the landscape below, all candidate genes/proteins that were 
implicated in POP through our exome chip study (Table 2), the other POP candidate 
genes/proteins (Supplementary Table 1) and three POP-linked signaling molecules 
(estradiol, glutathione and progesterone) are indicated in bold. 
Signaling through the molecular landscape is initiated at the cell membrane of epithelial 
cells and underlying fibroblasts of the urogenital tract (and more specifically the pelvic 
ligaments), where the binding of ligands from the extracellular matrix (ECM) to their 
respective receptors leads to the modulation of several downstream molecular cascades in 
the cytoplasm, cytoskeleton, endoplasmic reticulum (ER) and nucleus. These cascades 
converge on regulating epithelial-mesenchymal transition (EMT). In essence, EMT is 
characterized by a so-called 'cadherin switch' that is initiated when epithelial cells start 
producing less of the epithelial marker and membrane protein E-cadherin (CDH1) and 
more of the mesenchymal marker N-cadherin (CDH2) (not shown) [48]. This in turn results 
in the adherens junctions between epithelial cells letting loose and the epithelial cells 
gradually transforming into mesenchymal cells. 
In normally functioning epithelial cells, cytoplasmic AHNAK binds and stabilizes the 
epithelial cytoskeleton, which in turn results in CDH1 being anchored to and modulated 
by the (actin) cytoskeleton. Cytoskeleton-anchored CDH1 of opposite cells bind each 
other and hence positively regulate epithelial cell-cell contacts, preventing EMT [49, 50]. 
Further, NEB binds and stabilizes the (actin) cytoskeleton [51], the organization of which is 
also regulated by cytoplasmic ARHGEF19 [52], which is itself upregulated by the 
extracellular cytokine TGF-beta-1 (TGFB1) [53]. TGFB1 is a key positive regulator of EMT 
as it significantly downregulates CDH1 expression [54]. AHNAK shuttles between the 
cytoplasm and nucleus [55], and nuclear AHNAK can induce EMT [49]. A possible 
explanation for the role of AHNAK in inducing EMT may lie in the fact that in response to 
TGFB1, AHNAK promotes the activation and translocation of SMAD3 to the nucleus [56], 
which in turn downregulates CDH1 [54]. In addition and as further described below, 
SMAD3 regulates the expression of a number of EMT-involved extracellular proteins. 
ZFYVE9 (other name: SARA) is a peptidase that binds and retains SMAD3 in the cytoplasm. 
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Upon phosphorylation and activation by TGFB1 (see above), phosphorylated SMAD3 
translocates to the nucleus and promotes EMT [57, 58]. 
Further, ZFYVE9 binds and forms a functional complex with the ER membrane-located 
ANKLE2 [59], and inhibits EMT through upregulating the expression of CDH1 [60]. 
TGFB1 is additionally involved in modulating the SMAD3-ZFYVE9-ANKLE2 complex 
through downregulating the expression of ZFYVE9 [60] and regulating ANKLE2 
expression [61]. 
Within epithelial cells, the activation and translocation of SMAD3 to the nucleus is also 
positively regulated by the adaptor protein NFKB [62]. In turn, NFKB is activated by 
cytoplasmic FASTKD1 and RRM2 [63, 64], and downstream of TGFB1 signaling [65]. 
Furthermore, SMAD3 and TGFB1 upregulate each other's expression [66, 67]. When 
activated in the nucleus by e.g., AHNAK (see above), SMAD3 downregulates the 
expression of the nuclear estrogen receptor ESR1 [68]. In turn, through binding and 
forming a complex with its natural ligand, the female sex hormone estradiol (E), ESR1 
upregulates the expression of AHNAK [69, 70]. The POP-implicated microRNAs miR-221 
and miR-222 also negatively regulate ESR1 expression through binding and destabilizing 
the ESR1 mRNA [71]. Epithelial NOP56 [72] also binds and interacts with estradiol-bound 
ESR1 [70]. Moreover, USP4 is an enzyme that deubiquitinates ADORA2A - an epithelial and 
mesenchymal receptor that is bound and activated by extracellular adenosine (A) [73] - 
which increases the amount of functional receptors at the cell membrane [74]. The A-
ADORA2A complex is also involved in upregulating the expression of CDH1 [75] and 
hence inhibiting EMT [76] (see above). Apart from downregulating ESR1 and CDH1 (see 
above), nuclear SMAD3 upregulates the expression of the other nuclear estrogen receptor 
ESR2 [68]. Further, E-bound ESR1 and ESR2 upregulate and downregulate the expression 
of PGR - the nuclear receptor for the pregnancy hormone progesterone (P) - respectively 
[77]. Interestingly, through our exome chip analysis, we identified POP patients with 
mutations in the genes encoding AKR1C1 and AKR1D1, two functionally related enzymes 
that negatively regulate the production of P through promoting its conversion into 
inactive P metabolites [73]. P-activated PGR [78] and E-activated ESR2 [79] upregulate the 
expression of GGCT, one of the major enzymes involved in the metabolism of the 
important cellular antioxidant glutathione (G) [80] that is highly expressed in the nucleus 
and cytoplasm of epithelial cells of the reproductive system [81]. GPX1 and GSTP1 are 
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other enzymes with an important role in glutathione metabolism [73]. GSTP1 is involved 
in regulating the expression of ATP12A [82], a membrane-located transporter of 
potassium (K+) and hydrogen (H+) [73] that regulates epithelial cell function [83]. 
Moreover, E-bound ESR1 [84] and ESR2 [85] as well as P-bound PGR [86, 87] inhibit EMT 
through upregulating CDH1 expression. 
A part of the landscape is also involved in regulating the immune response in that beta-2-
microglobulin (B2M) - an EMT-inducing [88, 89] extracellular protein that mediates the 
presentation of antigens to the immune system [73] - is (up)regulated by TGFB1 [90]. 
Further, B2M binds and functionally interacts with HLA-E [91, 92] and LILRA1 [93] and it is 
involved in upregulating the expression of HLA-DQA1 and HLA-DQB1 [94], which form a 
functional complex with each other [95] and are both downregulated by TGFB1 [94]. HLA-
E belongs to the membrane-located class I major histocompatibility (MHC I) proteins while 
HLA-DQA1 and HLA-DQB1 are MHC class II (MHC II) proteins [73] and LILRA1 can 
function as a receptor for MHC class I proteins [73]. Both MHC I and MHC II proteins are 
expressed in epithelial cells of the female reproductive tract where they are involved in 
regulating the immune response through presenting foreign antigens to circulating T 
lymphocytes [96, 97] (not shown). 
Remodelling of the ECM constitutes another major signaling cascade within the landscape 
and almost all POP candidate genes identified prior to this study encode proteins that are 
involved in this process. Further, fibroblasts produce most of these extracellular POP 
candidates (see below). In addition, literature suggests that in both women with and 
without POP, mechanical stretch alters the response of (pelvic ligament) fibroblasts to ECM 
remodelling and the interaction between the ECM and these fibroblasts [38, 98, 99]. The 
ECM is composed of different molecules, including collagen (COL) and elastin (ELN) 
fibers as well as proteins that crosslink or regulate the degradation of COL and ELN 
molecules. First, A-activated ADORA2A (see above) is involved in upregulating the 
expression of the extracellular collagen COL3A1 [100, 101] and downregulating the 
extracellular matrix metalloproteinase MMP9 [102] - which itself is upregulated 
downstream of NFKB [103, 104] and degrades COL1A1 [105], ELN [106] and TGFB1 [76]. 
Moreover, the A-ADORA2A complex inhibits the degradation of ELN [102] while MMP9 is 
involved in upregulating the expression of another collagen, COL18A1 [107]. FBLN5 and 
LOXL1 preferentially bind each other [30, 108, 109] and the FBLN5-LOXL1 complex 
facilitates the crosslinking of elastic fibers through binding and interacting with ELN [108]. 
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In addition, LOX catalyzes the crosslinking and formation of elastic fibers through ELN 
binding [110-112]. Apart from elastic fiber crosslinking, LOX is essential for binding and 
hence crosslinking collagens such as COL1A1 and COL3A1 [113]. FBLN5 inhibits EMT 
through significantly enhancing the ability of TGFB1 to downregulate the expression of 
CDH1 [114] (not shown). FBLN5 also increases the expression of MMP2 [114] and 
regulates the activity of MMP9 [40, 114]. MMP2 is a key metalloproteinase (MMP) in the 
landscape as it degrades COL1A1 [105] and ELN [115] and is downregulated through 
estradiol-bound ESR2 [116] and upregulated by NFKB [117]. Further, MMP2 is involved in 
upregulating the other MMPs MMP1, MMP3 - which promotes EMT through degrading 
CDH1 [118, 119] - and MMP9 [120]. 
The extracellular protein TIMP2 binds and forms a complex with MMP1 [121] and MMP2 
[122] while it inhibits MMP1 [123], MMP2 [124] and MMP9 [125]. Moreover, MMP3 
activates both MMP9 [126] and MMP1 [127], with the latter being upregulated by ELN 
[128]. Both MMP1 and MMP3 also upregulate the expression of MMP9 [129]. Lastly, 
COL18A1 (see above) downregulates the expression of MMP1 [130] and inhibits MMP2 
[131], which itself is involved in upregulating COL18A1 expression [132]. 
TGFB1 is involved in ECM remodelling through regulating the expression of the majority 
of the above described ECM proteins. TGFB1 mediates collagen and elastin fiber 
deposition in the ECM through upregulating the expression of COL1A1 [133-136], 
COL3A1 [135], ELN [136], FBLN5 [114, 137], LOX and LOXL1 [136]. Moreover, TGFB1 
upregulates the expression of MMP2 [138], MMP3 [138, 139] and MMP9 [138, 140] while it 
is involved in decreasing the expression of MMP1 [141, 142]. In addition, cell surface 
localized MMP2 and MMP9 can cleave and hence activate latent TGFB1 (not shown) 
[143]. 
The extracellular proenzyme plasminogen (PLG) is cleaved by the PLAU and PLAT 
enzymes (not shown) to plasmin (PL) [73], an extracellular enzyme that dissolves the fibrin 
of blood clots and acts as a proteolytic factor in a variety of other biological processes, 
including ECM remodeling [73]. PLAU binding to its receptor (not shown), PLAUR, which is 
anchored in the fibroblast cell membrane and has a role in regulating fibroblast growth 
[144], promotes the cleavage of PLG to PL [73], a process that is also stimulated by TGFB1 
[145]. PL upregulates the expression of COL1A1 [146] and it activates MMP1, MMP2, 
MMP3 and MMP9 [147-149]. Further, PL is inhibited by the extracellular proteinase 
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cytoplasm and nucleus [55] and stimulates the TGFB1-induced activation and 
translocation of SMAD3 to the nucleus [56]. Further, CASP3 (negatively) regulates the 
activity of PARP1 [170, 171], a nuclear protein that modulates oxidative stress-induced 
apoptosis in fibroblasts [41]. Moreover, PARP1 binds and functionally interacts with the 
transcription factor ZNF423 [172, 173] and is activated by TRAIL [174]. Both SMAD3 [175] 
and YWHAB [176] bind and interact with WNK1, a kinase that is also upregulated by 
TGFB1 [177]. Further, as also mentioned before, SMAD3 upregulates the expression of 
ESR2 [68] and E-bound ESR2 upregulates the expression of BID [178], a kinase that is 
cleaved (and hence activated) by TRAIL [179] and promotes apoptosis through activating 
both CASP3 [180] and NFKB [181], with the latter also being downregulated through 
signaling involving COL18A1 [130]. 
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inhibitor SERPINA1, which itself is degraded by MMP1 (not shown), MMP2, MMP3 and 
MMP9 [150]. The extracellular form of YWHAB (see below) is also involved in upregulating 
the expression of MMP1 [151]. 
Since fibroblasts are responsible for the synthesis and secretion of the main ECM 
components through (e.g., AHNAK- or TGFB1-activated) SMAD3 - which also plays a 
major role in EMT (see above) - fibroblast survival and apoptosis (and hence proper 
functioning) is another important landscape process. In this respect, SMAD3 upregulates 
the expression of COL1A1, COL3A1 [135] and MMP9 [152], whereas it downregulates ELN 
[153] and MMP1 [142]. Further, nuclear SPOP belongs to an E3 ubiquitin-protein ligase 
complex that is involved in upregulating MMP1 expression [154]. This SPOP complex also 
represses the transcriptional activity of ESR1 [155] and its activity is regulated through 
binding and interacting with SPOPL [156]. In addition, IMUP - encoded by the C19orf33 
gene - is a nuclear protein that is a potent negative regulator of apoptosis in fibroblasts 
[157]. 
TRAIL (other name: TNFSF10) is a member of the tumor necrosis factor (TNF) family of 
extracellular cytokines that binds to its receptors, the transmembrane proteins TRAIL-R1 
(other name: TNFRSF10A), TRAIL-R2 (other name: TNFRSF10B) and TRAIL-R3 (other name: 
TNFRSF10C), which is anchored in the fibroblast cell membrane [73]. Upon binding TRAIL-
R1 [158] and TRAIL-R2 [159], TRAIL triggers fibroblast apoptosis through activating CASP3 
or NFKB [160, 161]. In contrast, TRAIL-R3 competes with TRAIL-R1 and TRAIL-R2 for TRAIL 
binding and, as TRAIL-R3 does not have a cytoplasmic 'death domain', it inhibits the 
TRAIL-R1/2-induced apoptotic cascades and hence protects fibroblasts against apoptosis 
[162]. 
TGFB1 (up)regulates the expression of TRAIL-R1 and CASP3 [163] and, as already 
mentioned above, NFKB is activated downstream of TGFB1 signaling [65]. In turn, NFKB 
regulates the activity of CASP3 [164, 165], providing additional regulation of the TRAIL-
R1/R2-apoptotic signaling cascade. 
In addition, TGFB1 promotes EMT through activating miR-155 [166], a microRNA that 
regulates inflammation and fibrosis and is involved in inhibiting CASP3 [167] and 
upregulating the expression of SMAD3 [168]. CASP3 also cleaves (and hence regulates the 
activity of) AHNAK [169], which, as already indicated above, shuttles between the 
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cytoplasm and nucleus [55] and stimulates the TGFB1-induced activation and 
translocation of SMAD3 to the nucleus [56]. Further, CASP3 (negatively) regulates the 
activity of PARP1 [170, 171], a nuclear protein that modulates oxidative stress-induced 
apoptosis in fibroblasts [41]. Moreover, PARP1 binds and functionally interacts with the 
transcription factor ZNF423 [172, 173] and is activated by TRAIL [174]. Both SMAD3 [175] 
and YWHAB [176] bind and interact with WNK1, a kinase that is also upregulated by 
TGFB1 [177]. Further, as also mentioned before, SMAD3 upregulates the expression of 
ESR2 [68] and E-bound ESR2 upregulates the expression of BID [178], a kinase that is 
cleaved (and hence activated) by TRAIL [179] and promotes apoptosis through activating 
both CASP3 [180] and NFKB [181], with the latter also being downregulated through 
signaling involving COL18A1 [130]. 
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demonstrated. This could (partly) be explained by the fact that medical information on the 
family members of the POP patients was obtained through the patients themselves, which 
may have led to underreporting of the disorders. In contrast, the family members of the 
controls were interviewed in person.  
Based on the hypothesis that POP results at least partially from a dysregulation of 
collagen-linked processes - which is supported by various literature studies [11, 12] - we 
then assessed in chapter 4 whether homozygous female carriers of a relatively common 
missense mutation in COL3A1 - rs1800255, 2209G>A - had a higher risk of POP. Using the 
polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) 
method, this was indeed confirmed in a Dutch population, with an odds ratio of 5.0 and a 
95% confidence interval of 1.4–17.1. At around the same time, a smaller study in 
Taiwanese women reported a similar result for rs1800255 [13]. 
In order to make routine screening of rs1800255 available for clinical practice, we 
evaluated in chapter 5 whether the high resolution melting (HRM) analysis, a less time-
consuming and relatively inexpensive method, was a reliable alternative for the PCR-RFLP 
analysis. Therefore, specific primers and a probe were developed for HRM analysis and a 
study was performed to compare the HRM method with analyses using the PCR-RFLP 
method and sequencing, the latter being the gold - but expensive - standard. The PCR-
RFLP analysis resulted in 2 incorrect diagnoses (6% of the samples) compared to sequence 
analysis, whereas the HRM analysis demonstrated 100% accuracy. This raised concerns 
about our initial finding and made it necessary to validate the results of our PCR-RFLP 
study in chapter 4 with the HRM method. Therefore, in chapter 6, a case-control study 
was performed - including 272 patients with POP and 82 controls - which confirmed the 
observed discrepancy (i.e., for 8% of the samples) between the HRM and PCR-RFLP results. 
In addition, a statistically significant association between POP and rs1800255 could no 
longer be demonstrated. Since most studies on single, hypothesis-driven candidate genes 
- i.e., genes that were selected because of their putative functional involvement in POP 
(e.g., collagen, fibulin, and other extracellular matrix (ECM) components) - are based on 
PCR-RFLP analysis, there may be some inconsistencies in the results of these studies as 
well, perhaps leading to false positive results in some cases. 
In recent years, novel large scale, high-throughput genetic analysis methods have been 
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Pelvic organ prolapse (POP) is a major health care problem in women, with a reported 
prevalence of up to 40% [1, 2]. In the Netherlands, approximately 40% of women above 
the age of 45 have POP of at least POP-Q-stage II [3]. Although POP is not life-threatening, 
its bothersome symptoms have a significant impact on all domains of quality of life. The 
life-time risk for any surgical intervention for prolapse is 19% [4] and the total costs for POP 
surgery are substantial [5]. POP has a multifactorial etiology in which both environmental 
and hereditary factors play a role. In this respect, parity, vaginal delivery, age, and high 
body mass index (BMI) have been firmly identified as environmental risk factors [6] and 
could all cause defects of fibrous and muscular pelvic floor tissues. Evidence for a genetic 
background of POP has emerged from family studies - including studies using a twin 
design [7, 8]. Initially, the focus of genetic research on POP was on candidate gene-specific 
single nucleotide polymorphisms (SNPs). In a number of these candidate genes, SNPs were 
found to be (putatively) associated with POP, including genes encoding steroid hormone 
receptors, collagens type I and III, and multiple matrix metalloproteinases. However, only 
one SNP, rs1800012 in the COL1A1 gene, has demonstrated replicable association with 
POP in a meta-analysis of all candidate gene association studies [9]. Further, a genome-
wide association study (GWAS) has identified five SNPs associated with POP that were 
nominally replicated [10]. 
The aim of this thesis was to gain insight into the pathogenesis of POP through the 
identification of novel genetic risk factors. 
Chapters 2 and 3 were dedicated to exploring and interpreting the epidemiological data 
we gathered in our own sample of POP cases, controls and their relatives, as well as to 
comparing and integrating similar data from the literature. 
We found that relatives of POP cases had a significantly increased risk of having the 
disease themselves and that a family history of POP was significantly associated with the 
presence of POP in individual women. This finding of family history as an important risk 
factor for POP added to the evidence for a role of genetics in the development of the 
disorder. In addition, our data showed that women with POP had a relatively higher risk of 
having other collagen-associated disorders, such as varicose veins, hypermobility and 
rectal prolapse. However, a significant difference in the prevalence of collagen-associated 
disorders in relatives of POP patients versus relatives of controls could not be 
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demonstrated. This could (partly) be explained by the fact that medical information on the 
family members of the POP patients was obtained through the patients themselves, which 
may have led to underreporting of the disorders. In contrast, the family members of the 
controls were interviewed in person.  
Based on the hypothesis that POP results at least partially from a dysregulation of 
collagen-linked processes - which is supported by various literature studies [11, 12] - we 
then assessed in chapter 4 whether homozygous female carriers of a relatively common 
missense mutation in COL3A1 - rs1800255, 2209G>A - had a higher risk of POP. Using the 
polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) 
method, this was indeed confirmed in a Dutch population, with an odds ratio of 5.0 and a 
95% confidence interval of 1.4–17.1. At around the same time, a smaller study in 
Taiwanese women reported a similar result for rs1800255 [13]. 
In order to make routine screening of rs1800255 available for clinical practice, we 
evaluated in chapter 5 whether the high resolution melting (HRM) analysis, a less time-
consuming and relatively inexpensive method, was a reliable alternative for the PCR-RFLP 
analysis. Therefore, specific primers and a probe were developed for HRM analysis and a 
study was performed to compare the HRM method with analyses using the PCR-RFLP 
method and sequencing, the latter being the gold - but expensive - standard. The PCR-
RFLP analysis resulted in 2 incorrect diagnoses (6% of the samples) compared to sequence 
analysis, whereas the HRM analysis demonstrated 100% accuracy. This raised concerns 
about our initial finding and made it necessary to validate the results of our PCR-RFLP 
study in chapter 4 with the HRM method. Therefore, in chapter 6, a case-control study 
was performed - including 272 patients with POP and 82 controls - which confirmed the 
observed discrepancy (i.e., for 8% of the samples) between the HRM and PCR-RFLP results. 
In addition, a statistically significant association between POP and rs1800255 could no 
longer be demonstrated. Since most studies on single, hypothesis-driven candidate genes 
- i.e., genes that were selected because of their putative functional involvement in POP 
(e.g., collagen, fibulin, and other extracellular matrix (ECM) components) - are based on 
PCR-RFLP analysis, there may be some inconsistencies in the results of these studies as 
well, perhaps leading to false positive results in some cases. 
In recent years, novel large scale, high-throughput genetic analysis methods have been 
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EFFECT SIZE OF INDIVIDUAL GENETIC RISK FACTORS 
Of the identified variants from our exome chip study, almost half have a predicted 
damaging effect on protein function, and are among the 1-10 % most deleterious 
mutations in the human genome. Certainly, the 2209G>A allele of rs1800255 also has a 
predicted deleterious effect but, in contrast to the variants identified through the exome 
chip study, this variant nor any other exonic variants in COL3A1 were found to be 
significantly associated with POP in our Dutch population. The same applies to the 
findings from all other, hypothesis-driven POP candidate gene studies, i.e, no exonic 
variants in any of the 'classical' POP candidate genes survived multiple testing correction 
in our exome chip study. This implies that although the hypothesis-driven candidate 
genes do contribute to the genetic etiology of POP to some extent, their relative 
contribution to disease etiology is not substantial. 
 
INFLUENCE OF ENVIRONMENTAL FACTORS 
This thesis has focused on the familial aspects and genetic risk factors underlying POP. 
However, as the disease is caused by a complex interplay between genetic and 
environmental risk factors, the influence of the environment and environmental triggers 
on POP development and progression also has to be taken into account. 
There are many ways in which the environment can influence a disorder and one such way 
is through epigenetics. Epigenetics can be defined as the process of dynamic changes in 
gene expression in which genes can be switched on and off - i.e., transcriptional activation 
or repression - by environmental factors and without any alterations in DNA sequence. 
These environmental factors can for instance induce DNA methylation, which typically 
causes the repression of gene transcription and hence (protein) expression. During aging, 
a global loss of DNA methylation - i.e., a general loss of gene repression - occurs. However, 
some genetic loci become hypermethylated with increasing age, leading to less 
transcription and expression of the genes in these loci. In this respect, it is very interesting 
that genes that are hypermethylated during aging include the estrogen receptor (ER), E-
cadherin (CDH1), and collagen-α1 (COL1A1) genes [14], which all encode proteins in our 
POP landscape. Moreover, LOX, another gene that encodes a key protein in the landscape, 
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developed, allowing us to screen for novel genetic variants across the whole genome and 
hence in an unbiased way. These types of analyses are especially interesting for polygenic 
disorders such as POP, in which a combination of many genetic variants, each with a 
(relatively) small effect, leads to the disorder. 
In chapter 7, we have reported the first large scale exome chip study of POP that we 
conducted, yielding significant association between exonic variants - mainly missense 
mutations - in 44 unique genes and POP. 
The proteins encoded by approximately half of these genes fit into a molecular landscape, 
together with a number of other POP candidate proteins that have been implicated in the 
disease through genetic association and expression studies in POP patients. This 
integrated molecular POP landscape provides detailed and novel insights into the 
genetically determined mechanisms that are involved in the pathogenesis of POP - which 
can be broadly divided into four processes that interact with each other and are regulated 
through signaling involving female sex hormones and the cytokine TGFB1 - and provides 
leads for new treatment options of POP (see below). 
 
MAIN BIOLOGICAL PROCESSES INVOLVED IN POP ETIOLOGY 
As described in detail in chapter 7, four main biological processes operate within the 
molecular POP landscape, i.e., epithelial-mesenchymal transition (EMT), immune response 
activation, modulation of the extracellular matrix (ECM), and fibroblast survival and 
apoptosis. A deficit in any or a combination of these four processes or their constituting 
signaling cascades, possibly aggravated through environmental risk factors and caused by 
variants in one or more genes, can lead to POP in various degrees of severity. Until now, 
the vast majority of hypothesis-driven research has been focussed on ECM modulation, so 
extending the search for POP genes through the hypothesis-free exome chip study has 
greatly increased our knowledge and understanding about the processes affected in the 
disease. 
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EFFECT SIZE OF INDIVIDUAL GENETIC RISK FACTORS 
Of the identified variants from our exome chip study, almost half have a predicted 
damaging effect on protein function, and are among the 1-10 % most deleterious 
mutations in the human genome. Certainly, the 2209G>A allele of rs1800255 also has a 
predicted deleterious effect but, in contrast to the variants identified through the exome 
chip study, this variant nor any other exonic variants in COL3A1 were found to be 
significantly associated with POP in our Dutch population. The same applies to the 
findings from all other, hypothesis-driven POP candidate gene studies, i.e, no exonic 
variants in any of the 'classical' POP candidate genes survived multiple testing correction 
in our exome chip study. This implies that although the hypothesis-driven candidate 
genes do contribute to the genetic etiology of POP to some extent, their relative 
contribution to disease etiology is not substantial. 
 
INFLUENCE OF ENVIRONMENTAL FACTORS 
This thesis has focused on the familial aspects and genetic risk factors underlying POP. 
However, as the disease is caused by a complex interplay between genetic and 
environmental risk factors, the influence of the environment and environmental triggers 
on POP development and progression also has to be taken into account. 
There are many ways in which the environment can influence a disorder and one such way 
is through epigenetics. Epigenetics can be defined as the process of dynamic changes in 
gene expression in which genes can be switched on and off - i.e., transcriptional activation 
or repression - by environmental factors and without any alterations in DNA sequence. 
These environmental factors can for instance induce DNA methylation, which typically 
causes the repression of gene transcription and hence (protein) expression. During aging, 
a global loss of DNA methylation - i.e., a general loss of gene repression - occurs. However, 
some genetic loci become hypermethylated with increasing age, leading to less 
transcription and expression of the genes in these loci. In this respect, it is very interesting 
that genes that are hypermethylated during aging include the estrogen receptor (ER), E-
cadherin (CDH1), and collagen-α1 (COL1A1) genes [14], which all encode proteins in our 
POP landscape. Moreover, LOX, another gene that encodes a key protein in the landscape, 
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healthy controls. However, clear differences were observed between fibroblasts from the 
POP and non-POP sites within the same POP patient, suggesting an acquired effect - as a 
result of POP - rather than an intrinsic - and hence POP-causing – defect [20]. 
 
A REVISED MODEL OF POP DEVELOPMENT 
Concluding, it can be said that the genetically and environmentally determined processes 
that are affected in POP are numerous and complex. Readdressing the model for the 
development of pelvic floor dysfunctions - including POP - first postulated by Bump and 
Norton [21], this can be revised (and revisited) as follows: the genetic variants/mutations 
that were identified as part of this thesis can act as predisposing factors, making women 
more susceptible to the development of POP. This process can be facilitated by 
decompensating factors such as aging in which epigenetics play a role through 
transcriptional gene activation and (mainly) repression. Additionally, the process can be 
accelerated by inciting factors (e.g., vaginal delivery) and promoting factors (e.g., obesity), 
leading to mechanical stretching of VCs and thereby influencing protein expression. 
 
NOVEL PREVENTIVE AND THERAPEUTIC OPTIONS FOR POP 
Although we aim to replicate the POP exome chip study (see below), its findings provide 
(much) more detailed and novel insights into the genetically determined processes 
underlying the disease. Therefore, our molecular landscape could be used for developing a 
risk prediction model of POP that would include both genetic and environmental risk 
factors. Women carrying one or more (genetic) risk factors - such as mutations - could for 
instance specifically benefit from preventive measures like weight reduction or pelvic floor 
muscle training (PFMT), in order to reduce their high a priori disease risk. 
Generally speaking, therapeutic options for POP can be divided in two main categories, 
i.e., nonsurgical and surgical treatments, which both have their own pros and cons. 
Nonsurgical treatments (i.e., PFMT and pessary therapy) have the advantage of causing 
relatively minor side effects but discontinuation rates are high and further (surgical) 
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is affected by methylation. More specifically, hypermethylation of the promoter region of 
the LOX gene has been associated with POP, implying that the suppression of LOX 
expression due to methylation of its promoter region leads to or facilitates the 
development of POP [15]. This is in line with the finding that the expression of LOX mRNA 
in the anterior vaginal wall [16] and USL [17] of POP patients is significantly reduced. 
As mentioned before, parity, vaginal delivery and high BMI are among the main 
environmental risk factors for POP. In that perspective, it is interesting to investigate the 
influence of mechanical stretch on vaginal cells (VCs) caused by either increased intra-
abdominal pressure or dynamic stretching during the process of giving birth. In healthy 
tissues, mechanosensitive cells like (myo)fibroblasts are important regulators of ECM 
remodelling and homeostasis [18]. The group of Kufaishi et al. [18] showed that as a 
response to static mechanical stretching, VCs of premenopausal POP patients had 
significantly downregulated expression of collagens such as COL1A1, whereas the 
expression of (extracellular) matrix metalloproteinases (MMPs) - like MMP1 and MMP3 - 
and their inhibitors TIMP1 and TIMP3 was upregulated in these cells. VCs of women 
without POP did not show any significant changes in the expression of collagens nor the 
aforementioned MMPs and TIMPs, whereas the expression of some other MMPs (for 
instance MMP2 and MMP8) were downregulated [18]. In contrast, the research group of 
Ruiz-Zapata et al. [19] demonstrated a downregulation of COL1A1 expression in VCs of 
healthy controls in response to cyclic mechanical loading whereas COL1A1 expression in 
VCs of POP patients was not affected. Taken together, the response to mechanical 
stretching between VCs of women with and without POP appears to be different, 
suggesting an important role for ECM modulation in the pathogenesis of POP, and this 
response may be influenced by the type of stretching the VCs are exposed to, i.e., static or 
cyclic. 
The above being said, the question remains whether the abovementioned observed 
differences in protein expression are the cause or a result of the underlying disorder. In this 
respect, Ruiz-Zapata et al. performed a study in which they compared the 
mechanoresponses of vaginal fibroblasts obtained through biopsies from the prolapsed 
anterior vaginal wall (the 'POP site') and from non-affected anterior vaginal cuff tissue (the 
'non-POP' site) in POP patients. They showed that the fibroblasts from the non-POP site of 
POP patients did not respond differently than fibroblasts derived from the same site in 
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healthy controls. However, clear differences were observed between fibroblasts from the 
POP and non-POP sites within the same POP patient, suggesting an acquired effect - as a 
result of POP - rather than an intrinsic - and hence POP-causing – defect [20]. 
 
A REVISED MODEL OF POP DEVELOPMENT 
Concluding, it can be said that the genetically and environmentally determined processes 
that are affected in POP are numerous and complex. Readdressing the model for the 
development of pelvic floor dysfunctions - including POP - first postulated by Bump and 
Norton [21], this can be revised (and revisited) as follows: the genetic variants/mutations 
that were identified as part of this thesis can act as predisposing factors, making women 
more susceptible to the development of POP. This process can be facilitated by 
decompensating factors such as aging in which epigenetics play a role through 
transcriptional gene activation and (mainly) repression. Additionally, the process can be 
accelerated by inciting factors (e.g., vaginal delivery) and promoting factors (e.g., obesity), 
leading to mechanical stretching of VCs and thereby influencing protein expression. 
 
NOVEL PREVENTIVE AND THERAPEUTIC OPTIONS FOR POP 
Although we aim to replicate the POP exome chip study (see below), its findings provide 
(much) more detailed and novel insights into the genetically determined processes 
underlying the disease. Therefore, our molecular landscape could be used for developing a 
risk prediction model of POP that would include both genetic and environmental risk 
factors. Women carrying one or more (genetic) risk factors - such as mutations - could for 
instance specifically benefit from preventive measures like weight reduction or pelvic floor 
muscle training (PFMT), in order to reduce their high a priori disease risk. 
Generally speaking, therapeutic options for POP can be divided in two main categories, 
i.e., nonsurgical and surgical treatments, which both have their own pros and cons. 
Nonsurgical treatments (i.e., PFMT and pessary therapy) have the advantage of causing 
relatively minor side effects but discontinuation rates are high and further (surgical) 
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Taken together, the findings of this thesis can be instrumental for both testing repurposed 
and/or to be developed drugs as well as for developing treatment strategies that can e.g., 
reduce the need for multiple surgical interventions, help with the selection of women that 
would benefit most from certain surgical interventions and/or (eventually) prevent the 
disease from occurring in women at risk. 
 
FUTURE RESEARCH AND PERSPECTIVES 
This thesis provides an important step towards a better understanding of the 
pathophysiology of POP by providing detailed and novel insights in the underlying 
genetic causes of POP. However, further research is needed to further unravel the complex 
etiology of this disorder. 
Based on the above, interesting topics for future research could e.g., be: 
 The development of a risk prediction model for POP that would include both genetic 
and environmental risk factors. 
 Investigating whether certain genetic risk factors/mutations make women more 
prone to POP recurrences. 
 Investigating whether women with one or more specific genetic or environmental risk 
factors could especially benefit from certain preventive and therapeutic measures, 
like PFMT or first line therapy with mesh material. 
 Replication/genetic validation of the findings from the exome chip study. 
 Functionally validating the findings from the exome chip study in order to develop 
novel, disease-modifying drugs, based on the molecular landscape as well as testing 
repurposed compounds like halofuginone and metformin in (selected groups of) POP 
patients. 
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treatment is often needed. Alternative conservative/nonsurgical treatment options are 
therefore needed.  
In this respect, our molecular landscape provides some novel insights that could lead to 
the development of novel, disease-modifying drugs and it yields clues for existing, to be 
repurposed drugs that could be tested for their effect on POP onset and/or progression in 
a selected group of patients. Two examples of drugs that could be repurposed for POP 
treatment - i.e., halofuginone en metformin, which both affect multiple biological 
processes in our landscape - have already been discussed in chapter 7. 
As for the surgical treatment options, the high rate of recurrence remains a major problem, 
especially for surgery with native tissue repair. Transvaginal mesh repair is associated with 
lower failure rates but causes more and more serious side effects. This has led to the policy 
that mesh material should only be used as a second-line treatment option. However, 
patients with genetic variants making them more susceptible to the development of POP, 
may be more prone to recurrences and a more liberal treatment with mesh material could 
therefore be indicated for this group of patients. Only one article about the influence of 
genetic risk factors on recurrence risk has been published so far [22], showing that a 
missense mutation in the ZFYVE16 gene was significantly associated with early, 
multicompartment prolapse recurrence after robotic sacrocolpopexy. 
An interesting alternative to classical mesh surgery may be stem cell therapy, which could 
be used in a selected group of POP patients. An animal study in rats [23] showed that 
muscle-derived stem cells (MDSC) mounted on a scaffold of biodegradable small intestinal 
submucosa (SIS) and implanted in the defective vagina survived for an extended period, 
differentiated into smooth-muscle cells (SMC) in the muscularis layer, and promoted 
epithelium regeneration. This exploratory “proof of concept” approach was supported by 
finding a reduction in fibrosis and stimulation of the vaginal repair process, which seemed 
to occur more efficiently than with SIS implants - without stem cells - alone or in the 
spontaneously regenerative tissue in the absence of any treatment. Especially in POP 
patients without obvious genetic risk factors - and hence associated disturbances in 
underlying biological processes - but with altered gene expression that has been 
'acquired' as a result of mechanical stretching (see above), this could be an attractive 
treatment option. 
159
GENERAL DISCUSSIONGENE  I I  
 
Taken together, the findings of this thesis can be instrumental for both testing repurposed 
and/or to be developed drugs as well as for developing treatment strategies that can e.g., 
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would benefit most from certain surgical interventions and/or (eventually) prevent the 
disease from occurring in women at risk. 
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This thesis provides an important step towards a better understanding of the 
pathophysiology of POP by providing detailed and novel insights in the underlying 
genetic causes of POP. However, further research is needed to further unravel the complex 
etiology of this disorder. 
Based on the above, interesting topics for future research could e.g., be: 
 The development of a risk prediction model for POP that would include both genetic 
and environmental risk factors. 
 Investigating whether certain genetic risk factors/mutations make women more 
prone to POP recurrences. 
 Investigating whether women with one or more specific genetic or environmental risk 
factors could especially benefit from certain preventive and therapeutic measures, 
like PFMT or first line therapy with mesh material. 
 Replication/genetic validation of the findings from the exome chip study. 
 Functionally validating the findings from the exome chip study in order to develop 
novel, disease-modifying drugs, based on the molecular landscape as well as testing 
repurposed compounds like halofuginone and metformin in (selected groups of) POP 
patients. 
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associated diseases, since POP patients significantly more often report the coincidence of 
these disorders. 
Since preceding research pointed in the direction of collagen defects as a common 
denominator in the development of POP, the prevalence of single nucleotide 
polymorphisms (SNPs) in the alpha 1 chain of the type III collagen protein-encoding gene 
(COL3A1) was investigated in Chapter 4. First, a pilot study was performed in which the 
prevalence of six different SNPs was assessed in 50 POP patients versus 30 controls. 
Polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) analysis 
was used for this purpose. Only the COL3A1 2209G>A, rs1800255 polymorphism - a 
relatively common missense mutation - appeared to be related to the presence of POP and 
the prevalence of this polymorphism was further tested in 202 POP patients versus 102 
vaginally parous controls. In this larger case-control group, the crude odds ratio for the 
probability of POP in a woman with the homozygous 2209G>A, rs1800255 was 5.0 (95% CI 
1.4–17.1), making it a statistically significant risk factor. Using multivariate logistic 
regression, neither age nor parity were confounders for this risk factor. The presence of the 
heterozygous polymorphism did not correlate with the probability of POP. 
Because of this promising result, we wanted to bring the possibility to test for rs1800255 
within reach of everyday practice. Since high resolution melting (HRM) analysis is an 
accurate and less time-consuming and thereby more cost-effective method compared to 
PCR-RFLP analysis, it could be of great value during routine clinical practice. Therefore, we 
tested in Chapter 5 whether HRM analysis was a reliable alternative to PCR-RFLP analysis 
for the detection of rs1800255. Specific primers and a probe were developed and 
subsequently used for the detection of the SNP by means of HRM analysis in 36 women 
with POP, randomly selected from the women described in our previous study (Chapter 4). 
The DNA of these women was additionally analysed by sequence analysis, using the latter 
as the gold standard. When comparing PCR-RFLP analysis with sequencing, PCR-RFLP 
resulted in two incorrect diagnoses (5.6%). Both samples were determined as 
heterozygous by PCR-RFLP, but proved to be one homozygous substitution and one wild-
type when using sequencing. HRM analysis demonstrated unique melting profiles for wild-
type, as well as heterozygous and homozygous polymorphisms, with a 100% accuracy 
when compared to sequence analysis, making HRM a reliable method for the detection of 
rs1800255. 
  
 
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SUMMARY 
Chapter 1 provides a general introduction to the subject and describes the aims of the 
thesis. The main objective of this thesis was to identify genetic risk factors and biological 
processes contributing to pelvic organ prolapse (POP) etiology. 
In Chapter 2, the results of a systematic literature review and meta-analysis of clinical 
studies on a family history of POP as a risk factor for the disease in individual women are 
presented. In the literature search using ‘Pubmed’ and ‘Embase’, 16 studies that fulfilled 
the inclusion criteria were identified. Eight of those studies were designed as case-control 
studies including both POP cases and controls. In total, 1,107 cases and 1,941 controls 
could be included in the meta-analysis. The pooled odds ratio (OR) of POP when there was 
a positive family history as compared to a negative family history was 2.58 (95 % CI 2.12–
3.15). These results indicate that there is a substantially increased risk for POP when there 
is a positive family history and suggest that genetic predisposition plays an important role 
in the development of POP. 
There is substantial evidence that an alteration in collagen metabolism contributes to the 
development of POP. Because certain disorders such as varicose veins and umbilical hernia 
are also associated with changes in collagen quantity or composition, it seems plausible 
that these conditions are overrepresented in patients with POP and their family members. 
In Chapter 3, the results of an observational cohort study are presented, in which the 
prevalence of various collagen-associated disorders was compared between POP patients 
(n = 110) and controls (n = 100), and between the first and second degree family members 
of the patients (n = 341) and controls (n = 266). Collagen-associated disorders in general 
were significantly more prevalent among POP patients compared to controls. When 
looking at the disorders separately, varicose veins, joint hypermobility and rectal prolapse 
were significantly more often reported in the POP index cases. No difference was found in 
the presence of collagen-associated disorders among family members of cases versus 
controls. However, when focussing on the occurrence of POP in family members, mothers 
and sisters of POP patients were significantly more likely to have (had) POP as compared to 
mothers and sisters of controls. This supports the hypothesis that a genetic predisposition 
to POP exists. Furthermore, it seems likely that a common genetic defect affecting 
collagen strength or metabolism is responsible for both POP and other collagen-
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associated diseases, since POP patients significantly more often report the coincidence of 
these disorders. 
Since preceding research pointed in the direction of collagen defects as a common 
denominator in the development of POP, the prevalence of single nucleotide 
polymorphisms (SNPs) in the alpha 1 chain of the type III collagen protein-encoding gene 
(COL3A1) was investigated in Chapter 4. First, a pilot study was performed in which the 
prevalence of six different SNPs was assessed in 50 POP patients versus 30 controls. 
Polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP) analysis 
was used for this purpose. Only the COL3A1 2209G>A, rs1800255 polymorphism - a 
relatively common missense mutation - appeared to be related to the presence of POP and 
the prevalence of this polymorphism was further tested in 202 POP patients versus 102 
vaginally parous controls. In this larger case-control group, the crude odds ratio for the 
probability of POP in a woman with the homozygous 2209G>A, rs1800255 was 5.0 (95% CI 
1.4–17.1), making it a statistically significant risk factor. Using multivariate logistic 
regression, neither age nor parity were confounders for this risk factor. The presence of the 
heterozygous polymorphism did not correlate with the probability of POP. 
Because of this promising result, we wanted to bring the possibility to test for rs1800255 
within reach of everyday practice. Since high resolution melting (HRM) analysis is an 
accurate and less time-consuming and thereby more cost-effective method compared to 
PCR-RFLP analysis, it could be of great value during routine clinical practice. Therefore, we 
tested in Chapter 5 whether HRM analysis was a reliable alternative to PCR-RFLP analysis 
for the detection of rs1800255. Specific primers and a probe were developed and 
subsequently used for the detection of the SNP by means of HRM analysis in 36 women 
with POP, randomly selected from the women described in our previous study (Chapter 4). 
The DNA of these women was additionally analysed by sequence analysis, using the latter 
as the gold standard. When comparing PCR-RFLP analysis with sequencing, PCR-RFLP 
resulted in two incorrect diagnoses (5.6%). Both samples were determined as 
heterozygous by PCR-RFLP, but proved to be one homozygous substitution and one wild-
type when using sequencing. HRM analysis demonstrated unique melting profiles for wild-
type, as well as heterozygous and homozygous polymorphisms, with a 100% accuracy 
when compared to sequence analysis, making HRM a reliable method for the detection of 
rs1800255. 
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TGFB1. Our POP landscape provides novel insights into the genetically determined 
mechanisms that, when impaired, are involved in the pathogenesis of POP. Furthermore, 
the landscape yields valuable clues for existing drugs that could be repurposed, and for to-
be-developed, disease-modifying drugs that can be tested in selected groups of POP 
patients. 
Lastly, in Chapter 8, we have integrated and discussed the main findings of this thesis. 
  
 
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Because of the discrepancy between the results of the PCR-RFLP and HRM analyses in 
Chapter 5, the data in the entire group as described in Chapter 4 needed to be re-
assessed in order to validate whether the above-mentioned homozygous COL3A1 2209 
G>A, rs1800255 polymorphism as assessed with HRM was still associated with POP. 
Chapter 6 describes a case-control study in which 272 patients with POP and 82 controls 
were included. DNA from all subjects was analysed by HRM analysis. Two hundred thirteen 
of the DNA samples (60%) had been analysed previously in the PCR-RLFP analysis of the 
COL3A1 2209 G>A, rs1800255 polymorphism. A discrepancy between HRM and PCR-RFLP 
was found in 17 samples, leading to a misclassification rate of 7.5%. When using the HRM 
analysing method, 18 (7%) cases versus 3 (4%) controls had a homozygous COL3A1 2209 
G>A, rs1800255 polymorphism (OR 1.9; 95% CI 0.5-6.9), indicating that no association 
between POP and the homozygous polymorphism could be demonstrated. We therefore 
concluded that this specific polymorphism does not have an additional value in the 
prediction of POP. 
As the research projects included in this thesis progressed, a rapid evolution of genetic 
analysis methods took place, allowing for the screening of novel genetic variants across 
the whole genome and exome. Hence, we were able to perform an exome chip analysis in 
Chapter 7. The great advantage of this type of research is that it is non-candidate driven, 
i.e., hypothesis-free, and is able to identify more rare and exonic variants - i.e., variants that 
directly affect the exons, the protein coding regions of genes - without focusing on the 
most obvious gene candidates only. For this study, we genotyped blood samples of 526 
women with POP and 1,911 control individuals using an exome chip containing more than 
240,000 exonic markers. In this way, we identified statistically significant mutations in 44 
unique, protein-coding genes. The proteins encoded by 20 of those genes fit into a 
molecular landscape, together with 28 other POP candidate proteins and 2 microRNAs, 
identified through an elaborate literature search, including genetic association studies, 
mRNA/protein expression studies in POP patients and functional data. The molecular POP 
landscape that we built is located in the epithelial cells, extracellular matrix and fibroblasts 
of the urogenital tract and harbours four main biological processes, i.e., epithelial-
mesenchymal transition, immune response activation, modulation of the extracellular 
matrix, and fibroblast survival and apoptosis. Those processes interact with each other and 
are regulated through signaling involving the female sex hormones and the cytokine 
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TGFB1. Our POP landscape provides novel insights into the genetically determined 
mechanisms that, when impaired, are involved in the pathogenesis of POP. Furthermore, 
the landscape yields valuable clues for existing drugs that could be repurposed, and for to-
be-developed, disease-modifying drugs that can be tested in selected groups of POP 
patients. 
Lastly, in Chapter 8, we have integrated and discussed the main findings of this thesis. 
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Collageen is een belangrijk onderdeel van het bindweefsel, dat verantwoordelijk is voor de 
stevigheid en elasticiteit van de weefsels in ons lichaam. Er bestaan sterke aanwijzingen 
dat veranderingen in collageen bijdragen aan de ontwikkeling van POP. Aangezien ook 
andere aandoeningen zoals spataders en een navelbreuk worden geassocieerd met 
veranderingen in de hoeveelheid of samenstelling van het collageen, lijkt het aannemelijk 
dat deze aandoeningen vaker voorkomen bij patiënten met POP en hun familieleden. In 
Hoofdstuk 3 worden de resultaten van een observationele cohortstudie gepresenteerd, 
waarin het voorkomen van verschillende collageen-geassocieerde aandoeningen wordt 
vergeleken tussen POP-patiënten (n = 110) en controles (n = 100) en tussen de eerste- en 
tweedegraads familieleden van POP-patiënten (n = 341) en controles (n = 266). Collageen-
geassocieerde aandoeningen als groep, kwamen significant vaker voor bij de POP-
patiënten dan bij de controles. Wanneer werd gekeken naar elk van de aandoeningen 
afzonderlijk, dan werden spataders, gewrichtshypermobiliteit en rectum-prolaps 
significant vaker gerapporteerd door de POP-patiënten. Er werd geen verschil gevonden in 
de aanwezigheid van collageen-geassocieerde aandoeningen onder familieleden van de 
POP-patiënten versus familieleden van de controles. Echter, moeders en zussen van POP-
patiënten hadden wel significant vaker POP (nu of in het verleden) in vergelijking met 
moeders en zussen van de controles. Dit ondersteunt de hypothese dat er een genetische 
aanleg voor POP bestaat. Bovendien lijkt het waarschijnlijk dat een gemeenschappelijke 
genetische afwijking het ontstaan van zowel POP als van andere collageen-geassocieerde 
aandoeningen beïnvloedt. 
Zoals hierboven al aangehaald, wees eerder wetenschappelijk onderzoek erop dat 
collageen-afwijkingen in het algemeen een belangrijke oorzaak voor de ontwikkeling van 
POP zouden kunnen zijn. Genen zijn de dragers van ons erfelijk materiaal en een afwijking 
in een van de collageen-genen zou kunnen leiden tot vermindering van de sterkte van het 
collageen en dus tot verzakkingen. De kleinst mogelijke afwijking in onze genen wordt 
een ‘enkel-nucleotide polymorfisme’ (Engels: single nucleotide polymorphism, afgekort 
SNP) genoemd. In Hoofdstuk 4 werd het voorkomen van verschillende van deze SNPs in 
het collageen type III gen (COL3A1) onderzocht. Allereerst werd een kleinere studie 
uitgevoerd waarbij het voorkomen van zes verschillende SNPs in 50 POP-patiënten en 30 
controles werd onderzocht. Voor dit doel werd een ‘polymerase chain reaction – 
restriction fragment length polymorphism’ (PCR-RFLP) analyse gebruikt. Alleen het 
  
 
 
SAMENVATTING 
Vaginale prolaps (Engels: pelvic organ prolapse, afgekort POP) is een veel voorkomende 
klacht. Circa 40% van de Nederlandse vrouwen boven de 45 jaar heeft bij gynaecologisch 
onderzoek een verzakking [1]. Hoewel POP geen levensbedreigende ziekte is, kunnen de 
symptomen die hierdoor veroorzaakt worden zeer hinderlijk zijn en de kwaliteit van leven 
sterk beïnvloeden. Klachten kunnen variëren van het zien of voelen van een vaginale 
uitstulping, buikpijn, rugpijn, pijn bij het vrijen en blaasproblemen of problemen met de 
stoelgang [2]. 
De oorzaak van POP is multifactorieel, wat betekent dat er vele factoren zijn die het risico 
op het krijgen van POP kunnen verhogen. Voorbeelden hiervan zijn o.a. zwangerschap en 
bevalling en de menopauze. Daarnaast is familiaire/erfelijke aanleg een belangrijke 
risicofactor, hetgeen ook het hoofdthema is van dit proefschrift. 
Hoofdstuk 1 geeft een algemene inleiding over het onderwerp en beschrijft tevens de 
doelstellingen van dit proefschrift. De voornaamste doelstelling was het krijgen van een 
beter inzicht in de pathogenese cq. het onstaan van POP door het opsporen van nieuwe 
genetische varianten die bijdragen aan het verhoogde risico op het krijgen van POP. 
In Hoofdstuk 2 worden de resultaten van een systematische literatuurstudie en meta-
analyse gepresenteerd. Hierin werd onderzocht in hoeverre het hebben van vrouwelijke 
familieleden met POP (i.e., een positieve familieanamnese) een risicofactor is voor POP bij 
de individuele vrouw. Na een zoekopdracht in de wetenschappelijke databases ‘Pubmed’ 
en ‘Embase’ konden 16 studies worden geïdentificeerd die aan de inclusiecriteria 
voldeden. Acht van deze studies waren case-control studies, waarin zowel vrouwen met 
POP (de POP-patiënten) als vrouwen zonder POP (de controles) waren geïncludeerd. In 
totaal konden 1,107 POP-patiënten en 1,941 controles worden opgenomen in de meta-
analyse. De relatieve kans of odds-ratio (OR) op het hebben van POP in het geval van een 
positieve familieanamnese versus een negatieve familieanamnese was 2.58 (95% 
betrouwbaarheidsinterval 2.12-3.15). Deze resultaten geven aan dat er een aanzienlijk 
verhoogd risico op het hebben van POP bestaat indien er sprake is van een positieve 
familieanamnese en suggereren dat genetische aanleg een belangrijke rol speelt in de 
ontwikkeling van POP. 
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Collageen is een belangrijk onderdeel van het bindweefsel, dat verantwoordelijk is voor de 
stevigheid en elasticiteit van de weefsels in ons lichaam. Er bestaan sterke aanwijzingen 
dat veranderingen in collageen bijdragen aan de ontwikkeling van POP. Aangezien ook 
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Hoofdstuk 3 worden de resultaten van een observationele cohortstudie gepresenteerd, 
waarin het voorkomen van verschillende collageen-geassocieerde aandoeningen wordt 
vergeleken tussen POP-patiënten (n = 110) en controles (n = 100) en tussen de eerste- en 
tweedegraads familieleden van POP-patiënten (n = 341) en controles (n = 266). Collageen-
geassocieerde aandoeningen als groep, kwamen significant vaker voor bij de POP-
patiënten dan bij de controles. Wanneer werd gekeken naar elk van de aandoeningen 
afzonderlijk, dan werden spataders, gewrichtshypermobiliteit en rectum-prolaps 
significant vaker gerapporteerd door de POP-patiënten. Er werd geen verschil gevonden in 
de aanwezigheid van collageen-geassocieerde aandoeningen onder familieleden van de 
POP-patiënten versus familieleden van de controles. Echter, moeders en zussen van POP-
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Zoals hierboven al aangehaald, wees eerder wetenschappelijk onderzoek erop dat 
collageen-afwijkingen in het algemeen een belangrijke oorzaak voor de ontwikkeling van 
POP zouden kunnen zijn. Genen zijn de dragers van ons erfelijk materiaal en een afwijking 
in een van de collageen-genen zou kunnen leiden tot vermindering van de sterkte van het 
collageen en dus tot verzakkingen. De kleinst mogelijke afwijking in onze genen wordt 
een ‘enkel-nucleotide polymorfisme’ (Engels: single nucleotide polymorphism, afgekort 
SNP) genoemd. In Hoofdstuk 4 werd het voorkomen van verschillende van deze SNPs in 
het collageen type III gen (COL3A1) onderzocht. Allereerst werd een kleinere studie 
uitgevoerd waarbij het voorkomen van zes verschillende SNPs in 50 POP-patiënten en 30 
controles werd onderzocht. Voor dit doel werd een ‘polymerase chain reaction – 
restriction fragment length polymorphism’ (PCR-RFLP) analyse gebruikt. Alleen het 
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Hoofdstuk 6 wordt een case-controle studie gepresenteerd, waarin 272 POP-patiënten en 
82 controles werden geïncludeerd. De DNA-monsters van 213 van deze vrouwen (60%) 
waren reeds eerder geanalyseerd in de PCR-RFLP-analyse van het COL3A1 2209 G>A, 
rs1800255 polymorfisme. Voor deze studie werd het DNA van alle vrouwen geanalyseerd 
m.b.v. de HRM-analyse. Een discrepantie tussen HRM en PCR-RFLP werd gevonden in 17 
DNA-monsters, waardoor het percentage misclassificaties 7.5% bedroeg. Bij gebruik van 
de HRM analyse bleken 18 (7%) POP-patiënten versus 3 (4%) controles de homozygote 
vorm van het COL3A1 2209 G> A, rs1800255 polymorfisme te bezitten, wat leidde tot een 
OR van 1.9 (95% betrouwbaarheidsinterval 0.5-6.9). Er kon daarom geen verband tussen 
POP en het homozygote polymorfisme meer worden aangetoond, hetgeen tot de 
conclusie leidde dat dit specifieke polymorfisme geen meerwaarde heeft voor de 
voorspelling van het risico op POP. 
Tijdens het schrijven van dit proefschrift ontwikkelden zich in snel tempo nieuwe DNA-
analyse technieken. Hierdoor waren we in staat om in Hoofdstuk 7 een exoomchip- 
analyse uit te voeren. Een exoomchip kan een groot aantal (in dit geval meer dan 240,000) 
relatief zeldzame, genetische/erfelijke varianten binnen het exoom opsporen, waarbij het 
exoom dat deel van het menselijke DNA is dat alle informatie bevat om uit elk gen een 
eiwit te maken (dit noemt men ook het eiwit-coderende gedeelte van het DNA). Het grote 
voordeel van een exoomchip-analyse is dat het een hypothese-vrije vorm van onderzoek 
is. Dit wil zeggen dat het zich bij de zoektocht naar DNA-varianten niet alleen concentreert 
op de meest voor de hand liggende kandidaat-genen, maar op alle mogelijke genen. 
Voor deze studie werden bloedmonsters van 526 vrouwen met POP en 1,911 
controlepersonen gegenotypeerd cq. onderzocht met behulp van een exoomchip. Hierbij 
konden statistisch significante genetische/erfelijke varianten in 44 unieke genen worden 
geïdentificeerd. Dit stelde ons in staat om een ‘moleculair landschap’ te bouwen, waarin 
de gegevens van zowel de exoomchip-analyse als ook uit de beschikbare literatuur 
werden geïnterpreteerd en grafisch weergegeven. Dit moleculaire POP-landschap is 
gelocaliseerd in de epithelieelcellen, extracellulaire matrix en fibroblasten van het 
vrouwelijke urogenitaal stelsel en bevat in totaal 20 eiwitten van genen uit de exoomchip-
studie, tezamen met 28 andere POP kandidaat-genen en 2 zogenaamde 'microRNAs' 
afkomstig uit data uit de wetenschappelijke literatuur. Het landschap is onder te verdelen 
in vier belangrijke biologische processen, namelijk epitheliale-mesenchymale transitie, 
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COL3A1 2209G>A, rs1800255 polymorfisme leek gerelateerd te zijn met het voorkomen 
van POP. Aansluitend werd het voorkomen van dit polymorfisme getest in een grotere 
groep vrouwen, bestaande uit 202 POP-patiënten en 102 controles, die alle tenminste 1 
vaginale bevalling hadden doorgemaakt. In deze grotere case-controle-groep, bedroeg de 
OR voor de kans op POP bij een vrouw met het homozygote 2209G>A polymorfisme 5.0 
(95% betrouwbaarheidsinterval 1.4-17.1), waardoor het een statistisch significante 
risicofactor bleek. Leeftijd noch pariteit waren bij de multivariate logistische regressie 
analyse verstorende variabelen voor deze risicofactor. De aanwezigheid van het 
heterozygote polymorfisme bleek niet gerelateerd met het risico op POP. 
Een relatief nieuwe laboratoriummethode voor het opsporen van polymorfismen is de 
‘high resolution melting’ (afgekort HRM) analyse, waarbij de verschillende polymorfismen 
elk afzonderlijke smeltprofielen laten zien. De HRM analyse is, in vergelijking met de PCR-
RFLP analyse, een weinig tijdrovende en daardoor meer kosteneffectieve 
laboratoriummethode, waardoor deze methode in de dagelijkse klinische zorg van waarde 
zou kunnen zijn. Om die reden werd in Hoofdstuk 5 onderzocht of HRM analyse een 
betrouwbaar alternatief zou kunnen zijn voor PCR-RFLP analyse bij de detectie van het 
rs1800255 polymorfisme. Hiervoor werd het DNA van 36 POP-patiënten, willekeurig 
gekozen uit onze vorige studiegroep (Hoofdstuk 4), nogmaals geanalyseerd. Naast de 
PCR-RFLP analysemethode werden nu ook de HRM analyse en de sequencing analyse 
gebruikt, waarbij deze laatste methode gold als de gouden standaard. De resultaten van 
de PCR-RFLP-analyse toonden in twee gevallen een foute diagnose (5.6%). Beide DNA-
monsters waren bestempeld als zijnde heterozygoot door de PCR-RFLP analyse, maar 
bleken bij het gebruik van de sequencing methode homozygoot cq. wild-type. HRM 
analyse vertoonde in alle gevallen unieke smeltprofielen voor wild-type, heterozygote en 
homozygote polymorfismen. Hiermee werd aldus een nauwkeurigheid van 100% bereikt, 
waardoor de HRM analyse een snelle, relatief goedkope en betrouwbare methode voor 
het detecteren van het rs1800255 polymorfisme bleek te zijn. 
Vanwege de discrepantie tussen de resultaten van de PCR-RFLP en HRM analyse in de 
voorafgaande studie, moesten de resultaten van de gehele case-controle studie zoals 
beschreven in Hoofdstuk 4 opnieuw worden bekeken. Dit om te kunnen beoordelen of 
het bovengenoemde homozygote COL3A1 2209 G>A, rs1800255 polymorfisme, indien 
geanalyseerd middels de HRM analyse, nog steeds geassocieerd zou zijn met POP. In 
171
SUMMARY - SAMENVATTING S  - I  
 
 
Hoofdstuk 6 wordt een case-controle studie gepresenteerd, waarin 272 POP-patiënten en 
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rs1800255 polymorfisme. Voor deze studie werd het DNA van alle vrouwen geanalyseerd 
m.b.v. de HRM-analyse. Een discrepantie tussen HRM en PCR-RFLP werd gevonden in 17 
DNA-monsters, waardoor het percentage misclassificaties 7.5% bedroeg. Bij gebruik van 
de HRM analyse bleken 18 (7%) POP-patiënten versus 3 (4%) controles de homozygote 
vorm van het COL3A1 2209 G> A, rs1800255 polymorfisme te bezitten, wat leidde tot een 
OR van 1.9 (95% betrouwbaarheidsinterval 0.5-6.9). Er kon daarom geen verband tussen 
POP en het homozygote polymorfisme meer worden aangetoond, hetgeen tot de 
conclusie leidde dat dit specifieke polymorfisme geen meerwaarde heeft voor de 
voorspelling van het risico op POP. 
Tijdens het schrijven van dit proefschrift ontwikkelden zich in snel tempo nieuwe DNA-
analyse technieken. Hierdoor waren we in staat om in Hoofdstuk 7 een exoomchip- 
analyse uit te voeren. Een exoomchip kan een groot aantal (in dit geval meer dan 240,000) 
relatief zeldzame, genetische/erfelijke varianten binnen het exoom opsporen, waarbij het 
exoom dat deel van het menselijke DNA is dat alle informatie bevat om uit elk gen een 
eiwit te maken (dit noemt men ook het eiwit-coderende gedeelte van het DNA). Het grote 
voordeel van een exoomchip-analyse is dat het een hypothese-vrije vorm van onderzoek 
is. Dit wil zeggen dat het zich bij de zoektocht naar DNA-varianten niet alleen concentreert 
op de meest voor de hand liggende kandidaat-genen, maar op alle mogelijke genen. 
Voor deze studie werden bloedmonsters van 526 vrouwen met POP en 1,911 
controlepersonen gegenotypeerd cq. onderzocht met behulp van een exoomchip. Hierbij 
konden statistisch significante genetische/erfelijke varianten in 44 unieke genen worden 
geïdentificeerd. Dit stelde ons in staat om een ‘moleculair landschap’ te bouwen, waarin 
de gegevens van zowel de exoomchip-analyse als ook uit de beschikbare literatuur 
werden geïnterpreteerd en grafisch weergegeven. Dit moleculaire POP-landschap is 
gelocaliseerd in de epithelieelcellen, extracellulaire matrix en fibroblasten van het 
vrouwelijke urogenitaal stelsel en bevat in totaal 20 eiwitten van genen uit de exoomchip-
studie, tezamen met 28 andere POP kandidaat-genen en 2 zogenaamde 'microRNAs' 
afkomstig uit data uit de wetenschappelijke literatuur. Het landschap is onder te verdelen 
in vier belangrijke biologische processen, namelijk epitheliale-mesenchymale transitie, 
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immuunrespons-activatie, modulatie van de extracellulaire matrix, en overleving en 
apoptose (geprogrammeerde celdood) van fibroblasten. Deze processen beïnvloeden 
elkaar en worden gereguleerd door middel van de vrouwelijke geslachtshormonen en het 
cytokine TGFB1. Door het landschap hebben we nieuwe inzichten gekregen in de 
onderliggende genetische/erfelijke mechanismen die, wanneer zij niet optimaal verlopen, 
betrokken zijn bij het ontstaan van POP. Bovendien verschaft het landschap ons 
waardevolle aanknopingspunten voor mogelijke ziekte-modulerende medicamenten die 
getest zouden kunnen worden in een geselecteerd groep van POP-patiënten. 
Tenslotte hebben we in Hoofdstuk 8 de belangrijkste bevindingen van deze thesis 
geïntegreerd en besproken. 
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ABBREVIATIONS: 
 
AAA   Abdominal aorta aneurysm  
BMI   Body mass index 
CADD   Combined annotation-dependent depletion 
CI   Confidence interval 
CMO   Commissie mensgebonden onderzoek 
CS  Caesarean section 
DNA   Deoxyribonucleic acid 
ECM   Extracellular matrix 
EDS   Ehlers–Danlos syndrome 
EMT   Epithelial-mesenchymal transition 
ER  Endoplasmic reticulum 
ES  Exome sequencing 
GS   Grantham score 
GWAS   Genome-wide association study 
HRM   High resolution melting 
HRT  Hormone replacement therapy 
IRB   Institutional review board  
MAF   Minor allele frequency 
MDSC  Muscle-derived stem cells 
mRNA  messenger Ribonucleic acid 
miRNA   micro Ribonucleic acid 
NBS   Nijmegen Biomedical Study 
OR   Odds ratio 
PCR-RFLP  Polymerase chain reaction-restriction fragment length polymorphism 
PFMT   Pelvic floor muscle training 
POP   Pelvic organ prolapse 
POP-Q   Pelvic organ prolapse quantification  
POF   Premature ovarian failure 
RNA   Ribonucleic acid 
SIS  Small intestinal submucosa 
SMC  Smooth-muscle cell 
UDI   Urogenital Distress Inventory 
VC  Vaginal cell 
WGS  Whole-genome sequencing 
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Bij het schrijven van dit proefschrift ben ik door veel mensen geholpen, geïnspireerd en 
gemotiveerd. Zonder al jullie ondersteuning was deze ‘never-ending story’ waarschijnlijk 
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ervaring tijdens het ‘gynocamp’ in Nepal. Tevens gaf je me de ruimte alles in mijn eigen 
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enthousiast te maken en te motiveren om door te gaan! Zonder jouw ondersteuning had 
ik hier vandaag nooit kunnen staan. 
 
Beste Geert, toen ik echt niet meer wist hoe verder te gaan met mijn onderzoek, zorgde jij 
voor een doorstart…en wat voor een! Alhoewel jij tot dan toe eigenlijk vooral onderzoek 
op het gebied van de neuropsychiatrie had gedaan, ging je de uitdaging aan en stortte je 
je op dit voor jou onbekende terrein. Ontzettend bedankt voor het delen van al je kennis 
en ervaring, voor je eindeloze uitleg bij deze voor mij lastige materie en voor alle uren die 
je met mij gezocht hebt naar relaties tussen een, wat leek, eindeloze rij van genen. Zonder 
jouw hulp was het laatste, mooie artikel nooit tot stand gekomen. 
 
Beste Léon, beste Jeroen, jullie hebben engelengeduld gehad bij het mij uitleggen van de, 
voor jullie waarschijnlijk meest eenvoudige, lab-technieken. Hoe had een simpele arts-
assistent gynaecologie als ik zonder jullie hulp ooit leren pipetteren, centrifugeren, 
verdunnen en wat alles nog meer. En daarbij hebben jullie het zelfs voor elkaar gekregen 
dit werk leuk en gezellig te maken! 
 
De leden van de manuscriptcommissie en de corona wil ik hartelijk bedanken voor de tijd 
en moeite die ze gestoken hebben in het kritisch lezen van mijn manuscript en het stellen 
van vragen. 
 
Verder ben ik veel dank verschuldigd aan alle patiënten die bereid waren bloed te 
doneren en gegevens te delen in het kader van de verschillende onderzoeken in dit 
proefschrift. Zonder hen was dit proefschrift nooit tot stand gekomen. 
 
Ook alle co-auteurs ben ik zeer dankbaar voor hun hulp en waardevolle inbreng bij het 
schrijven van de artikelen. 
 
Alle gynaecologen in het Radboud, wat heb ik veel van jullie geleerd. Heel veel dank voor 
alle klinische lessen en voor het helpen verzamelen van de benodigde patiëntendata voor 
dit onderzoek. Ook alle poli-medewerkers wil ik hartelijk bedanken voor alle hulp en 
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ondersteuning bij dit onderzoek. Zonder jullie hulp bij het afnemen van bloed, het 
doorzoeken van archieven etc. was dit boekje er nooit gekomen. 
 
Alle gynaecologen, (oud)assistenten en poli- en OK-dames van de Gelderse Vallei, 
ontzettend bedankt voor alle gezelligheid, de vele kopjes koffie en soep tijdens de poli, 
jullie behulpzaamheid, interesse en wijze (levens)lessen. Ik heb het enorm naar m’n zin 
gehad bij jullie en op alle gebieden veel van jullie geleerd. 
 
Lieve Bertho, mijn carpoolmaatje in Nijmeegse tijden. Mijn ochtend was niet compleet als 
ik jou niet ’s ochtends eerst uit je bed kon toeteren, waarna je dan vervolgens bij mij in de 
auto je dag begon met koffie en muesli en ‘begin de dag met een dansje’ als 
achtergrondmuziek op de radio. Dank voor je altijd motiverende woorden (‘zonder 
wrijving geen glans’) en de eet- en slaapplek als ik voor mijn onderzoek weer een paar 
dagen naar Nijmegen moest (al moet ik voor het eten eerder je moeder bedanken). 
 
Lieve Sanne, mijn mede-kantoortuin-maatje, op-congresmaatje, koffiedrinkmaatje en wat 
al niet meer. We hebben heel wat gezellige uurtjes beleefd, onder andere op het 1-euro-
terras (met als enige minpuntje de Fado-avond). Op de een of andere manier heb ik het 
wel voor elkaar gekregen mijn zwangerschappen synchroon met jou te plannen…. het 
afronden van een proefschrift ging jou daarentegen ietsje sneller af. Maar dat mag de pret 
niet drukken. Op naar het volgende feestje! 
 
Lieve Frouke, jij had als belangrijke taak om voor de nodige ontspanning tussendoor te 
zorgen en dat is je goed gelukt. Heel erg bedankt voor de gezellige wijntjes in de stad, de 
dansjes, het heerlijke door jou gekookte eten, de slaapplek….wat fijn dat jouw deur altijd 
voor mij open staat. 
 
Lieve vrienden en familie, wat is het fijn om zo veel lieve mensen om me heen te hebben. 
Ondanks mijn ‘emigratie’ en het drukke bestaan zijn jullie er altijd voor mij als ik jullie 
nodig heb. 
 
Liebe Freund(Inn)e, danke, dass ihr mich so aufgenommen habt in eurem Leben. Ihr habt 
dafür gesorgt, dass ich in Deutschland ein neues Zuhause gefunden habe. Ich freue mich 
auf alle Tennisspielerfrauen-Essen, Spaziergeh-Truppe-Nachmittage usw. wo ich mich jetzt 
endlich nicht mehr über meine Doktorarbeit beklagen kann. 
 
Lieve pap en mam, ook al mochten jullie van mij al jaren niet meer vragen ‘hoe het nou zat 
met dat onderzoek en hoe lang het nog ging duren’ (mijn standaardantwoord: ‘nog twee 
jaar’. Pap, mam, eindelijk zijn die twee jaar om!) jullie bleven betrokken en geïnteresseerd 
en dat heb ik echt enorm gewaardeerd. En bovenal is en blijft het gewoon enorm fijn een 
weekend ‘thuis’ te kunnen komen en ouderwets verwend te worden en tot rust te kunnen 
komen. En de volgende keer kom ik echt zonder laptop! 
 
Lief zusje, ook al wonen we niet meer in hetzelfde studentenhuis, en zien we elkaar helaas 
niet meer zo vaak als we zouden willen, het is altijd weer even fijn en gezellig als ik bij jou 
ben. En ik beloof je, nu dit achter de rug is gaan we écht een (familie)weekendje weg. 
 
Liebe Familie Beckmann, ohne euch hätte ich mich in Deutschland nie so schnell wohl 
gefühlt. Und außerdem wäre ohne eure endlosen Spaziergänge und Spielplatzbesuche 
mit Mattis und Casper dieses Buch immer noch nicht fertig geworden. Danke, dass ihr 
immer für uns da seid. Ich bin froh, dass ich euch als Familie dazu bekommen habe. 
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Lieve Jan, wie had 7 jaar geleden in die après-ski-bar kunnen denken dat dit zo zou 
eindigen? En wat ben ik, een verhuizing naar Duitsland, een geweldige bruiloft en twee 
fantastische zoons verder, blij dat het zo gelopen is. Jij geeft mij de nodige rust en ruimte, 
stimuleert me als dat nodig is, maar zorgt vooral voor ontspanning als ik weer eens 
doordraaf. Zonder jou had ik dit nooit gered. Ik hou van je. 
 
Lieve Casper, eindelijk hoeft mama niet meer steeds achter de laptop en kan ze eindeloos 
met je voetballen (maar misschien kunnen we ook eens wat anders doen?!!). 
Lieve Mattis, eindelijk hoef je niet meer steeds mee op en neer naar Nijmegen om daar 
Geerts kantoor onveilig te maken en computerkabels los te trekken. 
Lieve jongens, dankzij jullie weet ik wat echt belangrijk is in het leven, wat ben ik blij dat 
jullie er zijn. 
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CURRICULUM VITAE 
Sabrina Laura Lince wordt op 14 oktober 1978 geboren in Brugge, België, als eerste in een 
gezin van twee dochters van een Italiaanse vader en Nederlandse moeder. Ze groeit op in 
Nieuwvliet, een klein dorpje aan zee in de buurt van de Belgische grens. In 1996 behaalt zij 
het gymnasiumdiploma aan het Zwincollege te Oostburg. Het spreekwoordelijke lot is 
haar gunstig gezind en nog datzelfde jaar begint ze aan de studie Geneeskunde aan de 
Maastricht University. 
Tijdens haar studie groeit ook haar interesse voor andere landen en culturen en besluit ze 
van de mogelijkheid gebruik te maken om meerdere co-schappen in het buitenland te 
lopen. Enthousiast geworden van de vele nieuwe ervaringen en indrukken, besluit ze haar 
studie uiteindelijk een jaar lang in de ijskast te zetten om rond te kunnen reizen en meer 
van de wereld te kunnen zien. Echter niet alleen het reizen, ook de wetenschap wekt in die 
periode haar belangstelling, waardoor ze ervoor kiest gedurende twee jaar parallel aan 
haar opleiding wetenschappelijk onderzoek bij de vakgroep huisartgeneeskunde te 
verrichten. Eind 2003 rondt ze haar studie Geneeskunde af en begint kort daarop als ‘arts-
assistent gynaecologie niet in opleiding’ in het Twee-Steden Ziekenhuis te Tilburg en later 
in het Rijnstate Ziekenhuis te Arnhem. Dolgelukkig kan ze uiteindelijk in juli 2006 met de 
opleiding tot gynaecoloog in cluster Nijmegen starten. Na zich aanvankelijk volledig op 
het klinische deel van haar vak te hebben gestort, begint tijdens het academische deel van 
haar opleiding het onderzoek weer te trekken. Het aanbod vanuit de pijler 
urogynaecologie om de onderzoekslijn naar de erfelijke oorzaken van urogenitale prolaps 
voort te zetten, komt dan ook als geroepen. Een leuke bijkomstigheid is het feit dat dit 
onderzoek ook haar liefde voor reizen nieuw leven inblaast en haar de gelegenheid geeft 
op verschillende internationale congressen voordrachten te houden. Daarnaast brengt het 
onderzoek haar zelfs in Nepal, waar ze tijdens een ‘gynocamp’ de mogelijkheid krijgt de 
lokale vrouwen te helpen en tevens data te verzamelen voor haar onderzoek. 
Niet lang daarna ontmoet ze in Frankrijk de man van haar dromen. Dat het uiteindelijk niet 
om een Fransman maar om een Duitser blijkt te gaan, doet dan al niet meer ter zake. In 
september 2012 vertrekt ze naar Duitsland, de liefde achterna, om daar het laatste deel 
van haar opleiding af te ronden. Inmiddels werkt ze als gynaecoloog in het St.-Marien-
Hospital te Lünen, Duitsland. Ze is getrouwd met Jan en samen hebben ze twee zoontjes. 
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